



(11)

EP 3 567 106 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
13.11.2019 Bulletin 2019/46

(51) Int Cl.:
C12N 15/00 (2006.01) C12N 15/86 (2006.01)
A61K 48/00 (2006.01)

(21) Application number: **18248250.5**

(22) Date of filing: **22.04.2011**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

- **Zhang, Hongwei**
Worcester, MA 01655 (US)
- **Wang, Hongyan**
Worcester, MA 01655 (US)
- **Xu, Zuoshang**
Wellesley, MA 02482 (US)

(30) Priority: **23.04.2010 US 32762710 P**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
18190083.8 / 3 536 781
14181861.7 / 2 826 860
11772784.2 / 2 561 073

(74) Representative: **Potter Clarkson**
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG (GB)

(71) Applicant: **University of Massachusetts**
Boston, MA 02110 (US)

Remarks:

This application was filed on 28-12-2018 as a divisional application to the application mentioned under INID code 62.

(72) Inventors:
• **Gao, Guangping**
Westborough, MA 01581 (US)

(54) **CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF**

(57) The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders.




Fig. 1-1

Description

RELATED APPLICATIONS

5 **[0001]** This application claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application USSN 61/327,627, filed April 23, 2010, and entitled "CNS Targeting AAV Vectors and Methods of Use Thereof," the entire contents of which are incorporated herein by reference.

FIELD OF THE INVENTION

10 **[0002]** The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof.

BACKGROUND OF THE INVENTION

15 **[0003]** Gene therapy has been investigated for delivery of therapeutic genes to the CNS cells for treatment of various CNS disease, *e.g.*, Canavan disease, ALS, Parkinson disease (PD), *etc.* In some limited cases, therapeutic benefits have been observed using certain viruses, *e.g.*, recombinant adenovirus (rAd), lentivirus (LV) and adeno-associated virus (AAV) to express a variety of therapeutic genes. AAV2 has been used in clinical trials for treatment of PD and Leber congenital amaurosis (an eye disease) and preliminary findings suggest symptomatic improvements without noticeable toxicity [2-4].

20 **[0004]** However, AAV-based gene therapy to treat CNS disease has still faced major obstacle. Many CNS diseases including, for example, ALS affect both cortical and spinal motor neurons that are distributed in a very broad area in the CNS. It has frequently been the case that viral vectors injected into CNS tissue transduce cells only in the vicinity of the injection site, have a very limited spread and generally have not impacted the lifespan in CNS disease animal models [See, *e.g.*, Ref. 5]. Still, a variety of other viral administration methods have been tested. One example, involves injecting the viral particles into skeletal muscle and allowing the nerve terminals to internalize the viral genome, which is then retrogradely transported back to the spinal motor neurons. This approach has shown some positive results in certain mouse models [68]. However, to apply this method in larger mammals, like adult humans, would be impractical. Overall, the transduction efficiency observed with muscle injection is relatively low. Some investigators have tried to improve this efficiency by modifying viral capsid proteins with the nerve binding domains of tetanus toxin or botulinum toxin. These efforts have not been fruitful due to various technical difficulties. Another problem with muscle injection in larger mammals, is a need for large doses, which is technically challenging, expensive, and carries a high risk for adverse effects, ranging from immune reaction to transduction of unintended cells (*e.g.*, germ cells).

30 **[0005]** Another method that has been evaluated for delivering transgenes into motor neurons is to inject the virus into large nerves, which maximizes that exposure of the virus to motor axons, allowing the motor neurons to internalize the viral genome and retrogradely transport them back to the cell body. This method has been demonstrated to be more efficient in transducing motor neurons than muscle injection [9]. Still, to implement a method such as this in larger mammals would be challenging.

SUMMARY OF THE INVENTION

40 **[0006]** Aspects of the invention, are based on the discovery of recombinant AAVs that achieve wide-spread distribution throughout CNS tissue of a subject. In some embodiments, the rAAVs spread throughout CNS tissue following direct administration into the cerebrospinal fluid (CSF), *e.g.*, via intrathecal and/or intracerebral injection. In other embodiments, the rAAVs cross the blood-brain-barrier and achieve wide-spread distribution throughout CNS tissue of a subject following intravenous administration. In some aspects the invention relates to rAAVs having distinct central nervous system tissue targeting capabilities (*e.g.*, CNS tissue tropisms), which achieve stable and nontoxic gene transfer at high efficiencies. Methods involving co-administration via intrathecal and intracerebral (*e.g.*, intraventricular) injection of rAAVs are provided in some aspects. For example, it has been discovered that rAAVs having a capsid protein comprising a sequence as set forth in SEQ ID NO: 9 achieves wide-spread distribution following intrathecal injection throughout the CNS, and thus, are particularly useful for treating CNS-associated disorders such as, for example, ALS. In still further aspects of the invention methods are provided for treating Canavan disease.

50 **[0007]** According to some aspects of the invention, methods for delivering a transgene to CNS tissue in a subject are provided. In some embodiments, the methods comprise administering an effective amount of a rAAV by intrathecal administration, wherein the rAAV comprises (i) a capsid protein comprising a sequence as set forth in SEQ ID NO: 9 and (ii) a nucleic acid comprising a promoter operably linked with a transgene. In some embodiments, the methods further comprise administering an effective amount of the rAAV by intracerebral administration. In some embodiments,

the methods comprise administering an effective amount of a rAAV by intrathecal administration and by intracerebral administration, wherein the rAAV infects cells of CNS tissue in the subject and comprises a nucleic acid comprising a promoter operably linked with a transgene. In certain embodiments, the intracerebral administration is an intraventricular administration. In one embodiment, the intraventricular administration is an administration into a ventricular region of the forebrain of the subject. In certain embodiments, the intrathecal administration is in the lumbar region of the subject. In some embodiments, the dose of the rAAV for intrathecal administration is in a range of 10^{10} genome copies/subject to 10^{11} genome copies/subject. In some embodiments, the dose of the rAAV for intrathecal administration is in a range of 10^{11} genome copies/subject to 10^{12} genome copies/subject. In some embodiments, the dose of the rAAV for intrathecal administration is in a range of 10^{12} genome copies/subject to 10^{13} genome copies/subject. In some embodiments, the dose of the rAAV for intrathecal administration is in a range of 10^{13} genome copies/subject to 10^{14} genome copies/subject. In some embodiments, the dose of the rAAV for intracerebral administration is in a range of 10^{10} genome copies/subject to 10^{11} genome copies/subject. In some embodiments, the dose of the rAAV for intracerebral administration is in a range of 10^{11} genome copies/subject to 10^{12} genome copies/subject. In some embodiments, the dose of the rAAV for intracerebral administration is in a range of 10^{12} genome copies/subject to 10^{13} genome copies/subject. In some embodiments, the dose of the rAAV for intracerebral or intrathecal administration is formulated for injection of a volume in a range of 1 μ l to 10 μ l. In some embodiments, the dose of the rAAV for intracerebral or intrathecal administration is formulated for injection of a volume in a range of 10 μ l to 100 μ l. In some embodiments, the rAAV for the intracerebral or intrathecal administration is formulated for injection of a volume in a range of 100 μ l to 1 ml. In some embodiments, the rAAV for the intracerebral or intrathecal administration is formulated for injection of a volume of 1 ml or more. In some embodiments, the transgene encodes a reporter protein. In certain embodiments, the reporter protein is a fluorescent protein, an enzyme that catalyzes a reaction yielding a detectable product, or a cell surface antigen. In certain embodiments, the enzyme is a luciferase, a beta-glucuronidase, a chloramphenicol acetyltransferase, an aminoglycoside phosphotransferase, an aminocyclitol phosphotransferase, or a Puromycin N-acetyltransferase. In some embodiments, the transgene is a CNS-associated gene. In some embodiments, the CNS-associated gene is neuronal apoptosis inhibitory protein (NAIP), nerve growth factor (NGF), glial-derived growth factor (GDNF), brain-derived growth factor (BDNF), ciliary neurotrophic factor (CNTF), tyrosine hydroxylase (TH), GTP-cyclohydrolase (GTPCH), amino acid decarboxylase (AADC) or aspartoacylase (ASPA). In some embodiments, the transgene encodes an inhibitory RNA that binds specifically to SOD1 mRNA and inhibits expression of SOD1 in the subject. In some embodiments, the inhibitory RNA is an antisense RNA, a shRNA or a miRNA. In some embodiments, the inhibitory RNA has a sequence as set forth in SEQ ID NO: 26. Thus, according to some aspects of the invention a nucleic acid comprising a sequence as set forth in SEQ ID NO: 26 is provided. In some embodiments, a nucleic acid comprising a promoter operably linked with a region having a sequence as set forth in SEQ ID NO: 26 is provided.

[0008] In further aspects of the invention a recombinant AAV comprising a nucleic acid comprising a sequence as set forth in SEQ ID NO: 26 is provided. In some aspects of the invention a recombinant AAV comprising a nucleic acid comprising a promoter operably linked with a region having a sequence as set forth in SEQ ID NO: 26 is provided. In some embodiments the recombinant AAV further comprises a capsid protein comprising a sequence as set forth in SEQ ID NO: 9.

[0009] According to some aspects of the invention, methods for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof are provided. In some embodiments, the methods comprise administering an effective amount of a rAAV to CNS tissue of the subject, wherein the rAAV comprises (i) a capsid protein comprising a sequence as set forth in SEQ ID NO: 9 and (ii) a nucleic acid comprising a promoter operably linked with a region encoding an inhibitory RNA that binds specifically to SOD1 mRNA and inhibits expression of SOD1 in the subject. In some embodiments, the inhibitory RNA is an antisense RNA, a shRNA or a miRNA. In some embodiments, the inhibitory RNA has a sequence as set forth in SEQ ID NO: 26. In some embodiments, the methods comprise administering an effective amount of a rAAV to the subject, wherein the rAAV comprises a nucleic acid comprising a promoter operably linked with a region encoding a sequence as set forth in SEQ ID NO: 26 and wherein the rAAV infects cells of CNS tissue in the subject.

[0010] According to some aspects of the invention, methods for delivering a transgene to a CNS tissue in a subject are provided that comprise administering an effective amount of a rAAV by intravenous administration, wherein the rAAV infects cells of CNS tissue in the subject and comprises a nucleic acid comprising a promoter operably linked with a transgene. In some embodiments, the dose of the rAAV for intravenous administration is in a range of 10^{10} genome copies/subject to 10^{11} genome copies/subject. In some embodiments, the dose of the rAAV for intravenous administration is in a range of 10^{11} genome copies/subject to 10^{12} genome copies/subject. In some embodiments, the dose of the rAAV for intravenous administration is in a range of 10^{12} genome copies/subject to 10^{13} genome copies/subject. In some embodiments, the dose of the rAAV for intravenous administration is in a range of 10^{13} genome copies/subject to 10^{14} genome copies/subject. In some embodiments, the dose of the rAAV for intravenous administration is in a range of 10^{14} genome copies/subject to 10^{15} genome copies/subject. In some embodiments, the dose of the rAAV for intravenous administration is in a range of 10^{10} genome copies/kg to 10^{11} genome copies/kg. In some embodiments, the dose of

the rAAV for intravenous administration is in a range of 10^{11} genome copies/kg to 10^{12} genome copies/kg. In some embodiments, the dose of the rAAV for intravenous administration is in a range of 10^{12} copies/kg to 10^{13} genome copies/kg. In some embodiments, the dose of the rAAV for intravenous administration is in a range of 10^{13} genome copies/kg to 10^{14} genome copies/kg.

[0011] According to some aspects of the invention, methods for delivering a transgene to a CNS tissue in a subject are provided that comprise administering to the subject an effective amount of a rAAV that comprises (i) a capsid protein having a sequence as set forth in any one of SEQ ID NO: 10 to 12 and (ii) a nucleic acid comprising a promoter operably linked with a transgene. In some embodiments, the methods comprise administering to the subject an effective amount of a rAAV comprising a transgene to a subject, wherein the rAAV comprises a capsid protein of a AAV serotype, or serotype variant, selected from the group consisting of: AAV1, AAV2, AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, rh.10, rh.39, rh.43 and CSp3, and wherein: (a) if the AAV serotype is AAV1, the administration route is not intracerebral, intramuscular, intranerve, or intraventricular and/or the subject is not a mouse, rat or feline; (b) if the AAV serotype is AAV2, the administration route is not intracerebral or intraventricular administration and/or the subject is not a rat, mouse, feline, marmoset, or macaque; (c) if the AAV serotype is AAV5, the administration route is not intracerebral or intraventricular administration and/or the subject is not a rat, mouse, or marmoset; (d) if the AAV serotype is AAV6, the subject is not a mouse; (e) if the AAV serotype is AAV7, the administration route is not intracerebral administration and/or the subject is not a mouse or macaque; (f) if the AAV serotype is AAV8, the administration route is not intracerebral, intraperitoneal, or intravascular administration and/or the subject is not a mouse or macaque; (g) if the AAV serotype is AAV9, the administration route is not intracerebral or intravascular administration and/or the subject is not a rat or mouse; and (h) if the AAV serotype is AAVrh.10, the administration route is not intracerebral or intravascular administration and/or the subject is not a rat or mouse. In some embodiments, the AAV serotype, or serotype variant, is selected from AAV1, AAV6, AAV7, rh.39, rh.43, and CSp3, and the administration route is intravascular administration. In some embodiments, the AAV serotype is AAV7 and the administration route is intravascular administration. In some embodiments, the CNS tissue is selected from cortex, hippocampus, thalamus, hypothalamus, cerebellum, brain stem, cervical spinal cord, thoracic spinal cord, and lumbar spinal cord. In some embodiments, the transgene encodes a reporter protein. In certain embodiments, the reporter protein is a fluorescent protein, an enzyme that catalyzes a reaction yielding a detectable product, or a cell surface antigen. In certain embodiments, the enzyme is a luciferase, a beta-glucuronidase, a chloramphenicol acetyltransferase, an aminoglycoside phosphotransferase, an aminocyclitol phosphotransferase, or a Puromycin N-acetyl-transferase. In some embodiments, the transgene is a CNS-associated gene. In certain embodiments, the CNS-associated gene is neuronal apoptosis inhibitory protein (NAIP), nerve growth factor (NGF), glial-derived growth factor (GDNF), brain-derived growth factor (BDNF), ciliary neurotrophic factor (CNTF), tyrosine hydroxylase (TH), GTP-cyclohydrolase (GTPCH), amino acid decarboxylase (AADC) or aspartoacylase (ASPA). In some embodiments, the rAAV is administered by intravenous injection.

[0012] According to some aspects of the invention a rAAV that comprises (i) a capsid protein having a sequence as set forth in any one of SEQ ID NO: 10 to 12 and (ii) a nucleic acid comprising a promoter operably linked with a CNS-associated gene is provided. In certain embodiments, the CNS-associated gene is neuronal apoptosis inhibitory protein (NAIP), nerve growth factor (NGF), glial-derived growth factor (GDNF), brain-derived growth factor (BDNF), ciliary neurotrophic factor (CNTF), tyrosine hydroxylase (TH), GTP-cyclohydrolase (GTPCH), amino acid decarboxylase (AADC) or aspartoacylase (ASPA). In some embodiments, mRNA expressed from the CNS-associated gene comprises a miRNA binding site of a miRNA that is preferentially expressed in non-CNS tissue. In certain embodiments, the miRNA binding site is a binding site for miR-122. In certain embodiments, the miRNA binding site is a binding site for miR-1. In some embodiments, mRNA expressed from the CNS-associated gene does not comprise a miRNA binding site of a miRNA that is preferentially expressed in CNS tissue. In some embodiments, the promoter is a CNS tissue specific promoter. In certain embodiments, the promoter is a promoter of a gene selected from: neuronal nuclei (NeuN), glial fibrillary acidic protein (GFAP), adenomatous polyposis coli (APC), and ionized calcium-binding adapter molecule 1 (Iba-1).

[0013] According to some aspects of the invention, a composition comprising a rAAV that comprises (i) a capsid protein having a sequence as set forth in SEQ ID NO: 10 to 12 and (ii) a nucleic acid comprising a promoter operably linked with a CNS-associated gene is provided. In certain embodiments the composition further comprises a pharmaceutically acceptable carrier. According to some aspects of the invention, a kit comprising a container housing the composition is provided. In some embodiments, the container is a sealed vial or ampule. In some embodiments, the container is a syringe.

[0014] According to some aspects of the invention, an isolated mammalian cell is provided that comprises a nucleic acid encoding a capsid protein having a sequence as set forth in any one of SEQ ID NO: 10 to 12 and a rAAV vector comprising a nucleic acid encoding a CNS-disease associated gene. In some embodiments, the isolated mammalian cell further comprises an AAV helper function vector. In some embodiments, isolated mammalian cell further comprises an accessory function vector. In certain embodiments, the CNS-associated gene is neuronal apoptosis inhibitory protein (NAIP), nerve growth factor (NGF), glial-derived growth factor (GDNF), brain-derived growth factor (BDNF), ciliary neurotrophic factor (CNTF), tyrosine hydroxylase (TH), GTP-cyclohydrolase (GTPCH), amino acid decarboxylase (AADC) or aspartoacylase (ASPA).

[0015] According to further aspects of the invention, a method for treating Canavan disease in a subject in need thereof is provided. In some embodiments, the methods comprise administering an effective amount of a rAAV to CNS tissue of the subject, wherein the rAAV comprises (i) a capsid protein other than a capsid protein of AAV serotype 2 and (ii) a nucleic acid comprising a promoter operably linked with a region encoding aspartoacylase (ASPA). Any of the rAAV serotypes disclosed herein may be used in the methods for treating Canavan disease. In some embodiments, the rAAV has a capsid protein having an amino acid sequence as set forth in SEQ ID NO: 8 or 9 or a variant thereof. In some embodiments, administering is performed intrathecally or intracerebrally. In some embodiments, administering is performed intravascularly.

[0016] In some embodiments, the methods comprise administering an effective amount of a rAAV to CNS tissue of the subject by a route other than intracerebral administration, wherein the rAAV comprises a nucleic acid comprising a promoter operably linked with a region encoding aspartoacylase (ASPA). In some embodiments, the methods comprise administering an effective amount of a rAAV to CNS tissue of the subject, wherein the rAAV comprises a nucleic acid comprising a promoter operably linked with a region encoding aspartoacylase (ASPA); and evaluating kidney function in the subject at least once after the administration. Any suitable method known in the art may be used to evaluate a subject's kidney function. The evaluation may involve, for example, an examination of blood or urine urea nitrogen levels, an examination of blood or urine creatinine levels, a creatinine clearance rate examination, a glomerular filtration rate examination, a filtration fraction examination, a renal plasma flow examination, an ultrasound examination, a microscopic examination of a kidney tissue biopsy or any other suitable kidney function test. It should be appreciated that in some embodiments an improvement in a subject's kidney function following treatment with an rAAV-mediated gene therapy is indicative of efficacy of the gene therapy for treating Canavan disease.

[0017] In some embodiments, the methods comprise administering an effective amount of a rAAV to CNS tissue of the subject, wherein the rAAV comprises a nucleic acid comprising a promoter operably linked with a region encoding aspartoacylase (ASPA); and evaluating vision of the subject at least once after the administration. Any suitable method known in the art may be used to evaluate a subject's vision. The evaluation may involve, for example, an external examination of the eye, a visual acuity examination, an examination of pupil function, a retinal examination, an ocular motility examination, an intraocular pressure test, or an ophthalmoscopic examination. The evaluation may involve a determination regarding a subject's ability to discriminate colors, objects or shapes or the ability of a subject to discern colors, objects or shapes from a particular distance. It should be appreciated that in some embodiments an improvement in a subject's vision following treatment with an rAAV-mediated gene therapy is indicative of efficacy of the gene therapy for treating Canavan disease.

[0018] In some embodiments, the nucleic acid expresses an aspartoacylase (ASPA) mRNA comprising one or more miRNA binds sites for one or more miRNAs that are more abundant in one or more non-CNS tissues in comparison to CNS tissue. Accordingly, in some embodiments, the mRNA is targeted for degradation by an miRNA in one or more non-CNS tissues. In some embodiments, the one or more non-CNS tissue is not kidney tissue or retinal tissue. In some embodiments, the one or more miRNAs that are more abundant in non-CNS tissues in comparison to CNS tissue are at least two-fold, at least three-fold, at least four-fold, at least five-fold, or at least ten-fold more abundant. MiRNAs that are more abundant in non-CNS tissue versus CNS tissue are known in the art. For example, one study discloses the expression levels of more than three-hundred different human miRNAs in 40 different tissues, including CNS tissue, kidney tissue. (See Liang Y, et al., Characterization of microRNA expression profiles in normal human tissues. BMC Genomics. 2007 Jun 12;8:166, the contents of which relating to miRNAs are incorporated herein by reference). Thus, in some embodiments, the skilled artisan could readily select (e.g., based on data such as are disclosed in Liang *et al.*) a suitable miRNA that is more abundant in non-CNS tissue and incorporate a binding site for that miRNA into the encoded mRNA.

[0019] Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention. This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways.

BRIEF DESCRIPTION OF THE DRAWINGS

[0020]

Figure 1 depicts quantitative results of EGFP intensities from fluorescence microscopic images of a panel of CNS tissue sections from neonatal mice infected with various rAAVs harboring EGFP expression vectors. Neonatal mice were administered the rAAVs by intravenous administration (superficial temporal vein injection).

Figure 2 depicts quantitative results of EGFP intensities from fluorescence microscopic images of a panel of CNS tissue sections from adult mice infected with various rAAVs harboring EGFP expression vectors. Adult mice were

administered the rAAVs by intravenous administration (tail vein injection).

Figure 3 depicts quantitation of EGFP expression in neonatal mice spinal cord (cervical, thoracic and lumbar regions) 21 days post IV injection (5 mice per group). Neonatal mice were administered the rAAVs by intravenous administration (superficial temporal vein injection).

Figure 4A depicts results showing that direct CSF injection of AAVrh.10 harboring a EGFP gene leads to EGFP expression in broad areas of the CNS. Tissue sections, prepared 60 days post virus injection, from brainstem, cervical spinal cord, thoracic spinal cord and lumbar spinal cord are shown. Gray/black pixels correspond with EGFP expression.

Figure 4B depicts results showing that direct CSF injection of AAVrh.10 harboring a EGFP gene leads to EGFP expression in astrocytes. Gray/black pixels correspond with EGFP expression.

Figure 5A depicts a rAAVrh.10 vector that expresses a microRNA targeting SOD1. The construct employs CAG (chicken β -actin promoter with a CMV enhancer) to drive the expression of EGFP and miR-SOD1 that is located in an intron in the 3'-UTR. pA stands for poly A signal. ITRs mark the inverted repeats of the AAV.

Figure 5B depicts results of experiments that test the silencing potency of 9 different miRNA constructs, miR-SOD1#5 was found to silence SOD1 expression most potently.

Figure 5C depicts results of experiments in which miR-SOD1#5 was packaged into AAVrh. 10 and used to infect HEK293 cells. Total cellular protein was extracted 43 hours after the infection and blotted to detect SOD1. Scr stands for scrambled miRNA; Sod stands for miR-SOD1#5; and C stands for a control that expresses EGFP only.

Figure 5D depicts a plasmid map of pAAVscCB6 EGFPmir SOD5 (5243bp) (SEQ ID NO: 21).

Figure 6A depicts results of gene transfer studies in SOD1 (G93A) mutant mice showing that rAAV rh.10-SOD1 miRNA knockdowns levels of mutant SOD1 in astrocytes. Staining in motor neurons was also observed.

Figure 6B depicts results of gene transfer studies in SOD1 (G93A) mutant mice showing that rAAV rh.10-SOD1 shRNA increases life span, compared with a rAAV rh.10-scrambled miRNA.

Figure 7A depicts quantitation of EGFP expression in cervical, thoracic, and lumbar spinal cord tissue compared with life spans individual mice infected with rAAV rh.10-SOD1 miRNA; rAAV rh.10-SOD1 was administered directly to the CSF.

Figure 7B depicts quantitation of EGFP expression in cervical, thoracic, and lumbar spinal cord tissue compared with life spans of individual mice infected with rAAV rh.10-scrambled miRNA; rAAV rh.10-scrambled miRNA was administered directly to the CSF.

Figure 8 depicts fluorescence microscopy analysis of mice that have been administered intrathecal injections of various AAVs. In this experiment, both AAV9 and AAVrh10 transduce cells along the full length of the spinal cord after a single injection into the CSF in lumbar subarachnoid space.

Figure 9 depicts the effects of AAV10-miR-SOD1 treatment. AAV10-miR-SOD1 treatment slows disease progression as indicated by the slower loss of body weight in treated compared with the control G93A mice.

Figure 10 depicts fluorescence microscopy analysis of mice that have been administered intrathecal injections of various AAVs. In this experiment, AAV9 and AAVrh10 can transduce cells in the broad forebrain areas after a single injection into the CSF in the third ventricle.

Figure 11 depicts fluorescence microscopy analysis of tissue sections from AAV9-injected mice. A single injection of AAV9 and AAVrh10 into the third ventricle can transduce cells in the broad forebrain areas, including cortex, hippocampus, striatum, thalamus, cerebellum and some scattered cells in the spinal cord. The same general pattern is also observed in AAV10-injected mice.

Figure 12 depicts an *in vitro* validation of artificial miRNA-binding sites for reporter silencing. Plasmids harboring the rAAVCBnLacZ genome with or without miR-1 or miR-122-binding sites were transfected into human hepatoma (HuH7) cells (a) which express miR-122 or cotransfected into 293 cells, together with a plasmid expressing either pri-miR-122 (b) or pri-miR-1 (c) at molar ratios of 1:3 (low) or 1:10 (high). 0X: no miRNA-binding site; 1X: one miRNA-binding site; 3X: three miRNA-binding sites. The cells were fixed and stained histochemically with X-gal 48 hours after transfection and blue cells counted. The percentage of nLacZ-positive cells in each transfection were compared to transfection of the control plasmid (prAAVCBnLacZ). CB, chicken β -actin; miR, microRNA; nLacZ, β -galactosidase reporter transgene; rAAV, recombinant adeno-associated viruses.

Figure 13 depicts an *in vivo* evaluation of endogenous miRNA-mediated transgene silencing in an rAAV9 transduction. (a-c) Adult male C58BL/6 mice were injected intravenously with 5×10^{13} genome copies per kg (GC/kg) each of rAAV9CBnLacZ (no binding site), (a) rAAV9CBnLacZmiR-122BS (one miR-122-binding site) and rAAV9CBnLacZ-(miR-122BS)₃ (three miR-122-binding sites), (b) rAAV9CBnLacZ-miR-1 BS (one miR-1 binding site) and rAAV9CBnLacZ-(miR-1BS)₃ (three miR-1-binding sites), (c) rAAV9CBnLacZ-miR-1BS-miR-122BS (IX each binding site) and rAAV9CBnLacZ-(miR-1BS)₃-(miR-122BS)₃ (three miR-1 and three miR-122-binding sites). The animals were necropsied 4 weeks after vector administration, and appropriate tissues were harvested for cryosectioning and X-gal histochemical staining. miR, microRNA; nLacZ, β -galactosidase reporter transgene; rAAV, recombinant adeno-associated viruses, and (d) quantification of β -galactosidase activities in liver tissue from animals that

received rAAVnLacZ vectors with and without miRNA-binding sites.

Figure 14 depicts an analysis of expression levels of cognate miRNA, mRNA, and protein of endogenous miRNA target genes in mice transduced with rAAV9CBnLacZ with or without miRNA-binding sites. Total cellular RNA or protein was prepared from (a-c) liver or (d) heart. (a) Northern blot detection of miRNAs. U6 small nuclear RNA provided a loading control. (b) Quantitative reverse-transcription PCR measuring cyclin G1 mRNA. The data are presented as relative *cyclin G1* mRNA levels normalized to β -actin. (c,d) Western blot analyses of protein levels of endogenous targets of miR-122 and miR-1. Total cellular protein prepared from (c) liver or (d) heart was analyzed for cyclin G1 and calmodulin. (e) Serum cholesterol levels. Serum samples from mice that received rAAV9 with or without miRNA-binding sites were collected after 4 weeks and measured for total cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein (LDL). miR, microRNA; nLacZ, β -galactosidase reporter transgene; rAAV, recombinant adeno-associated viruses.

Figure 15 depicts a molecular characterization of transgene mRNAs with or without miRNA binding sites. (a) Locations of the probes and primers, the sequences of mature miR-122 and its perfectly complementary binding site in the transgene mRNA are presented. (b) Total cellular RNA from liver was analyzed either by conventional reverse-transcription PCR (RT-PCR) by using primers that span a region between the 3' end of nLacZ and the 5' end of poly(A) signal (c) or by quantitative RT-PCR; data are presented as relative nLacZ mRNA levels normalized to β -actin. (d) For the northern blot analysis of nLacZ mRNA, 18S RNA served as a loading control, and the blots were hybridized with either a transgene DNA (e) or RNA probe. (f) In addition, poly(A) bearing mRNA from the liver of an animal received rAAV containing three miR-1- and three miR-122-binding sites was analyzed by 5' RACE; the PCR product was resolved on an ethidium bromide-stained agarose gel. miR, microRNA; nLacZ, β -galactosidase reporter transgene; rAAV, recombinant adeno-associated viruses.

Figure 16 depicts an alignment of sequences spanning the miRNA-binding sites and poly(A) signal regions recovered by 5' RACE. Poly(A)-containing mRNA was isolated from the (a) liver and (b) heart of an animal injected with rAAV9CBnLacZ-(miR-1BS)₃-(miR-122BS)₃. Twenty-one liver-derived and twenty-two heart-derived clones were sequenced. The putative cleavage sites in each clone are identified by arrows; the frequencies of miRNA-directed, site-specific cleavage for each miRNA-binding site are reported; triangles point to the positions of the expected miRNA-directed cleavage sites (a,b). miRNA, microRNA; nLacZ, β -galactosidase reporter transgene; rAAV, recombinant adeno-associated viruses.

Figure 17 depicts an endogenous miRNA-repressed, CNS-directed EGFP gene transfer by systemically delivered rAAV9. Ten-week-old male C57BL/6 mice were injected intravenously with scAAV9CBEGFP or scAAV9CBnLacZ(miR-1BS)₃-(miR-122BS)₃ at a dose of 2×10^{14} genome copies per kg (GC/kg) body weight. The animals were necropsied 3 weeks later for whole body fixation by transcardiac perfusion. (a) Brain, spinal cord, liver, heart, and muscle were harvested for cryosectioning, immunofluorescent staining for EGFP (brain and cervical spinal cord), and fluorescence microscopy to detect EGFP. Total cellular DNA and RNA were extracted from brain, liver, heart and muscle to measure the amount of persistent vector genome by qPCR and EGFP mRNA by qRT-PCR. (b) For each tissue, the relative abundance of the EGFP mRNA containing miRNA-binding sites was compared to that of the EGFP mRNA lacking miRNA-binding sites. For each sample, mRNA abundance was normalized to the amount of vector genome detected in the tissue. EGFP, enhanced green fluorescent protein; miRNA, microRNA; nLacZ, β -galactosidase reporter transgene; qRT-PCR, quantitative reverse-transcription PCR; rAAV, recombinant adeno-associated viruses.

Figure 18 depicts a molecular model for endogenous miRNA-regulated rAAV expression. miRNA, microRNA; rAAV, recombinant adeno-associated viruses.

Figure 19 depicts a quantification of GFP intensity levels in the brain and spinal cord of neonatal mice transduced with various AAV vectors. 4×10^{11} genome copies (GCs) of ten different AAV vectors were injected into neonatal P1 pups through superficial vein. The mice were sacrificed 21 days after injection. The brain tissues were extracted and 40 μ m thick cryosections were prepared. The sections were stained against anti-EGFP antibody. The images were analyzed and the intensity/pixel values of all AAV serotypes in various regions in brain and spinal cord (A) were calculated by using Nikon NIS elements AR software version 3.2. Average intensities of the brain and spinal cord regions for different rAAVs were also presented (B). Region of interest (ROI) of each anatomical structure was fixed for all vectors to ensure the parallel comparison.

Figure 20 depicts a strong and widespread EGFP expression in neonatal mouse brain after intravenous injection of rAAVs. 4×10^{11} genome copies (GCs) of rAAVs 7, 9, rh.10, rh.39 and rh.43 were injected into neonatal P1 pups through superficial vein. The mice were sacrificed 21 days after injection. The brain tissues were extracted and 40 μ m thick cryosections were prepared. The sections were stained against anti-EGFP antibody. Bars represent 100 μ m. The regions shown are: olfactory bulb, striatum, hippocampus, cortex, hypothalamus, cerebellum and medulla. Figure 21 depicts EGFP expression in neonatal mouse spinal cord after intravenous injection of rAAVs. 4×10^{11} GCs of rAAVs 7, 9, rh.10, rh.39 and rh.43 were injected into neonatal P1 pups through superficial vein. The mice were sacrificed 21 days after injection. The spinal cord tissues were extracted and 40 μ m thick cryosections were

prepared. The sections from cervical, thoracic and lumbar regions were stained against anti-EGFP antibody. Bars represent 100 μm .

Figure 22 depicts EGFP expression in dorsal root ganglia transduced by intravascularly delivered rAAVs, 2, 6, 6.2, 7, 9, rh.10 and rh.39. Neonatal pups received 4×10^{11} GCs of rAAVs at PI and were necropsied 21 days after injection. Forty μm thick cryosections were processed for double immunohistochemical staining for EGFP (green) and Neurons (NeuN, red). Bars represent 75 μm .

Figure 23 depicts confocal microscopic analysis of the transduced cell types in mouse CNS after systemic delivery of rAAVs to PI neonates. The 40 μm thick brain and spinal cord sections of the animals treated with different rAAVs were co-stained against anti-EGFP antibody and cell-type specific markers. Anti-NeuN was used to stain neuronal cells; anti-GFAP was used to stain astrocytes; anti-Calbindin was used to stain Purkinje cells; anti-ChAT was used to stain motor neurons; anti-DARPP was used to stain dopaminergic neurons in the substantia nigra. All rAAVs were examined, but for each cell type, only one representative picture was shown here.

Figure 24 depicts a transduction of the brain ventricular structures by intravascularly delivered rAAVs. Neonatal pups received 4×10^{11} GCs of rAAVs at PI and were necropsied 21 days after injection. The choroid plexuses in different ventricles were well preserved during tissue process. Forty μm thick cryosections were stained against anti-EGFP antibody. Bars represent 100 μm .

Figure 25 depicts an analysis of purity and morphological integrity of rAAV vectors. A. Silver stained SDS-Page analysis of CsCl gradient purified rAAVCBEGFP vectors used in this study. Approximately 1.5×10^{10} virus particles each of rAAVs 1, 2, 5, 6, 6.2, 7, 9, rh10, rh39 and rh43 were loaded in the corresponding lane. B. Transmission electron microscopy of negative stained recombinant AAV virions. rAAV virions were spread on a freshly prepared carbon coated- Formvar support film and stained with 1% uranyl acetate for transmission microscopy. The images of virus particles from representative vector lots were taken at 92,000X and presented.

Figure 26 depicts a transduction of neonatal mouse dorsal root ganglia by systemically delivered rAAVs 1, 6, 6.2 and rh43. Neonatal pups received 4×10^{11} GCs of rAAVs at PI were necropsied 21 days after injection. Forty μm thick cryosections were stained against anti-EGFP antibody. Bars represent 75 μm .

Figure 27 depicts a transduction of the brain capillary vessels by intravascularly delivered rAAVs. Neonatal pups received 4×10^{11} GCs of rAAVs at PI were necropsied 21 days after injection. Forty μm thick cryosections of the brains were stained against: (a) anti-EGFP antibody (AAV1, AAV6, AAV6.2, AAV7, AAV9, AAVrh.10, AAVrh.39 and AAVrh.43); (b) anti-EGFP and anti-CD34 antibodies (rh.10 only). Bars represent 100 μm .

Figure 28 depicts an evaluation of microgliosis in mice brain after systemic delivery of rAAVs to PI neonates. The 40 μm thick brain sections of the animals treated with different rAAVs were co-stained against anti-EGFP antibody and anti-IBA-1. Only the staining result of rAAVrh.10 was shown.

Figure 29 depicts native EGFP expression in mice CNS after systemic delivery of rAAVs to PI neonates. Neonatal pups received 4×10^{11} GCs of rAAVs at PI were necropsied 21 days after injection. Forty μm thick cryosections were mounted and observed under microscope without immunostaining. The exposure times for each image were indicated.

Figure 30 depicts results showing the effects of rAAV based gene therapy in the treatment of Canavan disease. Figure 30A shows that treatment corrected gait and motor function of the CD mice. Figure 30B shows that treatment mitigated retinopathy and restored vision in CD mice. Figure 30C shows that NAA levels in the treated CD mice approach those in the normal mice. Figure 30D indicates that APSA activity is detected in the brains of CD mice. Figure 30E indicates APSA expression is detected in the brains of CD mice.

Figure 31A depicts that vacuolation in both brain and spinal cord of the treated mice is more patchy and variable with generally smaller-sized vacuoles and that some areas of the cerebral cortex show almost no vacuolation. Figure 31B shows ASPA expression in the cerebral cortex *in situ*.

Figure 32 depicts results of a quantitative analysis of vacuolation in various brain regions. Figure 32A shows that olfactory bulb had a dramatic mitigation in the white matter degeneration after gene therapy and that the large vacuoles were essentially eliminated in other tissues. Figure 32B shows results from a similar analysis on spinal cord sections.

Figure 33 depicts results from a histopathological evaluation of kidneys in the CD mice. Figure 33A shows that the renal tubular epithelium of the kidney was diffusely attenuated and exhibited enlargement of the tubular lumens in untreated CD mice. Figure 33B shows that treated CD mouse had normal glomeruli. Figure 33C and 33D depict results of an analysis of two lead candidate vectors, rAAV9 and rh.10, respectively, for efficiency of kidney transduction after IV delivery.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

[0021] Adeno-associated virus (AAV) is a small (26 nm) replication-defective, nonenveloped virus, that depends on the presence of a second virus, such as adenovirus or herpes virus, for its growth in cells. AAV is not known to cause

disease and induces a very mild immune response. AAV can infect both dividing and non-dividing cells and may incorporate its genome into that of the host cell. Aspects of the invention provide methods for delivering a transgene to a CNS tissue in a subject using recombinant AAV-based gene transfer. Accordingly, methods and compositions for treating CNS-related disorders are provided herein. Further aspects of the invention, are based on the discovery of rAAVs that achieve wide-spread distribution throughout CNS tissue. In some embodiments, the rAAVs spread throughout CNS tissue following direct administration into the cerebrospinal fluid (CSF), e.g., via intrathecal and/or intracerebral injection. In other embodiments, the rAAVs cross the blood-brain-barrier and achieve wide-spread distribution throughout CNS tissue of a subject following intravenous administration. Such rAAVs are useful for the treatment of CNS-related disorders, including, for example, amyotrophic lateral sclerosis (ALS) and Canavan disease (CD).

Methods and Compositions for Targeting CNS tissue

[0022] Methods for delivering a transgene to central nervous system (CNS) tissue in a subject are provided herein. The methods typically involve administering to a subject an effective amount of a rAAV comprising a nucleic acid vector for expressing a transgene in the subject. An "effective amount" of a rAAV is an amount sufficient to infect a sufficient number of cells of a target tissue in a subject. An effective amount of a rAAV may be an amount sufficient to have a therapeutic benefit in a subject, e.g., to extend the lifespan of a subject, to improve in the subject one or more symptoms of disease, e.g., a symptom of ALS, a symptom of Canavan disease, etc. In some cases, an effective amount of a rAAV may be an amount sufficient to produce a stable somatic transgenic animal model. The effective amount will depend on a variety of factors such as, for example, the species, age, weight, health of the subject, and the CNS tissue to be targeted, and may thus vary among subject and tissue. An effective amount may also depend on the mode of administration. For example, targeting a CNS tissue by intravascular injection may require different (e.g., higher) doses, in some cases, than targeting CNS tissue by intrathecal or intracerebral injection. In some cases, multiple doses of a rAAV are administered. An effective amount may also depend on the rAAV used. For example, dosages for targeting a CNS tissue may depend on the serotype (e.g., the capsid protein) of the rAAV. For example, the rAAV may have a capsid protein of a AAV serotype selected from the group consisting of: AAV1, AAV2, AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, rh.10, rh.39, rh.43 and CSp3. In certain embodiments, the effective amount of rAAV is 10^{10} , 10^{11} , 10^{12} , 10^{13} , or 10^{14} genome copies per kg. In certain embodiments, the effective amount of rAAV is 10^{10} , 10^{11} , 10^{12} , 10^{13} , 10^{14} , or 10^{15} genome copies per subject.

[0023] A method for delivering a transgene to CNS tissue in a subject may comprise administering a rAAV by a single route or by multiple routes. For example, delivering a transgene to CNS tissue in a subject may comprise administering to the subject, by intravenous administration, an effective amount of a rAAV that crosses the blood-brain-barrier. Delivering a transgene to CNS tissue in a subject may comprise administering to the subject an effective amount of a rAAV by intrathecal administration or intracerebral administration, e.g., by intraventricular injection. A method for delivering a transgene to CNS tissue in a subject may comprise co-administering of an effective amount of a rAAV by two different administration routes, e.g., by intrathecal administration and by intracerebral administration. Co-administration may be performed at approximately the same time, or different times.

[0024] The CNS tissue to be targeted may be selected from cortex, hippocampus, thalamus, hypothalamus, cerebellum, brain stem, cervical spinal cord, thoracic spinal cord, and lumbar spinal cord, for example. The administration route for targeting CNS tissue typically depends on the AAV serotype. For example, in certain instances where the AAV serotype is selected from AAV1, AAV6, AAV6.2, AAV7, AAV8, AAV9, rh.10, rh.39, rh.43 and CSp3, the administration route may be intravascular injection. In some instances, for example where the AAV serotype is selected from AAV1, AAV2, AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, rh.10, rh.39, rh.43 and CSp3, the administration route may be intrathecal and/or intracerebral injection.

Intravascular Administration

[0025] As used herein the term "intravascular administration" refers to the administration of an agent, e.g., a composition comprising a rAAV, into the vasculature of a subject, including the venous and arterial circulatory systems of the subject. Typically, rAAVs that cross the blood-brain-barrier may be delivered by intravascular administration for targeting CNS tissue. In some cases, intravascular (e.g., intravenous) administration facilitates the use of larger volumes than other forms of administration (e.g., intrathecal, intracerebral). Thus, large doses of rAAVs (e.g., up to 10^{15} GC/subject) can be delivered at one time by intravascular (e.g., intravenous) administration. Methods for intravascular administration are well known in the art and include for example, use of a hypodermic needle, peripheral cannula, central venous line, etc.

Intrathecal and/or Intracerebral Administration

[0026] As used herein the term "intrathecal administration" refers to the administration of an agent, e.g., a composition

comprising a rAAV, into the spinal canal. For example, intrathecal administration may comprise injection in the cervical region of the spinal canal, in the thoracic region of the spinal canal, or in the lumbar region of the spinal canal. Typically, intrathecal administration is performed by injecting an agent, e.g., a composition comprising a rAAV, into the subarachnoid cavity (subarachnoid space) of the spinal canal, which is the region between the arachnoid membrane and pia mater of the spinal canal. The subarachnoid space is occupied by spongy tissue consisting of trabeculae (delicate connective tissue filaments that extend from the arachnoid mater and blend into the pia mater) and intercommunicating channels in which the cerebrospinal fluid is contained. In some embodiments, intrathecal administration is not administration into the spinal vasculature.

[0027] As used herein, the term "intracerebral administration" refers to administration of an agent into and/or around the brain. Intracerebral administration includes, but is not limited to, administration of an agent into the cerebrum, medulla, pons, cerebellum, intracranial cavity, and meninges surrounding the brain. Intracerebral administration may include administration into the dura mater, arachnoid mater, and pia mater of the brain. Intracerebral administration may include, in some embodiments, administration of an agent into the cerebrospinal fluid (CSF) of the subarachnoid space surrounding the brain. Intracerebral administration may include, in some embodiments, administration of an agent into ventricles of the brain, e.g., the right lateral ventricle, the left lateral ventricle, the third ventricle, the fourth ventricle. In some embodiments, intracerebral administration is not administration into the brain vasculature.

[0028] Intracerebral administration may involve direct injection into and/or around the brain. In some embodiments, intracerebral administration involves injection using stereotaxic procedures. Stereotaxic procedures are well known in the art and typically involve the use of a computer and a 3-dimensional scanning device that are used together to guide injection to a particular intracerebral region, e.g., a ventricular region. Micro-injection pumps (e.g., from World Precision Instruments) may also be used. In some embodiments, a microinjection pump is used to deliver a composition comprising a rAAV. In some embodiments, the infusion rate of the composition is in a range of 1 μ l / minute to 100 μ l / minute. As will be appreciated by the skilled artisan, infusion rates will depend on a variety of factors, including, for example, species of the subject, age of the subject, weight/size of the subject, serotype of the AAV, dosage required, intracerebral region targeted, etc. Thus, other infusion rates may be deemed by a skilled artisan to be appropriate in certain circumstances.

Methods and Compositions for Treating CNS-related Disorders

[0029] Methods and compositions for treating CNS-related disorders are also provided herein. As used herein, a "CNS-related disorder" is a disease or condition of the central nervous system. A CNS-related disorder may affect the spinal cord (e.g., a myelopathy), brain (e.g., a encephalopathy) or tissues surrounding the brain and spinal cord. A CNS-related disorder may be of a genetic origin, either inherited or acquired through a somatic mutation. A CNS-related disorder may be a psychological condition or disorder, e.g., Attention Deficient Hyperactivity Disorder, Autism Spectrum Disorder, Mood Disorder, Schizophrenia, Depression, Rett Syndrome, etc. A CNS-related disorder may be an autoimmune disorder. A CNS-related disorder may also be a cancer of the CNS, e.g., brain cancer. A CNS-related disorder that is a cancer may be a primary cancer of the CNS, e.g., an astrocytoma, glioblastomas, etc., or may be a cancer that has metastasized to CNS tissue, e.g., a lung cancer that has metastasized to the brain. Further non-limiting examples of CNS-related disorders, include Parkinson's Disease, Lysosomal Storage Disease, Ischemia, Neuropathic Pain, Amyotrophic lateral sclerosis (ALS), Multiple Sclerosis (MS), and Canavan disease (CD).

[0030] Methods for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof are provided herein. A subject in need of a treatment for ALS is a subject having or suspected of having ALS. In some cases, ALS has been linked to a mutation in the gene coding for superoxide dismutase (SOD1). Elevated levels of SOD1 appear to be associated with ALS in some instances. It has been shown that transgenic expression of shRNA against SOD1 can knockdown mutant SOD1 expression, delay disease onset and extend survival (Xia et al. 2006, Neurobiol Dis 23: 578). Intrathecal infusion of siRNA against SOD1 at disease onset has also been found to knockdown mutant SOD1 expression and extend survival (Wang et al. 2008, JBC 283: 15845). Furthermore, nerve injection of adenovirus expressing shRNA against SOD1 at the disease onset can knockdown mutant SOD1 expression and extend survival (Wu et al. 2009, Antiox Redox Sig 11: 1523).

[0031] Aspects of the invention, are based on the discovery of AAV-based therapies that achieve, with low-toxicity, long-term inhibition of SOD1 expression that is wide-spread throughout CNS tissue of the subject. Methods for treating ALS that are provided herein, typically involve administering to CNS tissue of a subject an effective amount of a rAAV that harbors a nucleic acid comprising a promoter operably linked with a region encoding an inhibitory RNA that binds specifically to SOD1 mRNA (e.g., that hybridizes specifically to a nucleic acid having a sequence as set forth in SEQ ID NO 17 or 19) and inhibits expression of SOD1 in the subject. It has been discovered that rAAVs having a capsid protein comprising a sequence as set forth in SEQ ID NO: 9 achieve wide-spread distribution throughout the CNS following intrathecal injection and/or intracerebral injection, and thus, are particularly useful for treating ALS. This result is surprising in light of certain other rAAVs that infect cells only within the immediate vicinity of the injection site, or the achieve only a limited distribution, following intrathecal injection. Thus, rAAVs that achieve wide-spread distribution throughout the

CNS are particularly useful as gene transfer vectors for treating ALS.

[0032] In some embodiments, it has been discovered that co-administration by intrathecal injection and intracerebral injection, e.g., intraventricular injection, of rAAVs having a capsid protein comprising a sequence as set forth in SEQ ID NO: 9 and a nucleic acid comprising a promoter operably linked with a region encoding an inhibitory RNA that binds specifically to SOD1 mRNA and inhibits expression of SOD1, achieves long-term inhibition of SOD1 and improves outcome (e.g., lifespan) in an animal model of ALS (See, e.g., Figure 6A). In some embodiments, the inhibitory RNA is an antisense RNA, a shRNA or a miRNA. The inhibitory RNA may have a sequence as set forth in SEQ ID NO: 26. The inhibitory RNA may have a sequence as set forth in any one of SEQ ID NO: 22 to 30. Thus, in some embodiments, a nucleic acid comprising a promoter operably linked with a nucleic acid having a sequence as set forth in any one of SEQ ID NO: 22 to 30 is provided. In some embodiments, a recombinant AAV that harbors a nucleic acid comprising a sequence as set forth in any one of SEQ ID NO: 22 to 30 is provided. The recombinant AAV may have a capsid protein comprising a sequence as set forth in SEQ ID NO: 9. The recombinant AAV may have a capsid protein comprising a sequence as set forth in any one of SEQ ID NO: 1 to 12.

[0033] Methods for treating Canavan disease (CD) in a subject in need thereof are provided herein. A subject in need of a treatment for CD is a subject having or suspected of having CD. Canavan disease is caused by a defective ASPA gene which is responsible for the production of the enzyme aspartoacylase. This enzyme normally breaks down the concentrated brain molecule N-acetyl aspartate. Decreased aspartoacylase activity in subjects with CD prevents the normal breakdown of N-acetyl aspartate, and the lack of breakdown appears to interfere with growth of the myelin sheath of the nerve fibers in the brain. Symptoms of Canavan disease, which may appear in early infancy and progress rapidly, may include mental retardation, loss of previously acquired motor skills, feeding difficulties, abnormal muscle tone (i.e., floppiness or stiffness), poor head control, and megalencephaly (abnormally enlarged head). Paralysis, blindness, or seizures may also occur. Aspects of the invention improve one or more symptoms of CD in a subject by administering to the subject a recombinant AAV harboring a nucleic acid that expresses aspartoacylase (ASPA). For example, a method for treating Canavan disease in a subject in need thereof may comprise administering an effective amount of a rAAV to CNS tissue of the subject by intravascular administration, wherein the rAAV comprises a nucleic acid comprising a promoter operably linked with a region encoding ASPA (e.g., a region having a sequence as set forth in SEQ ID NO: 14 or 16). A method for treating Canavan disease in a subject in need thereof may comprise administering an effective amount of a rAAV to CNS tissue of the subject by intrathecal administration, wherein the rAAV comprises a nucleic acid comprising a promoter operably linked with a region encoding ASPA. In some cases, methods for treating CD involve administering, to CNS tissue of the subject, an effective amount of a rAAV that comprises a capsid protein other than a capsid protein of AAV serotype 2 (e.g., other than a protein having an amino acid sequence as set forth in SEQ ID NO: 2) and a nucleic acid comprising a promoter operably linked with a region encoding ASPA. In another example, a method for treating Canavan disease in a subject in need thereof comprises administering an effective amount of a rAAV to CNS tissue of the subject by a route other than intracerebral administration, wherein the rAAV comprises a nucleic acid comprising a promoter operably linked with a region encoding ASPA. In some embodiments, ASPA expressed in CNS tissue following administration of the rAAV results in a decrease in aspartoacylase activity and breakdown of N-acetyl aspartate in the CNS tissue. Thus, in some embodiments, a recombinant AAV vector is provided that comprises a nucleic acid encoding a sequence as set forth in SEQ ID NO: 14 or 16. In some embodiments, a recombinant AAV is provided that harbors a nucleic acid comprising a promoter operably linked with a region having a sequence as set forth in SEQ ID NO: 14 or 16. In some embodiments, a recombinant AAV is provided that harbors a nucleic acid comprising a promoter operably linked with a region encoding a protein having a sequence as set forth in SEQ ID NO: 13 or 15. The recombinant AAV may have a capsid protein comprising an amino acid sequence as set forth in any one of SEQ ID NO: 1 to 12. The recombinant AAV may have a capsid protein comprising a sequence as set forth in any one of SEQ ID NO: 1 and 3 to 12.

Recombinant AAVs

[0034] In some aspects, the invention provides isolated AAVs. As used herein with respect to AAVs, the term "isolated" refers to an AAV that has been isolated from its natural environment (e.g., from a host cell, tissue, or subject) or artificially produced. Isolated AAVs may be produced using recombinant methods. Such AAVs are referred to herein as "recombinant AAVs". Recombinant AAVs (rAAVs) preferably have tissue-specific targeting capabilities, such that a transgene of the rAAV will be delivered specifically to one or more predetermined tissue(s). The AAV capsid is an important element in determining these tissue-specific targeting capabilities. Thus, a rAAV having a capsid appropriate for the tissue being targeted can be selected. In some embodiments, the rAAV comprises a capsid protein having an amino acid sequence as set forth in any one of SEQ ID NOs 1 to 12, or a protein having substantial homology thereto.

[0035] Methods for obtaining recombinant AAVs having a desired capsid protein are well known in the art (See, for example, US 2003/0138772, the contents of which are incorporated herein by reference in their entirety). AAVs capsid protein that may be used in the rAAVs of the invention include, for example, those disclosed in G. Gao, et al., J. Virol, 78(12):6381-6388 (June 2004); G. Gao, et al, Proc Natl Acad Sci USA, 100(10):6081-6086 (May 13, 2003); US

2003-0138772, US 2007/0036760, US 2009/0197338, and U.S. provisional application serial number 61/182,084, filed May 28, 2009, the contents of which relating to AAVs capsid proteins and associated nucleotide and amino acid sequences are incorporated herein by reference. Typically the methods involve culturing a host cell which contains a nucleic acid sequence encoding an AAV capsid protein (e.g., a nucleic acid encoding a protein having a sequence as set forth in any one of SEQ ID NOs 1-12) or fragment thereof; a functional *rep* gene; a recombinant AAV vector composed of, AAV inverted terminal repeats (ITRs) and a transgene; and sufficient helper functions to permit packaging of the recombinant AAV vector into the AAV capsid proteins.

[0036] The components to be cultured in the host cell to package a rAAV vector in an AAV capsid may be provided to the host cell in *trans*. Alternatively, any one or more of the required components (e.g., recombinant AAV vector, *rep* sequences, *cap* sequences, and/or helper functions) may be provided by a stable host cell which has been engineered to contain one or more of the required components using methods known to those of skill in the art. Most suitably, such a stable host cell will contain the required component(s) under the control of an inducible promoter. However, the required component(s) may be under the control of a constitutive promoter. Examples of suitable inducible and constitutive promoters are provided herein, in the discussion of regulatory elements suitable for use with the transgene. In still another alternative, a selected stable host cell may contain selected component(s) under the control of a constitutive promoter and other selected component(s) under the control of one or more inducible promoters. For example, a stable host cell may be generated which is derived from 293 cells (which contain E1 helper functions under the control of a constitutive promoter), but which contain the *rep* and/or *cap* proteins under the control of inducible promoters. Still other stable host cells may be generated by one of skill in the art.

[0037] The recombinant AAV vector, *rep* sequences, *cap* sequences, and helper functions required for producing the rAAV of the invention may be delivered to the packaging host cell using any appropriate genetic element (vector). The selected genetic element may be delivered by any suitable method, including those described herein. The methods used to construct any embodiment of this invention are known to those with skill in nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic techniques. See, e.g., Sambrook et al, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. Similarly, methods of generating rAAV virions are well known and the selection of a suitable method is not a limitation on the present invention. See, e.g., K. Fisher et al, *J. Virol.*, 70:520-532 (1993) and U.S. Pat. No. 5,478,745.

[0038] In some embodiments, recombinant AAVs may be produced using the triple transfection method (e.g., as described in detail in U.S. Pat. No. 6,001,650, the contents of which relating to the triple transfection method are incorporated herein by reference). Typically, the recombinant AAVs are produced by transfecting a host cell with a recombinant AAV vector (comprising a transgene) to be packaged into AAV particles, an AAV helper function vector, and an accessory function vector. An AAV helper function vector encodes the "AAV helper function" sequences (i.e., *rep* and *cap*), which function in *trans* for productive AAV replication and encapsidation. Preferably, the AAV helper function vector supports efficient AAV vector production without generating any detectable wild-type AAV virions (i.e., AAV virions containing functional *rep* and *cap* genes). Non-limiting examples of vectors suitable for use with the present invention include pHLP19, described in U.S. Pat. No. 6,001,650 and pRep6cap6 vector, described in U.S. Pat. No. 6,156,303, the entirety of both incorporated by reference herein. The accessory function vector encodes nucleotide sequences for non-AAV derived viral and/or cellular functions upon which AAV is dependent for replication (i.e., "accessory functions"). The accessory functions include those functions required for AAV replication, including, without limitation, those moieties involved in activation of AAV gene transcription, stage specific AAV mRNA splicing, AAV DNA replication, synthesis of *cap* expression products, and AAV capsid assembly. Viral-based accessory functions can be derived from any of the known helper viruses such as adenovirus, herpesvirus (other than herpes simplex virus type-1), and vaccinia virus.

[0039] In some aspects, the invention provides transfected host cells. The term "transfection" is used to refer to the uptake of foreign DNA by a cell, and a cell has been "transfected" when exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are generally known in the art. See, e.g., Graham et al. (1973) *Virology*, 52:456, Sambrook et al. (1989) *Molecular Cloning*, a laboratory manual, Cold Spring Harbor Laboratories, New York, Davis et al. (1986) *Basic Methods in Molecular Biology*, Elsevier, and Chu et al. (1981) *Gene* 13:197. Such techniques can be used to introduce one or more exogenous nucleic acids, such as a nucleotide integration vector and other nucleic acid molecules, into suitable host cells.

[0040] A "host cell" refers to any cell that harbors, or is capable of harboring, a substance of interest. Often a host cell is a mammalian cell. A host cell may be used as a recipient of an AAV helper construct, an AAV minigene plasmid, an accessory function vector, or other transfer DNA associated with the production of recombinant AAVs. The term includes the progeny of the original cell which has been transfected. Thus, a "host cell" as used herein may refer to a cell which has been transfected with an exogenous DNA sequence. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.

[0041] In some aspects, the invention provides isolated cells. As used herein with respect to cell, the term "isolated" refers to a cell that has been isolated from its natural environment (e.g., from a tissue or subject). As used herein, the

term "cell line" refers to a population of cells capable of continuous or prolonged growth and division *in vitro*. Often, cell lines are clonal populations derived from a single progenitor cell. It is further known in the art that spontaneous or induced changes can occur in karyotype during storage or transfer of such clonal populations. Therefore, cells derived from the cell line referred to may not be precisely identical to the ancestral cells or cultures, and the cell line referred to includes such variants. As used herein, the terms "recombinant cell" refers to a cell into which an exogenous DNA segment, such as DNA segment that leads to the transcription of a biologically-active polypeptide or production of a biologically active nucleic acid such as an RNA, has been introduced.

[0042] As used herein, the term "vector" includes any genetic element, such as a plasmid, phage, transposon, cosmid, chromosome, artificial chromosome, virus, virion, etc., which is capable of replication when associated with the proper control elements and which can transfer gene sequences between cells. Thus, the term includes cloning and expression vehicles, as well as viral vectors. In some embodiments, useful vectors are contemplated to be those vectors in which the nucleic acid segment to be transcribed is positioned under the transcriptional control of a promoter. A "promoter" refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene. The phrases "operatively positioned," "under control" or "under transcriptional control" means that the promoter is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the gene. The term "expression vector or construct" means any type of genetic construct containing a nucleic acid in which part or all of the nucleic acid encoding sequence is capable of being transcribed. In some embodiments, expression includes transcription of the nucleic acid, for example, to generate a biologically-active polypeptide product or inhibitory RNA (e.g., shRNA, miRNA) from a transcribed gene.

[0043] The foregoing methods for packaging recombinant vectors in desired AAV capsids to produce the rAAVs of the invention are not meant to be limiting and other suitable methods will be apparent to the skilled artisan.

Recombinant AAV vectors

[0044] "Recombinant AAV (rAAV) vectors" of the invention are typically composed of, at a minimum, a transgene and its regulatory sequences, and 5' and 3' AAV inverted terminal repeats (ITRs). It is this recombinant AAV vector which is packaged into a capsid protein and delivered to a selected target cell. In some embodiments, the transgene is a nucleic acid sequence, heterologous to the vector sequences, which encodes a polypeptide, protein, functional RNA molecule (e.g., miRNA, miRNA inhibitor) or other gene product, of interest. The nucleic acid coding sequence is operatively linked to regulatory components in a manner which permits transgene transcription, translation, and/or expression in a cell of a target tissue.

[0045] The AAV sequences of the vector typically comprise the cis-acting 5' and 3' inverted terminal repeat sequences (See, e.g., B. J. Carter, in "Handbook of Parvoviruses", ed., P. Tijsser, CRC Press, pp. 155 168 (1990)). The ITR sequences are about 145 bp in length. Preferably, substantially the entire sequences encoding the ITRs are used in the molecule, although some degree of minor modification of these sequences is permissible. The ability to modify these ITR sequences is within the skill of the art. (See, e.g., texts such as Sambrook et al, "Molecular Cloning. A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory, New York (1989); and K. Fisher et al., J Virol., 70:520 532 (1996)). An example of such a molecule employed in the present invention is a "cis-acting" plasmid containing the transgene, in which the selected transgene sequence and associated regulatory elements are flanked by the 5' and 3' AAV ITR sequences. The AAV ITR sequences may be obtained from any known AAV, including presently identified mammalian AAV types.

[0046] In addition to the major elements identified above for the recombinant AAV vector, the vector also includes conventional control elements which are operably linked to the transgene in a manner which permits its transcription, translation and/or expression in a cell transfected with the plasmid vector or infected with the virus produced by the invention. As used herein, "operably linked" sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation (polyA) signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (*i.e.*, Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance secretion of the encoded product. A great number of expression control sequences, including promoters which are native, constitutive, inducible and/or tissue-specific, are known in the art and may be utilized.

[0047] As used herein, a nucleic acid sequence (e.g., coding sequence) and regulatory sequences are said to be operably linked when they are covalently linked in such a way as to place the expression or transcription of the nucleic acid sequence under the influence or control of the regulatory sequences. If it is desired that the nucleic acid sequences be translated into a functional protein, two DNA sequences are said to be operably linked if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of

the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably linked to a nucleic acid sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide. Similarly two or more coding regions are operably linked when they are linked in such a way that their transcription from a common promoter results in the expression of two or more proteins having been translated in frame. In some embodiments, operably linked coding sequences yield a fusion protein. In some embodiments, operably linked coding sequences yield a functional RNA (e.g., shRNA, miRNA).

[0048] For nucleic acids encoding proteins, a polyadenylation sequence generally is inserted following the transgene sequences and before the 3' AAV ITR sequence. A rAAV construct useful in the present invention may also contain an intron, desirably located between the promoter/enhancer sequence and the transgene. One possible intron sequence is derived from SV-40, and is referred to as the SV-40 T intron sequence. Another vector element that may be used is an internal ribosome entry site (IRES). An IRES sequence is used to produce more than one polypeptide from a single gene transcript. An IRES sequence would be used to produce a protein that contain more than one polypeptide chains. Selection of these and other common vector elements are conventional and many such sequences are available [see, e.g., Sambrook et al, and references cited therein at, for example, pages 3.18 3.26 and 16.17 16.27 and Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989]. In some embodiments, a Foot and Mouth Disease Virus 2A sequence is included in polypeptide; this is a small peptide (approximately 18 amino acids in length) that has been shown to mediate the cleavage of polypeptides (Ryan, M D et al., EMBO, 1994; 4: 928-933; Mattion, N M et al., J Virology, November 1996; p. 8124-8127; Furler, S et al., Gene Therapy, 2001; 8: 864-873; and Halpin, C et al., The Plant Journal, 1999; 4: 453-459). The cleavage activity of the 2A sequence has previously been demonstrated in artificial systems including plasmids and gene therapy vectors (AAV and retroviruses) (Ryan, M D et al., EMBO, 1994; 4: 928-933; Mattion, N M et al., J Virology, November 1996; p. 8124-8127; Furler, S et al., Gene Therapy, 2001; 8: 864-873; and Halpin, C et al., The Plant Journal, 1999; 4: 453-459; de Felipe, P et al., Gene Therapy, 1999; 6: 198-208; de Felipe, P et al., Human Gene Therapy, 2000; 11: 1921-1931.; and Klump, H et al., Gene Therapy, 2001; 8: 811-817).

[0049] The precise nature of the regulatory sequences needed for gene expression in host cells may vary between species, tissues or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, enhancer elements, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region that includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

[0050] Examples of constitutive promoters include, without limitation, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the β -actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1 α promoter [Invitrogen].

[0051] Inducible promoters allow regulation of gene expression and can be regulated by exogenously supplied compounds, environmental factors such as temperature, or the presence of a specific physiological state, e.g., acute phase, a particular differentiation state of the cell, or in replicating cells only. Inducible promoters and inducible systems are available from a variety of commercial sources, including, without limitation, Invitrogen, Clontech and Ariad. Many other systems have been described and can be readily selected by one of skill in the art. Examples of inducible promoters regulated by exogenously supplied promoters include the zinc-inducible sheep metallothioneine (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system (WO 98/10088); the ecdysone insect promoter (No et al, Proc. Natl. Acad. Sci. USA, 93:3346-3351 (1996)), the tetracycline-repressible system (Gossen et al, Proc. Natl. Acad. Sci. USA, 89:5547-5551 (1992)), the tetracycline-inducible system (Gossen et al, Science, 268:1766-1769 (1995), see also Harvey et al, Curr. Opin. Chem. Biol., 2:512-518 (1998)), the RU486-inducible system (Wang et al, Nat. Biotech., 15:239-243 (1997) and Wang et al, Gene Ther., 4:432-441 (1997)) and the rapamycin-inducible system (Magari et al, J. Clin. Invest., 100:2865-2872 (1997)). Still other types of inducible promoters which may be useful in this context are those which are regulated by a specific physiological state, e.g., temperature, acute phase, a particular differentiation state of the cell, or in replicating cells only.

[0052] In another embodiment, the native promoter, or fragment thereof, for the transgene will be used. The native promoter may be preferred when it is desired that expression of the transgene should mimic the native expression. The native promoter may be used when expression of the transgene must be regulated temporally or developmentally, or in a tissue-specific manner, or in response to specific transcriptional stimuli. In a further embodiment, other native expression control elements, such as enhancer elements, polyadenylation sites or Kozak consensus sequences may also be used to mimic the native expression.

[0053] In some embodiments, the regulatory sequences impart tissue-specific gene expression capabilities. In some cases, the tissue-specific regulatory sequences bind tissue-specific transcription factors that induce transcription in a

tissue specific manner. Such tissue-specific regulatory sequences (*e.g.*, promoters, enhancers, *etc.*) are well known in the art. Exemplary tissue-specific regulatory sequences include, but are not limited to the following tissue specific promoters: neuronal such as neuron-specific enolase (NSE) promoter (Andersen et al., Cell. Mol. Neurobiol., 13:503-15 (1993)), neurofilament light-chain gene promoter (Piccioli et al., Proc. Natl. Acad. Sci. USA, 88:5611-5 (1991)), and the neuron-specific vgf gene promoter (Piccioli et al., Neuron, 15:373-84 (1995)). In some embodiments, the tissue-specific promoter is a promoter of a gene selected from: neuronal nuclei (NeuN), glial fibrillary acidic protein (GFAP), adenomatous polyposis coli (APC), and ionized calcium-binding adapter molecule 1 (Iba-1). Other appropriate tissue specific promoters will be apparent to the skilled artisan. In some embodiments, the promoter is a chicken Beta-actin promoter.

[0054] In some embodiments, one or more bindings sites for one or more of miRNAs are incorporated in a transgene of a rAAV vector, to inhibit the expression of the transgene in one or more tissues of a subject harboring the transgenes, *e.g.*, non-CNS tissues. The skilled artisan will appreciate that binding sites may be selected to control the expression of a transgene in a tissue specific manner. For example, expression of a transgene in the liver may be inhibited by incorporating a binding site for miR-122 such that mRNA expressed from the transgene binds to and is inhibited by miR-122 in the liver. Expression of a transgene in the heart may be inhibited by incorporating a binding site for miR-133a or miR-1, such that mRNA expressed from the transgene binds to and is inhibited by miR-133a or miR-1 in the heart. The miRNA target sites in the mRNA may be in the 5' UTR, the 3' UTR or in the coding region. Typically, the target site is in the 3' UTR of the mRNA. Furthermore, the transgene may be designed such that multiple miRNAs regulate the mRNA by recognizing the same or multiple sites. The presence of multiple miRNA binding sites may result in the cooperative action of multiple RISCs and provide highly efficient inhibition of expression. The target site sequence may comprise a total of 5-100, 10-60, or more nucleotides. The target site sequence may comprise at least 5 nucleotides of the sequence of a target gene binding site.

Transgene Coding Sequences: CNS-Related Genes

[0055] The composition of the transgene sequence of a rAAV vector will depend upon the use to which the resulting vector will be put. For example, one type of transgene sequence includes a reporter sequence, which upon expression produces a detectable signal. In another example, the transgene encodes a therapeutic protein or therapeutic functional RNA. In another example, the transgene encodes a protein or functional RNA that is intended to be used for research purposes, *e.g.*, to create a somatic transgenic animal model harboring the transgene, *e.g.*, to study the function of the transgene product. In another example, the transgene encodes a protein or functional RNA that is intended to be used to create an animal model of disease. Appropriate transgene coding sequences will be apparent to the skilled artisan.

[0056] In some aspects, the invention provides rAAV vectors for use in methods of preventing or treating one or more gene defects (*e.g.*, heritable gene defects, somatic gene alterations) in a mammal, such as for example, a gene defect that results in a polypeptide deficiency or polypeptide excess in a subject, and particularly for treating or reducing the severity or extent of deficiency in a subject manifesting a CNS-associated disorder linked to a deficiency in such polypeptides in cells and tissues. In some embodiments, methods involve administration of a rAAV vector that encodes one or more therapeutic peptides, polypeptides, shRNAs, microRNAs, antisense nucleotides, *etc.* in a pharmaceutically-acceptable carrier to the subject in an amount and for a period of time sufficient to treat the CNS-associated disorder in the subject having or suspected of having such a disorder.

[0057] A rAAV vector may comprise as a transgene, a nucleic acid encoding a protein or functional RNA that modulates or treats a CNS-associated disorder. The following is a non-limiting list of genes associated with CNS-associated disorders: neuronal apoptosis inhibitory protein (NAIP), nerve growth factor (NGF), glial-derived growth factor (GDNF), brain-derived growth factor (BDNF), ciliary neurotrophic factor (CNTF), tyrosine hydroxylase (TH), GTP-cyclohydrolase (GTPCH), aspartoacylase (ASPA), superoxide dismutase (SOD1) and amino acid decarboxylase (AADC). For example, a useful transgene in the treatment of Parkinson's disease encodes TH, which is a rate limiting enzyme in the synthesis of dopamine. A transgene encoding GTPCH, which generates the TH cofactor tetrahydrobiopterin, may also be used in the treatment of Parkinson's disease. A transgene encoding GDNF or BDNF, or AADC, which facilitates conversion of L-Dopa to DA, may also be used for the treatment of Parkinson's disease. For the treatment of ALS, a useful transgene may encode: GDNF, BDNF or CNTF. Also for the treatment of ALS, a useful transgene may encode a functional RNA, *e.g.*, shRNA, miRNA, that inhibits the expression of SOD1. For the treatment of ischemia a useful transgene may encode NAIP or NGF. A transgene encoding Beta-glucuronidase (GUS) may be useful for the treatment of certain lysosomal storage diseases (*e.g.*, Mucopolysaccharidosis type VII (MPS VII)). A transgene encoding a prodrug activation gene, *e.g.*, HSV-Thymidine kinase which converts ganciclovir to a toxic nucleotide which disrupts DNA synthesis and leads to cell death, may be useful for treating certain cancers, *e.g.*, when administered in combination with the prodrug. A transgene encoding an endogenous opioid, such a β -endorphin may be useful for treating pain. Other examples of transgenes that may be used in the rAAV vectors of the invention will be apparent to the skilled artisan (See, *e.g.*, Costantini LC, et al., Gene Therapy (2000) 7, 93-109).

[0058] In some embodiments, the cloning capacity of the recombinant RNA vector may be limited and a desired coding

sequence may involve the complete replacement of the virus's 4.8 kilobase genome. Large genes may, therefore, not be suitable for use in a standard recombinant AAV vector, in some cases. The skilled artisan will appreciate that options are available in the art for overcoming a limited coding capacity. For example, the AAV ITRs of two genomes can anneal to form head to tail concatamers, almost doubling the capacity of the vector. Insertion of splice sites allows for the removal of the ITRs from the transcript. Other options for overcoming a limited cloning capacity will be apparent to the skilled artisan.

Recombinant AAV Administration

[0059] rAAVs are administered in sufficient amounts to transfect the cells of a desired tissue and to provide sufficient levels of gene transfer and expression without undue adverse effects. Conventional and pharmaceutically acceptable routes of administration include, but are not limited to, direct delivery to the selected tissue (e.g., intracerebral administration, intrathecal administration), intravenous, oral, inhalation (including intranasal and intratracheal delivery), intraocular, intravenous, intramuscular, subcutaneous, intradermal, intratumoral, and other parental routes of administration. Routes of administration may be combined, if desired.

[0060] Delivery of certain rAAVs to a subject may be, for example, by administration into the bloodstream of the subject. Administration into the bloodstream may be by injection into a vein, an artery, or any other vascular conduit. Moreover, in certain instances, it may be desirable to deliver the rAAVs to brain tissue, meninges, neuronal cells, glial cells, astrocytes, oligodendrocytes, cerebrospinal fluid (CSF), interstitial spaces and the like. In some embodiments, recombinant AAVs may be delivered directly to the spinal cord or brain by injection into the ventricular region, as well as to the striatum (e.g., the caudate nucleus or putamen of the striatum), and neuromuscular junction, or cerebellar lobule, with a needle, catheter or related device, using neurosurgical techniques known in the art, such as by stereotactic injection (see, e.g., Stein et al., J Virol 73:3424-3429, 1999; Davidson et al., PNAS 97:3428-3432, 2000; Davidson et al., Nat. Genet. 3:219-223, 1993; and Alisky and Davidson, Hum. Gene Ther. 11:2315-2329, 2000). In certain circumstances it will be desirable to deliver the rAAV-based therapeutic constructs in suitably formulated pharmaceutical compositions disclosed herein either subcutaneously, intrapancreatically, intranasally, parenterally, intravenously, intramuscularly, intracerebrally, intrathecally, intracerebrally, orally, intraperitoneally, or by inhalation. In some embodiments, the administration modalities as described in U.S. Pat. Nos. 5,543,158; 5,641,515 and 5,399,363 (each specifically incorporated herein by reference in its entirety) may be used to deliver rAAVs.

Recombinant AAV Compositions

[0061] The rAAVs may be delivered to a subject in compositions according to any appropriate methods known in the art. The rAAV, preferably suspended in a physiologically compatible carrier (e.g., in a composition), may be administered to a subject, e.g., a human, mouse, rat, cat, dog, sheep, rabbit, horse, cow, goat, pig, guinea pig, hamster, chicken, turkey, or a non-human primate (e.g., Macaque). The compositions of the invention may comprise a rAAV alone, or in combination with one or more other viruses (e.g., a second rAAV encoding having one or more different transgenes). In some embodiments, a compositions comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more different rAAVs each having one or more different transgenes.

[0062] Suitable carriers may be readily selected by one of skill in the art in view of the indication for which the rAAV is directed. For example, one suitable carrier includes saline, which may be formulated with a variety of buffering solutions (e.g., phosphate buffered saline). Other exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, and water. The selection of the carrier is not a limitation of the present invention.

[0063] Optionally, the compositions of the invention may contain, in addition to the rAAV and carrier(s), other conventional pharmaceutical ingredients, such as preservatives, or chemical stabilizers. Suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, and parachlorophenol. Suitable chemical stabilizers include gelatin and albumin.

[0064] The dose of rAAV virions required to achieve a desired effect or "therapeutic effect," e.g., the units of dose in vector genomes/per kilogram of body weight (vg/kg), will vary based on several factors including, but not limited to: the route of rAAV administration, the level of gene or RNA expression required to achieve a therapeutic effect, the specific disease or disorder being treated, and the stability of the gene or RNA product. One of skill in the art can readily determine a rAAV virion dose range to treat a subject having a particular disease or disorder based on the aforementioned factors, as well as other factors that are well known in the art. An effective amount of the rAAV is generally in the range of from about 10 μ l to about 100 ml of solution containing from about 10^9 to 10^{16} genome copies per subject. Other volumes of solution may be used. The volume used will typically depend, among other things, on the size of the subject, the dose of the rAAV, and the route of administration. For example, for intrathecal or intracerebral administration a volume in range of 1 μ l to 10 μ l or 10 μ l to 100 μ l may be used. For intravenous administration a volume in range of 10 μ l to 100 μ l, 100 μ l to 1 ml, 1 ml to 10 ml, or more may be used. In some cases, a dosage between about 10^{10} to 10^{12} rAAV

genome copies per subject is appropriate. In certain embodiments, 10^{12} rAAV genome copies per subject is effective to target CNS tissues. In some embodiments the rAAV is administered at a dose of 10^{10} , 10^{11} , 10^{12} , 10^{13} , 10^{14} , or 10^{15} genome copies per subject. In some embodiments the rAAV is administered at a dose of 10^{10} , 10^{11} , 10^{12} , 10^{13} , or 10^{14} genome copies per kg.

[0065] In some embodiments, rAAV compositions are formulated to reduce aggregation of AAV particles in the composition, particularly where high rAAV concentrations are present (e.g., $\sim 10^{13}$ GC/ml or more). Methods for reducing aggregation of rAAVs are well known in the art and, include, for example, addition of surfactants, pH adjustment, salt concentration adjustment, etc. (See, e.g., Wright FR, et al., *Molecular Therapy* (2005) 12, 171-178, the contents of which are incorporated herein by reference.)

[0066] Formulation of pharmaceutically-acceptable excipients and carrier solutions is well-known to those of skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens. Typically, these formulations may contain at least about 0.1% of the active ingredient or more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 70% or 80% or more of the weight or volume of the total formulation. Naturally, the amount of active ingredient in each therapeutically-useful composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.

[0067] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. In many cases the form is sterile and fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0068] For administration of an injectable aqueous solution, for example, the solution may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, a sterile aqueous medium that can be employed will be known to those of skill in the art. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the host. The person responsible for administration will, in any event, determine the appropriate dose for the individual host.

[0069] Sterile injectable solutions are prepared by incorporating the active rAAV in the required amount in the appropriate solvent with various of the other ingredients enumerated herein, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0070] The rAAV compositions disclosed herein may also be formulated in a neutral or salt form. Pharmaceutically-acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as injectable solutions, drug-release capsules, and the like.

[0071] As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids,

and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Supplementary active ingredients can also be incorporated into the compositions. The phrase "pharmaceutically-acceptable" refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a host.

[0072] Delivery vehicles such as liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, and the like, may be used for the introduction of the compositions of the present invention into suitable host cells. In particular, the rAAV vector delivered *transgenes* may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, or a nanoparticle or the like.

[0073] Such formulations may be preferred for the introduction of pharmaceutically acceptable formulations of the nucleic acids or the rAAV constructs disclosed herein. The formation and use of liposomes is generally known to those of skill in the art. Recently, liposomes were developed with improved serum stability and circulation half-times (U.S. Pat. No. 5,741,516). Further, various methods of liposome and liposome like preparations as potential drug carriers have been described (; U.S. Pat. Nos. 5,567,434; 5,552,157; 5,565,213; 5,738,868 and 5,795,587).

[0074] Liposomes have been used successfully with a number of cell types that are normally resistant to transfection by other procedures. In addition, liposomes are free of the DNA length constraints that are typical of viral-based delivery systems. Liposomes have been used effectively to introduce genes, drugs, radiotherapeutic agents, viruses, transcription factors and allosteric effectors into a variety of cultured cell lines and animals. In addition, several successful clinical trials examining the effectiveness of liposome-mediated drug delivery have been completed.

[0075] Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs)). MLVs generally have diameters of from 25 nm to 4 μ m. Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 \AA , containing an aqueous solution in the core.

[0076] Alternatively, nanocapsule formulations of the rAAV may be used. Nanocapsules can generally entrap substances in a stable and reproducible way. To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 μ m) should be designed using polymers able to be degraded *in vivo*. Biodegradable polyalkylcyanoacrylate nanoparticles that meet these requirements are contemplated for use.

[0077] In addition to the methods of delivery described above, the following techniques are also contemplated as alternative methods of delivering the rAAV compositions to a host. Sonophoresis (ie., ultrasound) has been used and described in U.S. Pat. No. 5,656,016 as a device for enhancing the rate and efficacy of drug permeation into and through the circulatory system. Other drug delivery alternatives contemplated are intraosseous injection (U.S. Pat. No. 5,779,708), microchip devices (U.S. Pat. No. 5,797,898), ophthalmic formulations (Bourlais et al., 1998), transdermal matrices (U.S. Pat. Nos. 5,770,219 and 5,783,208) and feedback-controlled delivery (U.S. Pat. No. 5,697,899).

Kits and Related Compositions

[0078] The agents described herein may, in some embodiments, be assembled into pharmaceutical or diagnostic or research kits to facilitate their use in therapeutic, diagnostic or research applications. A kit may include one or more containers housing the components of the invention and instructions for use. Specifically, such kits may include one or more agents described herein, along with instructions describing the intended application and the proper use of these agents. In certain embodiments agents in a kit may be in a pharmaceutical formulation and dosage suitable for a particular application and for a method of administration of the agents. Kits for research purposes may contain the components in appropriate concentrations or quantities for running various experiments.

[0079] The kit may be designed to facilitate use of the methods described herein by researchers and can take many forms. Each of the compositions of the kit, where applicable, may be provided in liquid form (e.g., in solution), or in solid form, (e.g., a dry powder). In certain cases, some of the compositions may be constitutable or otherwise processable (e.g., to an active form), for example, by the addition of a suitable solvent or other species (for example, water or a cell culture medium), which may or may not be provided with the kit. As used herein, "instructions" can define a component of instruction and/or promotion, and typically involve written instructions on or associated with packaging of the invention. Instructions also can include any oral or electronic instructions provided in any manner such that a user will clearly recognize that the instructions are to be associated with the kit, for example, audiovisual (e.g., videotape, DVD, etc.), Internet, and/or web-based communications, etc. The written instructions may be in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which instructions can also reflect approval by the agency of manufacture, use or sale for animal administration.

[0080] The kit may contain any one or more of the components described herein in one or more containers. As an example, in one embodiment, the kit may include instructions for mixing one or more components of the kit and/or isolating and mixing a sample and applying to a subject. The kit may include a container housing agents described herein. The agents may be in the form of a liquid, gel or solid (powder). The agents may be prepared sterilely, packaged in syringe and shipped refrigerated. Alternatively it may be housed in a vial or other container for storage. A second

container may have other agents prepared sterilely. Alternatively the kit may include the active agents premixed and shipped in a syringe, vial, tube, or other container. The kit may have one or more or all of the components required to administer the agents to a subject, such as a syringe, topical application devices, or IV needle tubing and bag.

EXAMPLES

EXAMPLE 1: Characterization of 12 AAV vectors for intravascular delivery to target CNS and detarget non-CNS tissues by miRNA regulation

[0081] The CNS gene transfer properties of 12 scAAVEGFP vectors of different serotypes, or natural variants were evaluated. RAAVs that cross the blood-brain-barrier (BBB) and target oligodendrocytes were discovered. Experiments were performed in neonatal mice (1 day old) and in adult mice (10 week old) (C57BL/6). The following AAV serotypes were tested: AAV1, AAV2, AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, rh.10 (also referred to herein as AAVrh.10), rh.39, rh.43, CSp3.

[0082] The recombinant AAV vectors expressed an enhanced GFP reporter gene under the CMV-enhanced chicken β -actin hybrid promoter and were produced by transient transfection in 293 cells. The neonatal day 1 pups were anesthetized with isoflurane. Then 100 μ L of rAAV vectors (4×10^{11} GC per mouse) was injected to the pups via superficial temporal vein under a dissection microscope. In adult mice, rAAV was administered by tail vein injection (two different doses were evaluated 4×10^{11} GC per mouse or 4×10^{12} GC per mouse). Twenty-one days post injection, the treated animals were anesthetized and transcardially perfused with cold PBS and 4% (v/v) paraformaldehyde. Brains were extracted, immersed in 20% sucrose, and embedded in Tissue-Tek OCT. 40 μ m thick sections were cut and stained in 12-well plate with primary antibodies, e.g., anti-NeuN, anti-EGFP and anti-GFAP, overnight at 4°C, then with secondary antibodies for 2 h at room temperature. Control mice received PBS injections.

[0083] In the neonatal study, the distribution of EGFP (+) cells throughout the brain at 3 wks post-infusion was observed. Large numbers of EGFP (+) cells with variable intensities were visible in different regions of the brains from the animals treated with 10 out of 12 vectors. In many instances the choroid plexus showed very strong EGFP expression, and transduced brain parenchyma cells appeared predominantly in periventricular regions. This indicates that a fraction of IV delivered vectors may enter the CNS via the choroid plexus-blood interface. In adults, substantial staining of brain vasculature was observed. Overall targeting efficiencies by AAVs to different regions of the brain was ranked as hypothalamus > medulla > cortex > hippocampus > cerebellum > thalamus. EGFP expression was not detected at high levels in neonatal mice that were administered rAAV2 or rAAV5 harboring the EGFP reporter gene by injection of 4×10^{11} GC per mouse in the superficial temporal vein. (See Table 1 and Figures 1 and 2 for summary data).

[0084] Tissue sections were also immunofluorescently stained with anti-EGFP and -cell type specific marker antibodies to classify EGFP (+) cell types in the CNS. Detection sensitivity for EGFP (+) cells, particularly neurons and oligodendrocytes, was improved dramatically. Although different vectors transduced neurons at variable efficiencies, all 10 vectors (including AAV9) exhibited stronger tropisms to non-neuronal cells, especially astrocytes. One vector (AAV7) targeted oligodendrocytes more efficiently than the other 9 vectors. Several rAAVs transduced both neurons and/or astrocytes at higher efficiencies as compared to AAV9 (AAVrh.10, rh.34, and rh.43). Extensive astrocyte transduction was observed in hypothalamus and medulla. Injection of certain vectors resulted in substantial neuron transduction in different regions of the brain, including neocortex, hippocampus, and hypothalamus. Some vectors appeared to transduce Purkinje cells in cerebella cortex (e.g., CSp3), while others effectively transduced blood vessel in neocortex, thalamus and hypothalamus. In addition, choroid plexuses in 3rd ventricle, lateral ventricle and 4th ventricle showed strong EGFP expression. EGFP expression was also evaluated in different spinal cord regions of neonatal and adult mice (results for neonatal studies are shown in Figure 3).

[0085] Transduction of non-CNS tissues such as heart and skeletal muscle was observed (e.g., for AAV9, AAV8, and CSp3). In some cases, this may lead to some undesirable side effects. To address this issue, miRNA binding sites were incorporated into the 3' UTR of the transgene cassette and achieved highly specific and effective detargeting of AAV transduction from non-CNS tissues. To inhibit expression in liver, miRNA binding(s) for mR-122 were used. To inhibit expression in skeletal muscle and heart, miRNA binding(s) for mR-1 were used.

Table 1: AAV CNS TROPISMS

		AAV1	AAV2	AAV5	AAV6	AAV6.2	AAV7	AAV8	AAV9	rh.10	rh.39	rh.43	CSp3
5	Adult	Cortex	+		+	+	++	++	+++	++	+	-	+
		Hippocampus	+		+	+	++	++	+++	++	+	-	+
		Thalamus	+		+	+	++	++	++++	+++	++	+	+
		Hypothalamus	+		++	+	+++	++	++	+++	+++	+	++
		Cerebellum	+		++	+	++	+++	+++	++++	+	+	+
		Brain Stem	+		++	+	++	++	++++	+++	++	-	+
		Cervical	+++		+	+	+++	+++	++++	+++	+++	-	+
		Thoracic	+++		+	+	+++	+++	++++	+++	++	-	+
		Lumbar	+++		+	+	+++	+++	+++++	+++	++	-	+
10	Neo-Natal	Cortex	++	+	-	++	+	++	++	++	++	++	++
		Hippocampus	+	+	-	-	+++	++	+	+	++	++	+
		Thalamus	+	+	-	-	++	+	+	+	++	+	+
		Hypothalamus	++	-	-	+	+++++	+++++	+	+	+++++	+++	-
		Cerebellum	++	-	-	+	+	+	+	+	++	+	+
		Brain Stem	++	-	-	+	++	+	+	+	+++++	+++	+++
		Cervical	-	-	-	+	++	+++	++	+++++	++++	+++	++
		Thoracic	+	-	-	+	++	++	++	++	++++	+++	+
		Lumbar	+	-	-	+	++	+	+	++	+++	+++	+

Extent of Tissue Tropism (- no tropism; +++++ high tropism) Based on Data in Figures 1 and 2.

Example 2: Construction and evaluation of a recombinant AAVrh.10 vector to treat CD

[0086] Canavan disease (CD) is an inherited neurodegenerative disorder caused by mutations in the aspartoacylase gene (ASPA), leading to accumulation of N-acetyl-aspartic acid (NAA) in oligodendrocytes with resultant spongy degeneration of white matter in the brain. An initial clinical study on rAAV2-based ASPA gene therapy for CD achieved very limited success. It is believed, without wishing to be bound by theory, that an effective CD gene therapy will transduce oligodendrocytes throughout the CNS.

[0087] A rAAV vector is constructed that comprises a promoter operably linked with a region encoding ASPA protein (SEQ ID NO: 13 or 15) as a gene therapy vector for CD. The construct employs CAG (chicken β -actin promoter with CMV enhancer) to drive the expression of ASPA having a coding sequence as set forth in SEQ ID NO: 14 or 16. The rAAV vector is packaged into rAAV particles using the triple transfection method. To evaluate its effectiveness, rAAV-ASPA is examined in an ASAP knock-out mouse model of CD for its ability to eliminate or attenuate the CD-like phenotypic of homozygous ASPA knock-out mice (Matalon R et al. The Journal of Gene Medicine, Volume 2 Issue 3, Pages 165 - 175). Homozygous ASPA knock-out mice exhibit neurological impairment, macrocephaly, generalized white matter disease, deficient ASPA activity and high levels of NAA in urine. Magnetic resonance imaging (MRI) and spectroscopy (MRS) of the brain of the homozygous mice show white matter changes characteristic of Canavan disease and elevated NAA levels. Heterozygous ASPA knock-out mice, which have no overt phenotype at birth, serve as controls.

Example 3: Therapeutic Efficacy and Safety Evaluation of an AAV vector to treat CD

[0088] The mouse model of CD is a C57BL/6 derived ASPA gene KO strain. The homozygous KO animals present biochemical and neurological defects similar to those observed in CD patients. CD mice provide an animal model for evaluating gene therapy and other therapeutics for the treatment of CD. CD mice are used to study the efficacy and safety of the novel gene therapy strategies for the treatment of CD.

Experiment design

[0089] To examine therapeutic efficacy and safety, scAAV vectors (e.g., AAV7, AAV8, CSp3 and AAV9) carrying an optimized ASPA expression cassette are investigated in a preclinical gene therapy trial of CD. The vectors include miRNA binding site(s) to inhibit ASPA expression in non-CNS tissues. Both postnatal day-1 and 3-month-old adult animals are treated with each vector at two doses, 1 and 3×10^{14} GC/kg by intravenous administration. For the neonatal CD mice, two litters of animals receive each vector at each dose via temporal vein injections for necropsy of one litter each at 1- and 3-month time points. For the 3-month-old adult CD mice, 12 male animals are treated with each vector at each dose via tail vein injections. Six each of the treated animals are necropsied 1 and 3 months later. In further experiments, both postnatal day-1 and 3-month-old adult animals are treated with vectors at a dose in a range of 10^{11}

to 10^{12} GC/subject by direct intraventricular administration.

Functional and neurological measurements during the live phase of the study

[0090]

1). NAA metabolism. Urine samples are collected from the treated, untreated control, and wild type animals at days 14, 30, 45, 60, 75, and 90. The samples are analyzed by HPLC to determine the NAA levels.

2). NAA accumulation and NAA-induced water retention in brain. MRI/MRS-based neuroimaging studies are performed on the live animals in all study groups at 1, 2, and 3 months after the vector treatment to measure spectral peak integrals for creatine/phosphocreatine and NAA as well as abnormal hyperintense areas in the brain.

3). Liver function tests. Serum samples are collected from the animals in all study groups at days 14, 30, 60, and 90 to measure the levels of alanine transaminase (ALT) and aspartate aminotransferase (AST) as indicators of vector-related liver toxicity.

4). Neurological tests. Tremors, walking with splayed legs at a slow and shaky pace, and ataxia are among the prominent neurological features of the CD mice. At 1, 2, and 3 months after the gene therapy treatment, the animals in all study groups are subjected to a walking-pattern analysis by staining their feet with color ink and then recording their walking patterns as footprints on white paper. The animals also are tested and scored on a rotarod test for their ability to maintain balance.

Enzymatic and histopathological analyses at the endpoints of the study

[0091]

1). ASPA activities in the brain and non-CNS tissues. On-target and off-target expression of ASPA are analyzed by collecting brain, liver, heart and pancreatic tissues at necropsy to measure ASAP activities in the respective tissue homogenates.

2). Brain white matter and liver pathologies. To examine potential improvement in brain white-matter pathology and vector-related liver toxicity resulting from the gene therapy, brain and liver tissues are harvested and fixed, paraffin-embedded and sectioned, and stained with hematoxylin and eosin. Histopathological examination is performed by a pathologist.

Example 4: Delivery of therapeutic genes to the CNS cells by AAVrh.10

[0092] A screen of different AAV serotypes, was developed to identify candidates for a therapeutic gene transfer to the CNS. A recombinant AAV vector was constructed that expresses EGFP. The rAAV vector was packaged into four different AAVs: AAV1, 8, 9 and 10. Adult mice were injected with the AAVs into the CSF in the lumbar position. AAV1, 8 and 9 transduced cells only in the vicinity of the injection site at the lumbar region of the spinal cord following administration of $\sim 4.8 \times 10^{10}$ particles. Surprisingly, AAVrh.10 transduced cells in the gray matter along the entire spinal cord and brainstem following the same injection protocol and dosage as AAV1, AAV8 and AAV9 (Fig. 4A). Recently, AAV9 has been shown to cross the blood brain barrier (BBB) and transduce spinal cord cells after intravenous injection. A weak signal was observed in the cerebellum and strong signals in the brainstem and spinal cord. A weak signal (similar to the cerebellum) in the forebrain was also observed. Without wishing to be bound by theory, it is believed that CSF flow and diffusion allows the virus spread along the entire spinal cord, but that the ability of a virus to flow and diffuse depends on the structure of the viral capsid. The transduced cell types include neurons and oligodendrocytes. But the majority appears to be astrocytes (Fig. 4B), as indicated by overlap of EGFP with GFAP-positive cells. Substantial overlap with the microglia marker, Iba-1 was not observed. A number of motor neurons were transduced as indicated by overlap of EGFP expression and NeuN staining. It was surprising that among the astrocytes, only those situated in the gray matter were transduced and those that were situated in the white matter and beneath the pia matter were not transduced. This was striking because the virus is likely to be exposed to astrocytes in these areas since it was administered in the subarachnoid space.

Example 5: Construction of a recombinant AAVrh.10 vector to treat ALS

[0093] An recombinant AAV system was developed as a treatment for ALS. A rAAVrh. 10 vector was constructed that expresses a microRNA targeting SOD1 (Figure 5A). This microRNA was identified as miR-SOD1. The construct employed CAG (chicken β -actin promoter with CMV enhancer) to drive the expression of EGFP and miR-SOD1 that was located in an intron in the 3'-UTR.

[0094] The silencing potency of 9 miRNA constructs was evaluated. The constructs were transfected into HEK293 cells. After 48 hours, RNA was isolated and Northern blot was carried out to detect SOD1 mRNA (Figure 5B). MiR-SOD1#5 (SEQ ID NO: 26) silenced SOD1 expression most potently. Next, miR-SOD1#5 was packaged into AAVrh.10 (Figure 5D), which was used to infect HEK293 cells. Total cellular protein was extracted 43 hours after the infection and blotted to detect SOD1 (Figure 5C). Inhibition of expression of SOD1 at the protein level was observed.

Example 6: Delivery of therapeutic genes to the CNS cells to treat ALS

[0095] Large batches of AAVrh.10-miR-SOD1 and AAVrh.10-miR-Scr (scrambled miRNA) were produced using standard techniques. Self-complementary AAV (scAAV) was made because it mediates transduction with higher efficiency than conventional single stranded AAV [14]. A scAAVrh.10 was tested and found to express EGFP more rapidly (within 1 week) and stronger than a single stranded AAV.

[0096] AAVrh.10-miR-SOD1 was administered to one group of G93A mice (high SOD1 expressers) and AAVrh.10-miR-Scr to another group of G93A mice (n=15). The AAVrh.10 was injected intrathecally into the CSF in the lumbar area and injected intraventricularly into the forebrain in mice of 60 days of age ($\sim 4.8 \times 10^{10}$ particles in 8ul).

[0097] The animals were allowed to live their natural lifespan before succumbing to ALS. The lifespan was compared between the two groups. It was found that mice receiving the AAVrh.10-miR-SOD1 virus, which expresses a SOD1miR5 (SEQ ID NO: 26), lived on average 135 days (± 14 days), whereas mice receiving the AAVrh.10-miR-Scr, which expresses a scrambled miRNA (SEQ ID NO: 31), lived on average 122 days (± 6 days) (Figure 6B). Moreover, by examining the extent of EGFP expression in cervical, thoracic, and lumbar spinal cord tissue, a correlation in the levels of expression in these tissues, particularly with cervical tissue, and lifespan was observed in AAVrh.10-miR-SOD1 treated mice (Figure 7A), but not AAVrh.10-miR-Scr treated mice (Figure 7B). These results suggest that silencing mutant SOD1 expression in the cervical spinal cord is particularly beneficial in extending survival. A subset of the animals from each group were perfused with fixative, sectioned and stained for SOD1 in the spinal cord. SOD1 was detected using standard techniques [9]. SOD1 staining intensity in EGFP expressing cells was reduced compared with the non-EGFP cells that are transduced with AAVrh.10-miR-SOD1 (Figure 6A, showing knockdown of SOD1 expression in astrocytes). Reduction of expression of SOD1 was not observed in cells transduced with AAVrh.10-miR-Scr.

[0098] Tissues from another subset of animals in both groups were dissected to estimate transduction levels. The levels of transduction were estimated by determining the viral genome content using PCR on DNA samples obtained from different CNS and non-CNS regions. Measurements in non-CNS tissues (e.g. liver) provided an indication of whether virus had leaked to the periphery. Northern and Western analysis was performed to measure the SOD1 levels in the spinal cord. The antibody used for SOD1 detection was polyclonal, sheep anti-human SOD1, by Biodesign International, catalog#K90077C.

Example 7: Combined Intrathecal/Intraventricular Administration Protocol

[0099] AAV viruses were injected into mouse CSF by lumbar intrathecal injection and/or brain third ventricle injection. Injection into mice lumbar subarachnoid space was carried out using a method modified from Wu et al. [22]. A thin catheter (about 5cm) was made by stretching PE10 tube to the inner diameter 0.12 mm. The stretched section was cut to 1.7 to 1.9 mm, and two beads (1 mm apart) were made between the thin and the thick sections by heating and pressing the tube. To implant the catheter, the mouse was anesthetized by injection of Avertin (1.2% 2,2,2-tribromoethanol in 2% tert-amyl alcohol and PBS) intraperitoneally at 0.23 ml/10 g of body weight [23]. The catheter was then implanted between the L5 and L6 vertebra. The catheter was stitched to the surface muscle at the beaded area. Viruses of dose from $4.80\text{E}+10$ Genome Copy (for virus screening, in 6ul) to $2.40\text{E}+10$ Genome copy (for therapy, in 8ul) were injected via the catheter by a Hamilton syringe at a speed of 2 ul/minute. The catheter was sealed at the end by heat and left in place for one day. Wound was closed by clips. Injection into brain third ventricle was carried out using a Stoelting Stereotaxic Instrument and micro-injection pumps from World Precision Instruments following standard stereotaxic procedure. Same doses of virus were injected into the third ventricle at a rate of 1 ul/minutes.

[0100] Estimated doses for human and monkeys and comparison with IV injection are shown below. The two types of monkey are similar in size.

Table 2 - Estimated Doses for Human and Monkeys

Species	Avg CSF ml	Estimated CSF production rate ml/hour	Estimate dose (GC)	particles/g of body weight
mouse	0.035	0.018	$2.40\text{E}+10$	$1.2\text{E}+09$

(continued)

Species	Avg CSF ml	Estimated CSF production rate ml/hour	Estimate dose (GC)	particles/gofbody weight
human	140	21	9.6E+13	1.3E+09
Macaca mulatta (rhesus monkeys)	14	2.5	9.6E+12	1.7E+09
Macaca fascicularis (cynomolgus macaque)	See, Foust KD, et al., Nature Biotechnology, Volume 28, Number 3, March 2010, 271-274		1.00E+14	2.20E+11

References for Background and Examples 1-7**[0101]**

1. Daya S, Berns KI: Gene Therapy Using Adeno-Associated Virus Vectors. Clin Microbiol Rev 2008, 21:583-593.
2. Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, Aminoff MJ: Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008, 70:1980-1983.
3. Feigin A, Kaplitt MG, Tang C, Lin T, Mattis P, Dhawan V, Durr MJ, Eidelberg D: Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proceedings of the National Academy of Sciences 2007, 104:19559-19564.
4. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL, Windsor EAM, Conlon TJ, Sumaroka A, Pang J-j, et al: Human RPE65 Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 Year. Hum Gen Ther, 0.
5. Raoul C, Abbas-Terki T, Bensadoun J-C, Guillot S, Haase G, Szulc J, Henderson CE, Aebischer P: Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005, 11:423-428.
6. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH: Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model. Science 2003, 301:839-842.
7. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, Carmeliet P, Mazarakis ND: VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004, 429:413-417.
8. Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, Lee DCP, Wong L-F, Bilsland LG, Greensmith L, Kingsman SM, et al: Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005, 11:429-433.
9. Wu R, Wang H, Xia X, Zhou H, Liu C, Castro M, Xu Z: Nerve Injection of Viral Vectors Efficiently Transfers Transgenes into Motor Neurons and Delivers RNAi Therapy Against ALS. Antioxidants & Redox Signaling 2009, 11:1523-1534.
10. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK: Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009, 27:59-65.
11. Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, Fyfe J, Moullier P, Colle MA, Barkats M: Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009, 17:1187-1196.
12. Vandenberghe LH, Wilson JM, Gao G: Tailoring the AAV vector capsid for gene therapy. Gene Ther 2009, 16:311-319.
13. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, Gilmore BL, Burstein H, Peluso RW, Polisky B, et al: Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi. Proceedings of the National Academy of Sciences 2008, 105:5868-5873.
14. McCarty DM: Self-complementary AAV Vectors; Advances and Applications. Mol Ther 2008, 16:1648-1656.
15. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW: Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006, 312:1389-1392.
16. Xia X, Zhou H, Huang Y, Xu Z: Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol Dis 2006, 23:578-586.
17. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, Takahashi R, Misawa H, Cleveland DW: Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat

Neurosci 2008, 11:251253.

18. Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K: Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. *Nat Neurosci* 2007, 10:608-614.

19. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, Przedborski S: Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. *Nat Neurosci* 2007, 10:615-622.

20. Wang Y, Ou Mao X, Xie L, Banwait S, Marti HH, Greenberg DA, Jin K: Vascular Endothelial Growth Factor Overexpression Delays Neurodegeneration and Prolongs Survival in Amyotrophic Lateral Sclerosis Mice. *J Neurosci* 2007, 27:304-307.

21. Storkebaum E, Lambrechts D, Dewerchin M, Moreno-Murciano M-P, Appelmans S, Oh H, Van Damme P, Rutten B, Man WY, De Mol M, et al: Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. *Nat Neurosci* 2005, 8:85-92.

22. Wu, W. P., Xu, X. J., and Hao, J. X. (2004) *J. Neurosci. Methods* 133, 65-69

23. Papaioannou, V. E., and Fox, J. G. (1993) *Lab. Anim. Sci.* 43, 189-192

Example 8. MicroRNA-regulated, Systemically Delivered rAAV9

Introduction to the Example

[0102] This example involves the use of tissue-specific, endogenous microRNAs (miRNAs) to repress rAAV expression outside the CNS, by engineering perfectly complementary miRNA-binding sites into the rAAV9 genome. The example describes recombinant adeno-associated viruses (rAAVs) that can cross the blood-brain-barrier and achieve efficient and stable transvascular gene transfer to the central nervous system (CNS), while de-targeting certain other tissues (e.g., liver, heart, skeletal muscle and other tissues) The approaches described in this example allowed simultaneous multi-tissue regulation and CNS-directed stable transgene expression without detectably perturbing the endogenous miRNA pathway. Regulation of rAAV expression by miRNA was primarily via site-specific cleavage of the transgene mRNA, generating specific 5' and 3' mRNA fragments.

[0103] Gene transfer mediated by recombinant adeno-associated virus (rAAV), as disclosed herein, is useful for treatment of a large number of neurological disorders. It has been found that rAAV vectors disclosed herein cross the blood-brain barrier and are specifically expressed in the CNS. Thus, the vectors may be used for intravascular delivery of rAAV for gene therapy of CNS diseases, including those that affect large areas of the brain and spinal cord.

[0104] This example describes the use of endogenous microRNAs (miRNAs) to suppress transgene expression outside the CNS. miRNAs are small, noncoding RNAs that regulate gene expression by post-transcriptional silencing. In general, miRNAs may silence genes by two mechanisms. When partially complementary to mRNA sequences, they typically reduce target mRNA stability and protein expression (e.g., by two- to fourfold or less), a mode of regulation thought to tune mRNA expression. In contrast, when miRNAs are nearly perfectly complementary to their mRNA targets, they typically bring about cleavage of the mRNA, triggering its wholesale destruction.

[0105] In particular, this example describes the use of miRNAs to detarget rAAV9 expression both separately and concurrently in the liver, heart, and skeletal muscle, the three tissues that are most efficiently targeted by intravenously delivered rAAV9. Silencing of transgene expression in liver, heart, and muscle exploited the natural expression of the abundant ($\geq 60,000$ copies/cell) miRNAs, miR-122, which is expressed in hepatocytes, and miR-1, a miRNA found in the heart and skeletal muscle of virtually all animals. miR-122-binding sites have been successfully used to prevent hepatotoxicity of a transgene from an adenovirus vector. Perfectly complementary sites for miR-1, miR-122, or both were engineered into the 3' untranslated region (UTR) of a nuclear-targeted, β -galactosidase (*nLacZ*) reporter transgene whose expression was driven by a cytomegalovirus-enhancer, chicken β -actin (CB) promoter. This example presents multiple independent results indicating that the miRNAs repress *nLacZ* expression by cleaving the transgene mRNA at exactly the same site as by all Argonaute-bound small RNAs in eukaryotic cells. When delivered systemically *in vivo*, the miRNA-detargeted rAAV9 vector successfully expressed the reporter transgene in the CNS, but not the liver or heart or skeletal muscle.

Results

miRNAs efficiently repress reporter gene expression in cultured cells

[0106] To evaluate a strategy for rAAV-mediated transduction, one or three tandem copies of a perfectly complementary binding site for miR-1 or miR-122 were introduced into the 3' UTR of *nLacZ* in a rAAV plasmid vector. The constructs were transfected into HuH7 cells, a human hepatoma cell line expressing $\sim 16,000$ copies of miR-122 per cell, and measured the number of *nLacZ*-positive cells. The number of *nLacZ*-expressing HuH7 cells for the one-site plasmid was about half that of the no site control; three sites reduced the number of *nLacZ*-expressing cells more than sevenfold

(Figure 12a).

[0107] Next, expression of the *nLacZ* constructs was analyzed in human embryonic kidney 293 cells, which naturally express low levels of both miR-122 and miR-1, when miR-1 or miR122 was introduced as a pri-miRNA from a second plasmid. 293 cells were transfected with the *nLacZ* reporter plasmids carrying 0, 1, or 3 miR-122 or miR-1-binding sites, together with a plasmid expressing either pri-miR-122 (Figure 12b) or pri-miR-1 (Figure 12c). To vary the concentration of the miRNA, either a low (1:3) or a high (1:10) molar ratio of the *nLacZ*-binding site plasmid to the miRNA expression plasmid was used. When miR-122 or miR-1 was introduced into the cells, *nLacZ* expression was repressed only when the *nLacZ* reporter mRNA contained the corresponding miRNA-binding sites; there was no reduction of nLacZ-positive cells when miR-1 was coexpressed with *nLacZ* containing miR-122-binding sites or when miR-122 was coexpressed with *nLacZ* containing miR-1-binding sites (Figure 12b,c).

Tissue-specific endogenous miRNAs regulate expression of rAAV9 delivered systemically in adult mice

[0108] To evaluate miRNA regulation of systemically delivered AAV9CBn*LacZ* vectors *in vivo*, AAV9CBn*LacZ* vectors carrying 0, 1, or 3 miRNA-binding sites perfectly complementary to either miR-122 or miR-1 were produced. The vectors were administered by tail vein injection to adult male C56BL/6 mice at a dose of 5×10^{13} genome copies per kg (GC/kg) body weight. Four weeks later, the liver and heart of the transduced animals were examined. LacZ staining revealed that the *nLacZ* transgene was silenced by the endogenous miRNAs in the cell type and organ in which they are predominantly expressed: the transgene was specifically silenced by miR-122 in the liver and by miR-1 in the heart (Figure 13a,b). While nLacZ positive cells were reduced in the livers of the animals treated with rAAV9CBn*LacZ* bearing one or three miR-122-binding sites, nLacZ expression levels in the hearts of the same animals were similar to those in the animals treated with AAV9CBn*LacZ* bearing no sites (Figure 13a). Similarly, nLacZ expression was not detected in the hearts of the animals that received AAV9CBn*LacZ* containing one or three miR-1-binding sites, but nLacZ expression in the livers of the same animals was not affected as compared to that in the control animal (Figure 13b). These data suggest that the greater the number of sites for a miRNA in rAAV, the lower the nLacZ expression in the tissue where the corresponding miRNA was expressed (Figure 13a,b).

[0109] Next, to evaluate whether transgene silencing could be achieved simultaneously in multiple tissues, different numbers of both miR-122- and miR-1-binding sites were inserted in the 3' UTR of the rAAV9CBn*LacZ* genome and examined for their expression in rAAV9 transduced mice. Histochemical staining of tissue sections showed that nLacZ expression was suppressed in both heart and liver for rAAV9CBn*LacZ* containing one or three copies each of the miR-1- and miR-122-binding sites, but nLacZ was readily detectable in pancreas, where expression of both miR-122 and miR-1 was low (Figure 13c). Quantitative, β -galactosidase assays of homogenized liver tissue similarly showed that nLacZ expression was significantly lower when the transgene contained the miRNA-binding sites (one miR-122-binding site: $7.8 \pm 7.4\%$, P value = 0.005; three miR-122-binding sites: $1.6 \pm 1.0\%$, P value = 0.005; one miR-1- plus one miR-122-binding site: $8.6 \pm 5.7\%$, P value = 0.005; three miR-1-plus three miR-122- binding sites: $3.1 \pm 1.2\%$, P value = 0.005; three miR-1-binding sites: $105.7 \pm 11.6\%$) (Figure 13d).

miRNA repression of rAAV expression does not perturb endogenous miRNA pathways

[0110] Highly expressed transgenes bearing miRNA-complementary sites have been reported to promote degradation of the corresponding miRNA. The levels of miR-122, miR-22, miR-26a, and *let-7* were determined in rAAV transduced liver. No difference in abundance of the four miRNAs was detected among the three study groups (Figure 14a). Moreover, data from high throughput sequencing analyses of small RNA from the livers of one animal each from the three study groups show no change in miRNA levels.

[0111] In order to determine whether the miRNA-binding sites in the transgene transcripts would deregulate the expression of the known endogenous target mRNAs of miR-122 or miR-1, the expression of cyclin G1, a miR-122 target in liver (Figure 14b,c) and calmodulin, a miR-1 target in heart (Figure 14d) were analyzed. No significant alteration in cyclin G1 or calmodulin expression was detected. miR-122 regulates cholesterol biosynthesis in the liver, and agents that block miR-122 function may produce readily detectable changes in serum cholesterol levels. No change in total cholesterol, high-density lipoprotein, or low-density lipoprotein levels was detected in mice 4 weeks after transduction with either control rAAV9 or rAAV9 expressing a transgene bearing miR-122-binding sites (Figure 14e). It was concluded that in this example miRNA-mediated detargeting of rAAV expression had no detectable effect on endogenous miRNA expression or function.

Endogenous miRNAs silence rAAV transduction by site-specific cleavage of transgene mRNA

[0112] To determine how miRNAs suppress expression of transgenes delivered by rAAV *in vivo*, the transgene mRNA in liver was characterized by conventional PCR (Figure 15b), quantitative reverse transcription PCR (qRT-PCR) (Figure

15c), Northern hybridization (Figure 15d,e), and rapid amplification of 5' complimentary DNA (cDNA) ends (5' RACE; Figure 15f). When primers were used that amplify the region between the 3' end of *nLacZ* (A⁺F primer) and the 5' end of the poly(A) signal (A⁺R primer), an amplicon that spans the miRNA-binding sites, a 145 basepair (bp) product was detected after 26 cycles of amplification for the samples that received control rAAV. An additional six cycles of amplification were required to detect a weak 220bp band for the samples transduced by rAAV containing three miR-122-binding sites. These data are consistent with low levels of intact *nLacZ* mRNA (Figure 15a,b).

[0113] To quantitatively assess the extent of the miRNA-directed repression of the transgene transcripts, qRT-PCR was performed using either oligo(dT) or random hexamer primers for reverse-transcription and PCR primer pairs that span either a 5' (*nLacZ*5'F/5'R), or 3' (*nLacZ* 3'F13'R) region of the *nLacZ* coding sequence (Figure 15a). The levels of *nLacZ* mRNA were examined with intact 5' and 3' ends in total liver RNA extracted from four animals that received the control rAAV9CB*nLacZ* and four that received rAAV9CB*nLacZ* containing three miR-122-binding sites in the 3' UTR. Reductions ranging from 3 ± 1 (random hexamer) to 7 ± 1 (oligo[dT])-fold in *nLacZ* mRNA with an intact 3' end were observed in the animals that had received rAAV9 containing miR-122-binding sites, relative to the control. In contrast, little or no decrease in *nLacZ* mRNA with an intact 5' end were detected for the same samples using the 5'F/5'R primer pair (Figure 15c). These results indicate that the primary mode of turnover of the mRNA that has been cleaved by a miRNA was 3'-to-5' exonucleolytic degradation.

[0114] To further characterize the fate of the transgene mRNA targeted by miR-1 or miR-122, Northern blot analyses were performed. A transgene probe binding to the 5' end of *nLacZ* mRNA detected a ~3.4 kb RNA in an animal injected with control rAAV9CB*nLacZ*, the expected size of the full-length *nLacZ* transcript; a slightly larger band was detected in the liver sample from a mouse treated with rAAV9CB*nLacZ* bearing three miR1-binding sites (Figure 15a,d). In contrast to the single transcript detected for the rAAV9 expressing *nLacZ* bearing three miR-1- binding sites, two RNAs of different sizes were detected for the rAAV expressing *nLacZ* bearing three miR-122 sites (Figure 15d).

[0115] The lengths of these transcripts indicate that the longer transcript likely represents the full-length mRNA, whereas the shorter, more abundant transcript corresponds to 5' fragments of *nLacZ* RNA cleaved by miR-122 at the corresponding miR-122-binding sites in the 3' UTR (Figure 15d).

[0116] To confirm this observation, the Northern analysis was repeated using an RNA probe spanning a portion of 3' UTR of the transgene mRNA. In addition to detecting full-length *nLacZ* transcripts in the samples transduced by rAAV9 lacking miRNA-binding sites, two closely migrating species smaller than the 281 nucleotide RNA marker were detected. The size of these fragments was consistent with miRNA-directed 3' cleavage products of the *nLacZ* mRNA (Figure 15e). These two 3' cleavage products were also detected by gel electrophoresis of the product from the 5' RACE experiment described below (Figure 15f).

[0117] To determine whether such target cleavage occurs *in vivo* when the *nLacZ* transcript contained miR-1 or miR-122-binding sites, rapid amplification of 5' cDNA ends (5' RACE) was performed. Figure 16 presents the sequences of 21 clones recovered using 5' RACE from liver RNA (Figure 16a) and 22 clones isolated from heart RNA (Figure 16b) from the animals injected with rAAV9 in which the *nLacZ* 3' UTR contained three miR-1 and three miR-122-binding sites. In liver, the sequence signatures for miR-122- directed cleavage of the transgene mRNA were detected at each miR-122-binding site: 5% for the first binding site, 48% for the second binding site, and 43% for the third binding site. All 5' ends mapped to the phosphate that lies between the target nucleotides that pair with positions 10 and 11 of the sequence perfectly complementary to miR-122, the precise site cleaved by small RNAs bound to Argonaute proteins in all eukaryotes (Figure 17a). Similar results were obtained in the heart for the miR-1 sites (Figure 17b).

[0118] Table 3 presents an expanded 5' RACE analysis for additional vector groups. It was noted that none of the 5' RACE products sequenced corresponded to miR-1-directed site-specific cleavage in liver or miR-122-directed site-specific cleavage in heart (Table 3). Although no cleavage was detected within miR-1-binding sites in the liver, some clones from heart were cleaved within the miR-122-binding sites, but not at the hallmark position for miRNA-directed cleavage.

Intravascularly delivered rAAV9 can be efficiently controlled by endogenous miRNAs

[0119] MiRNA-1 and miRNA-122-binding sites were added into the scAAV9CB enhanced GFP (EGFP) vector genome and injected 10-week-old C57BL/6 male mice with 2×10^{14} GC/kg. After 3 weeks, 40 μ m sections of brain and spinal cord and 8 μ m sections of liver, heart, and skeletal muscle were prepared and examined for EGFP protein expression. It was found that intravenously delivered scAAV9CBEGFP efficiently transduced the CNS; EGFP was readily detectable in the thalamus region of the brain and the cervical region of the spinal cord, but also in non-CNS tissues such as liver, heart, and muscle (Figure 17a). In contrast, transgene expression in those non-CNS tissues was reduced when miR-1 and miR122-binding sites were included in the transgene; EGFP expression was unaltered in the CNS, where miR-1 and miR-122 were not present (Figure 17a). Quantitative RT-PCR was used to measure the differential expression of the miRNA-repressed EGFP transgene in brain ($41.2 \pm 7.7\%$), liver ($3.0 \pm 0.5\%$), heart ($0.4 \pm 0.1\%$), and muscle ($1.3 \pm 0.4\%$), relative to the EGFP transgene lacking miRNA-binding sites (Figure 17b). To eliminate changes associated

with transduction efficiency between experiments, the data were normalized to the number of vector genomes detected in the experimental and control samples. Similar to the microscopic analyses of native EGFP expression, the qRT-PCR data show that the presence of miR-122- or miR-1-binding sites reduced transgene expression in liver (20-fold), heart (100-fold), and muscle (50-fold), but did not detectably alter transgene expression in brain.

Discussion Of Results

[0120] This example shows that rAAV9 can be engineered so that endogenous miRNAs repress transgene expression outside the CNS. The results indicate that such engineered rAAV9s may be used in therapies for the degenerating neurons associated with Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis, by expressing neurotrophic growth factors such as insulin-like growth factor, brain-derived neurotrophic factor or glial-derived neurotrophic factor in the transduced astrocytes. This approach eliminates or lessens non-CNS expression derived from the peripheral tissues transduced by systemically delivered rAAV9.

[0121] Achieving transgene expression in primarily only the target tissues is a consideration for the clinical development of safe CNS gene delivery. The results in this example indicate that endogenous miRNAs can be harnessed to restrict the tissue- and cell-type specificity of rAAV expression, as was initially shown for lentiviral vectors. The data demonstrate that endogenous miRNAs can effectively repress transgene expression from rAAV. In both heart and liver, the miRNAs repressed transgene expression by directing endonucleolytic cleavage of the transgene mRNA (Figure 18). MiRNA regulation of rAAV expression did not perturb the expression or function of the corresponding endogenous miRNA, allowing transgene expression to be restricted to the CNS in mice. The example indicates that a strategy that combines multiple binding sites for miRNAs expressed in the periphery but not the CNS is useful for the development of safer, CNS-specific gene therapy vectors.

Materials And Methods

[0122] *Vector design, construction, and production.* Perfectly complementary miRNA-binding sites were designed based on the annotated miR-1 and miR-122 sequences in miRBase and inserted into the *BstBI* restriction site in the 3' UTR of the nLacZ expression cassette of the ubiquitously expressed pAAVCB nuclear-targeted β -galactosidase (nLacZ) plasmid using synthetic oligonucleotides (Figure 15a and Table 3). This vector uses a hybrid cytomegalovirus enhancer/CB promoter cassette that is active in most cells and tissues. To express miR-122 and miR-1, pri-miR-122 and pri-miR-1 fragments were amplified by PCR from C57/B6 mouse genomic DNA (Table 4) and inserted into the *XbaI* restriction site 3' to a firefly luciferase cDNA in the pAAVCBELuc plasmid. The identity of each pri-miRNA was verified by sequencing. AAV9 vectors used in this study were generated, purified, and tittered.

[0123] *Cell culture and transfection.* HEK-293 and HuH7 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 100 mg/l of penicillin-streptomycin (Hyclone, South Logan, UT). Cells were maintained in a humidified incubator at 37°C and 5% CO₂. Plasmids were transiently transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.

[0124] *Mouse studies.* Male C57BL/6 mice (Charles River Laboratories, Wilmington, MA) were obtained and maintained. To monitor lipid profiles of the study animals, serum samples were collected 4 weeks after rAAV9 injection and analyzed for total cholesterol, high-density lipoprotein and low-density lipoprotein on a COBAS C 111 analyzer (Roche Diagnostics, Lewes, UK). To evaluate endogenous miRNA-mediated, CNS-restricted EGFP gene transfer, 10-week-old male C57BL/6 mice were injected intravenously (tail vein) with AAV9CBnLacZ-[miR-122-binding site (BS)₁]. AAV9CBnLacZ-(miR-122BS)₃. AAV9CBnLacZ-(miR-1BS)₁. AAV9CBnLacZ-(miR-1BS)₃. AAV9CBnLacZ-(miR-1BS)₁-(miR-122BS)₁, and AAV9CBnLacZ-(miR-1BS)₃-(miR-122BS)₃, respectively, at 5 x 10¹³ GC/kg body weight) or scAAV9CBEGFP at 2 x 10¹⁴ GC/kg body weight). Animals receiving nLacZ vectors were necropsied 4 weeks later; 8 μ m cryosections of liver, heart, and pancreas tissues were prepared for X-gal-histochemical staining. Animals that received EGFP vectors were necropsied 3 weeks later and fixed by transcardial perfusion with 4% (wt/vol) paraformaldehyde. Brain, spinal cord, liver, heart, and muscle were harvested for cryosectioning. Brain and cervical spinal cord tissue were stained as floating sections in a 12-well plate using rabbit anti-EGFP antibody (Invitrogen) diluted 1:500, followed by goat anti-rabbit secondary antibody (Invitrogen) diluted 1:400. Outside the CNS, EGFP expression was detected directly by fluorescence. EGFP and antibody fluorescence was recorded using a Nikon TE-2000S inverted microscope at x10 magnification and an exposure time of 3 seconds for liver, heart, and muscle, and 5 seconds for thalamus (brain) and cervical spinal cord.

[0125] *Vector genome quantification by qPCR.* Genome DNA was extracted from the selected tissues using QIAamp DNA Mini Kit (Qiagen, West Sussex, UK), according to the manufacturer's instructions. Quantitative PCR were carried out in triplicate using Ring DNA and 0.3 μ mol/l EGFP-specific primers (EGFP-F and EGFP-R) using GoTaq qPCR master mix (Promega, Madison, WI) in a StepOne Plus real-time PCR instrument (Applied Biosystems, Foster City, CA).

[0126] *qRT-PCR analysis.* RNA was extracted using Trizol (Invitrogen), according to the manufacturer's instructions.

Total RNA (0.5-1.0 µg) was primed with random hexamers or oligo(dT) and reverse-transcribed with MultiScribe Reverse Transcriptase (Applied Biosystems). Quantitative PCR were performed in triplicate with 0.3 µmol/l gene-specific primer pairs (nLacZ5'F/5'R, nLacZ 3'F/3'R, cyclinG1F/R and EGFP-F/EGFP-R) using the GoTaq qPCR master mix in a StepOne Plus Real-time PCR device. The specificity of qRT-PCR products derived from the 5' and 3' ends of *nLacZ* mRNA was confirmed by gel electrophoresis.

[0127] Northern blot analysis. Total RNA was extracted from mouse liver and analyzed by Northern hybridization. To detect *nLacZ* mRNA, a 618 bp fragment of *nLacZ* cDNA was isolated by NcoI and PciI digestion of pAAVCBnLacZ and labeled with α -³²P dCTP by random priming (Takara, Shiga, Japan). To detect 3' fragments of the cleaved *nLacZ* mRNA, an 111 bp fragment of the poly(A) sequence in the vector genome was cloned into pCR4-TOPO (Invitrogen) for preparation of antisense RNA probe labeled with α -³²P CTP during *in vitro* transcription using the Riboprobe System T7 kit (Promega). To detect miR-122, miR-26a, miR-22, and let-7 or U6 in total liver RNA, small RNAs were resolved by denaturing 15% polyacrylamide gels, transferred to Hybond N+ membrane (Amersham BioSciences, Pittsburgh, PA), and crosslinked with 254 nm light (Stratagene, La Jolla, CA). Synthetic oligonucleotides, 5' end-labeled with γ -³²P ATP using T4 polynucleotide kinase (New England Biolabs, Beverly, MA), were used as DNA probes (Table 4) and hybridized in Church buffer (0.5 mol/l NaH₂PO₄, pH 7.2, 1 mmol/l EDTA, 7% (w/v) sodium dodecyl sulphate) at 37°C. Membranes were washed using 1 x SSC (150 mM sodium chloride, 15 mM sodium citrate), 0.1% sodium dodecyl sulphate buffer, and then visualized using an FLA-5100 Imager (Fujifilm, Tokyo, Japan).

[0128] Western blot analysis. Proteins were extracted with radioimmunoprecipitation assay buffer [25 mmol/l Tris-HCl, pH 7.6, 150 mmol/l NaCl, 1% (vol/vol) NP-40, 1% (wt/vol) sodium deoxycholate, 0.1% (w/v) sodium dodecyl sulphate] containing a protease inhibitor mixture (Boston BP, Boston, MA). Protein concentration was determined using the Bradford method (Bio-Rad, Melville, NY). Protein samples, 50 µg each, were loaded onto 12% polyacrylamide gels, electrophoresed, and transferred to nitrocellulose membrane (Amersham BioSciences). Briefly, membranes were blocked with blocking buffer (LI-COR Biosciences, Lincoln, NE) at room temperature for 2 hours, followed by incubation with either anti-GAPDH (Millipore, Billerica, MA), anti-cyclin G1 (Santa Cruz Biotechnology, Santa Cruz, CA) or anti-calmodulin (Millipore) for 2 hours at room temperature. After three washes with PBS containing 0.1% (vol/vol) Tween-20, membranes were incubated with secondary antibodies conjugated to LI-COR IRDye for 1 hour at room temperature, and then antibodies detected using the Odyssey Imager (LI-COR).

[0129] β -Galactosidase assay. Proteins were extracted with radioimmunoprecipitation assay buffer and quantified as described above. Fifty micrograms of protein was used for each β -galactosidase assay using the Galacto-Star System (Applied Biosystems), according to the manufacturer's instructions.

[0130] 5' RACE. 5' RACE was performed as described. The 5' RACE Outer Primer and the *nLacZ* gene-specific primer bGHPolyAR (Table 4) were used for the first round of nested PCR. The 5' RACE Inner Primer and the *nLacZ* gene-specific primer nLacZpolyR, which is located near the stop codon of *nLacZ* cDNA, were used for the second round of nested PCR (Table 4). PCR products were TOPO-cloned into pCR-4.0 (Invitrogen) and sequenced.

[0131] Statistical analysis. All results are reported as mean \pm SD and compared between groups using the two-tailed Student's t-test.

Table 3 Summary of microRNA-guided transgene mRNA cleavage in mouse liver and heart

		Cleavage site						
miR BS cleavage	Position	Between 10 and 11 nt		Between 17 and 18 nt		Between 18 and 19 nt		Random site
Liver 1 Copy of miR-122 BS (21 clones)	1	17/21	81%	ND		ND		19%
3 Copies of miR-122 BS (11 clones)	1	ND	100%	ND		ND		0%
	2	4/11						
	3	7/11						
3 Copies each of miR-1 and miR 122 miR 13x BS	1	ND	ND	ND		ND		0%
BS in a single vector (21 clones)	2	ND						
	3	ND						

(continued)

5			Cleavage site						
	miR BS cleavage	Position	Between 10 and 11 nt		Between 17 and 18 nt		Between 18 and 19 nt		Random site
	miR-122 3x BS	1	1/21	95%	ND		ND		5%
		2	10/21						
		3	9/21						
10	Heart 1 Copy of miR-IBS (12 clones)	1	12/12	100%	ND		ND		0%
15	3 Copies of miR 1BS (21 clones)	1	ND	80%	4/21	20%	ND		0%
		2	16/21		ND				
		3	1/21		ND				
20	3 Copies each of miR 1 and miR 122 miR-122 3x BS	1	ND	ND	ND		1/22	14%	4%
	BS in a single vector (22 clones)	2	ND				1/22		
25		3	ND				ND		
	miR 1 3x BS	1	1/22	73%	ND	9%	ND		0%
		2	7/22		1/22				
		3	8/22		1/22				
30									

Table 4. Oligonucleotide primers and probes used in Example 8.

			Sequence		SEQ ID NO
	Oligo nucleotides				
35	(miR-1) ₁ sense		[PHOS]CGAAATACATACTTCTTTACATTCC ATT		SEQ ID NO: 32
	(miR-1) ₁ anti-sense		[PHOS]CGAATGGAATGTAAAGAAGTATGT ATT		SEQ ID NO: 33
40	(miR-122) ₁ sense		[PHOS]CGAAACAAACACCATTGTCACACT CCATT		SEQ ID NO: 34
	(miR-122) ₁ anti-sense		[PHOS]CGAATGGAGTGTGACAATGGTGTT TGTTT		SEQ ID NO: 35
45	(miR-1) ₃ sense		[PHOS]CGAAATACATACTTCTTTACATTCC AATACATACTTCTTTACATTCCAATACATA CTTCTTTACATTCCATT		SEQ ID NO: 36
50	(miR-1) ₃ anti-sense		[PHOS]CGAATGGAATGTAAAGAAGTATGT ATTGGAATGTAAAGAAGTATGTATTGGAA TGTAAGAAGTATGTATTT		SEQ ID NO: 37
55	(miR-122) ₃ sense		[PHOS]CGAAACAAACACCATTGTCACACT CCAACAAACACCATTGTCACACTCCAACA AACACCATTGTCACACTCCATT		SEQ ID NO: 38

(continued)

	Oligo nucleotides	Sequence	SEQ ID NO
5	(miR-122) ₃ anti-sense	[PHOS]CGAATGGAGTGTGACAATGGTGTT TGTTGGAGTGTGACAATGGTGTTTGGTGG AGTGTGACAATGGTGTTTGT	SEQ ID NO: 39
10	(miR-1) ₁ -(miR-122) ₁ sense	[PHOS]CGAAATACATACTTCTTTACATTCC AACAAACACCATTGTCACACTCCATT	SEQ ID NO: 40
	(miR-1) ₁ -(miR-122) ₁ anti-sense	[PHOS]CGAATGGAGTGTGACAATGGTGTT TGTTGGAATGTAAAGAAGTATGTATT	SEQ ID NO: 41
15	Synthesized (miR-1) ₃ - (miR-122) ₃ fragment	TTCGAACTCGAGATACATACTTCTTTACAT TCCAATACATACTTCTTTACATTCCAATAC ATACTTCTTTACATTCCACCATGGACTAGT ACAAACACCATTGTCACACTCCAACAAAC ACCATTGTCACACTCCAACAAACACCATT GTCACACTCCAGCGGCCGCTTCGAA	SEQ ID NO: 42
20	Pri-miR-122F	ATCGGGCCCCGACTGCAGTTTCAGCGTTTG	SEQ ID NO: 43
	Pri-miR-122R	CGCGGGCCCCGACTTTACATTACACACAAT	SEQ ID NO: 44
	Pri-miR-1F	CGCGGGCCCCGACTGATGTGTGAGAGAGAC	SEQ ID NO: 45
25	Pri-miR-1R	CGCGGGCCCCGACTTTCGGCCTCCCGAGGC	SEQ ID NO: 46
	nLacZS ϕ F(5 ϕ F)	TGAAGCTGAAGCCTGTGATG	SEQ ID NO: 47
	nLacZ 5 ϕ R(5 ϕ R)	GAGCACCTGACAGCATTGAA	SEQ ID NO: 48
	nLacZ3 ϕ F(3 ϕ F)	CTCAGCAACAGCTCATGGAA	SEQ ID NO: 49
30	nLacZ3 ϕ R(3 ϕ R)	TTACTTCTGGCACCACACCA	SEQ ID NO: 50
	nLacZpolyF(A ⁺ F)	TGGTGTGGTGCCAGAAGTAA	SEQ ID NO: 51
	nLacZpolyR(A ⁺ R)	CAACAGATGGCTGGCAACTA	SEQ ID NO: 52
35	bGHPolyAR(bGH ⁺ AR)	TGGGAGTGGCACCTTCCA	SEQ ID NO: 53
	EGFP-F	CGACCACTACCAGCAGAACA	SEQ ID NO: 54
	EGFP-R	CTTGTACAGCTCGTCCATGC	SEQ ID NO: 55
	CyclinG1F	AATGGCCTCAGAAATGACTGC	SEQ ID NO: 56
40	CyclinG1R	AGTCGCTTTCACAGCCAAAT	SEQ ID NO: 57
	MM-ActinF	ATGCCAACACAGTGCTGTCTGG	SEQ ID NO: 58
	MM-ActinR	TGCTTGCTGATCCACATCTGCT	SEQ ID NO: 59
45	miR-122 probe	TGGAGTGTGACAATGGTGTTTG	SEQ ID NO: 60
	Let-7 probe	AACATACAACCTACTACCTCA	SEQ ID NO: 61
	miR-26a probe	AGCCTATCCTGGATTACTTGAA	SEQ ID NO: 62
	miR-22 Probe	ACAGTTCTTCAACTGGCAGCT T	SEQ ID NO: 63
50	U6 probe	CTCTGTATCGTTCCAATTTTAGTATA	SEQ ID NO: 64

Example 9: Intravenous injection of rAAVs mediated widespread transduction in neonatal mouse CNS

55 Introduction to the Example

[0132] This example describes an analysis of nine scAAV vectors for CNS gene transfer properties after systemic administration. This study involved identifying more effective vectors for the CNS gene transfer, In some aspects the

study examined serotypes or natural variants of rAAVs for enhanced-permeation of the BBB. In some cases, the study sought to identify rAAV vectors with improved delivery of enhanced green fluorescent protein (EGFP) to the CNS following facial vein injection on postnatal day 1 (P1). AAV9 was included in the study. Except for rAAV2 and rAAV5, all other 7 vectors crossed the BBB with varied transduction efficiency, among which rAAVrh.10, rAAVrh.39, rAAVrh.43, rAAV9 and rhAAV7 rank in the top 5, mediating robust EGFP expression in both neuronal and glial cells throughout the CNS in this study. The performance of rAAVrh. 10 was comparable to that of rAAV9 and in some case better. Several rAAVs efficiently transduce neurons, motor neurons, astrocytes and Purkinje cells; among them, rAAVrh. 10 is at least as efficient as rAAV9 in many of the regions examined. Intravenously delivered rAAVs did not cause abnormal microgliosis in the CNS. The rAAVs that achieve stable widespread gene transfer in the CNS are useful as therapeutic vectors for neurological disorders affecting large regions of the CNS as well as convenient biological tools for neuroscience research.

Results

[0133] Twenty one days after vector administration in PI mice, the CNS transduction profiles of the following recombinant AAV vectors encoding EGFP: rAAV1, rAAV2, rAAV5, rAAV6, rAAV6.2, rAAV7, rAAV9, rAAVrh.10, rAAVrh.39 and rhAAVrh.43 were compared. The vectors used in this study were comparable in purity and morphological integrity (Figure 19). As assessed by the scoring system described in the methods, rAAV9 was among the top performers; most other rAAVs tested (rAAV1, rAAV6, rAAV6.2, rAAV7, rAAVrh.10, rAAVrh.39 and rAAVrh.43) also gave rise to EGFP expression throughout the CNS (Table 2). The number of apparent EGFP positive cells (Table 5) among sub-anatomical structures was influenced by the particular vector used. For these seven rAAVs, and rAAV9 (total of eight rAAVs), that permeated the BBB and accomplished CNS transduction after i.v. delivery, EGFP positive cells were found in hypothalamus followed by medulla, striatum, hippocampus, cortex and cerebellum. In contrast, the transduction efficiency in olfactory bulb and thalamus was relatively low (Table 5). A quantitative assessment of EGFP gene transfer efficiency was made of each rAAV. 12 sub-anatomically and functionally important regions in the brain were selected for quantitative analysis of the mean EGFP intensity/pixel in each region for each rAAV by using Nikon NIS elements AR software V. 32 (Figure 19a) (see Methods). For the eight vectors that achieved CNS transduction after i.v. injection, the mean EGFP intensity/pixel was relatively low in cortex, habenular nucleus, cornu ammonis, dentate gyrus, thalamus, cerebellum and olfactory bulb, moderate in choroid plexus and caudate-putamen, but high in hypothalamus, medulla and amygdale (Figure 19a). The average EGFP intensities of all 12 regions for different rAAVs were compared in Figure 19b. AAVrh.10, AAVrh.39 and AAVrh.43 were noted for gene transduction efficiency in brain, followed by AAV7, AAV9, and AAV1 (Figures 19a and 19b). Those eight effective serotypes also mediated EGFP expression throughout the spinal cord, to different degrees. The same quantitative analysis was performed for each rAAV in the cervical, thoracic and lumbar sections of the spinal cord (Figure 19a); the average EGFP intensities of the three sections for different rAAVs were also compared (Figure 19b). AAV1, AAV9, AAVrh10, AAV.rh39 and AAV.rh43 displayed strong transduction in the spinal cord with the high EGFP intensity observed in the cervix, followed by thoracic and lumbar sections of the spinal cord (Figures 19a and 19b). For rAAV2 there were few EGFP-positive cells in hippocampus, cortex and hypothalamus. EGFP-positive cells were observed in the hypothalamus in AAV5-injected mice. A description of the observations made in different CNS structures is provided below. The subanatomic CNS structures may serve as a target for CNS gene therapy. In some cases, the subanatomic CNS structures are associated with pathological changes in one or more neurological disorders. In some cases, the subanatomic CNS structure have distinct transduction profiles for one or more rAAVs.

[0134] Striatum. Pathology of the striatum is associated with Huntington's disease, choreas, choreoathetosis, and dyskinesias. Addiction may involve plasticity at striatal synapses. Systemic injection of rAAV9 in neonatal mice transduces striatal tissue. In this study, a large number of cells with neuronal morphology in this region were also transduced by rAAVrh.10 (Figure 20), which was confirmed by co-staining with a neuronal marker as described below. Other vectors, including rAAVrh.39 and rAAV7, also mediated moderate transduction in striatum (Figure 20). In contrast, rAAV6, rAAV6.2, and rAAV1 resulted in relatively lower EGFP expression in this structure (Figure 20).

[0135] Hippocampus. The hippocampus is a region associated with long-term memory and spatial navigation, which is usually damaged by stress and pathogenesis of diseases such as epilepsy and Schizophrenia. Large numbers of EGFP-positive neurons were observed bilaterally in all regions of the hippocampus, namely dentate gyrus, hilus, CA1, CA2 and CA3 for the mice received intravenous rAAVrh.10, rAAV9, rAAV7, rAAVrh.39, and rAAVrh.43 (ranked by transduction efficiency in this structure, Table 5 and Figures 19 and 20). In addition to the neuronal transduction pattern, EGFP-positive cells had morphologic appearance of astrocytes (Figure 20). This was further confirmed by double staining with antibodies against EGFP and astrocytic marker as described below. For intravenously delivered rAAV1, rAAV6 and rAAV6.2 vectors there were small numbers of EGFP-positive cells in the hippocampus (Figure 20).

[0136] Cortex. Pathological changes in the cortex have been implicated in Alzheimer's and Parkinson's diseases. AAV7, AAV9, AAVrh.10, AAVrh.39 and AAVrh.43 vectors achieved moderate EGFP transduction in cortex (Table 5 and Figures 19 and 20). The morphology of transduced cells was consistent with both neurons and astrocytes as further

confirmed by cellular marker staining and confocal microscopic analysis described below. Prominent EGFP-positive cells were typically observed in the ventrolateral regions of the cortex, including posterior agranular insular cortex, piriform cortex, lateral entorhinal cortex, posterolateral cortical amygdaloid nucleus and posteromedial cortical amygdaloid nucleus (Figure 20). Strong EGFP signals spread from +1.5 to -3.3 mm in relation to the Bregma (0.0 mm). The cortical transduction efficiency of rAAVrh.10, rAAV9, rAAVrh.39 and rAAVrh.43 was comparable (Table 5 and Figures 19 and 20). AAV1, AAV6 and AAV6.2 vectors also transduced cells in the cortex (Figure 20).

[0137] Hypothalamus. A role for the hypothalamus is to secrete neurohormones to control certain metabolic processes. The hypothalamus is also indicated in the etiology of diabetes. EGFP signal was observed in the hypothalamus for eight vectors. Intravenous administration of rAAVrh.10 resulted in the highest EGFP expression in the entire hypothalamus, followed by rAAVrh.39, rAAV7, rAAV6.2, rAAVrh.43, rAAV9, rAAV1 and rAAV6 (Figures 19 and 20 and Table 5). Interestingly most EGFP-positive cells in this structure have an astrocytic morphology which was ascertained by immunostaining for an astrocytic cell type specific marker as described below. The astrocytic EGFP signal tended to obscure direct examination of morphological details of other transduced cells. However, this was clarified by double immunofluorescent staining of tissue sections with antibodies for EGFP and neuronal cell markers as described below.

[0138] Cerebellum. The pathological lesions in cerebellum are often found in diseases such as cerebellar-cognitive affective syndrome, developmental coordination disorder, posterior fossa syndrome, linguistic deficits, aging, attention deficit hyperactivity disorder, autism, dementia and schizophrenia. EGFP-positive cells and fibers were detected in cerebellum for most rAAV vectors (Table 5 and Figures 19 and 20). A large number of EGFP-expressing cells were found in the Purkinje and granule cell layers for rAAV7, rAAV9, rAAVrh.10, rAAVrh.39 and rAAVrh.43 (Figure 20). The transduction profile of rAAV1 vector indicated expression in cells in the granule cell layer, while rAAV6 and rAAV6.2 were localized in cells in the Purkinje cell layer (Figure 20).

[0139] Medulla. The medulla is a potential gene therapy target for treating chronic pain. Most rAAVs mediated moderate to robust EGFP expression in medulla with most green cells being present in the outer rim (Figure 20). Transduction efficiencies of these rAAV in this region are ranked in the following order: rAAVrh.39 = rAAVrh.43 > rAAVrh.10 > rAAV1 > rAAV9 > rAAV7 > rAAV6.2 > rAAV6 (Table 5 and Figure 19a). The morphology of most EGFP-transduced cells was consistent with the cells being astrocytes.

[0140] Spinal cord. The spinal cord is involved with motor neurons diseases. rAAVrh.10, rAAV9, rAAVrh.39 and rAAVrh.43 gave rise to very robust EGFP expression in cervical gray and white matter, while rAAV1, rAAV6.2 and rAAV7 showed moderate EGFP intensity (Table 5 and Figures 19 and 21). For rAAV1 the EGFP signal was observed in white matter. The transduction ability of all effective rAAVs decreased from cervical to lumbar spinal cord. EGFP-positive cells were visible in the latter region. Large populations of EGFP-positive cells with astrocytic morphology were observed throughout the spinal cord (Figure 21). In addition, rAAVrh.10, rAAV9, rAAVrh.39, rAAVrh.43 and rAAV7 also transduced cells with motor neuron morphology in the ventral regions of spinal cord (Figure 21). Ascending dorsal column fibers showed clear EGFP signal. In addition, dorsal root ganglia (DRG) displayed remarkable transduction with strong EGFP expression in DRG neurons (Figure 22 and Figure 26). The identities of rAAV transduced cell types in the spinal cord were characterized by co-immunofluorescence staining with antibodies against EGFP and cell type specific markers as described below.

IV administration of AAV vectors leads to transduction of different cell types in the CNS

[0141] To confirm the identity of transduced cells in different regions of the CNS, double immunofluorescent staining was performed with antibodies for EGFP and NeuN (generic neuronal marker), glial fibrillary acid protein (GFAP; astrocyte marker), calbindin-D28K (Purkinje cell marker), and choline acetyl transferase (ChAT; motor neuron marker) (Figure 23). The immunostaining results showed that a large number of NeuN positive cells expressed EGFP throughout the mouse brain, which indicated widespread neuronal transduction. The regions with high density of transduced neurons included striatum, hippocampus, cortex and hypothalamus. rAAVrh.10, rAAV9, rAAV7 and rAAVrh.39 vectors were efficient in mediating neuronal transduction, followed by AAV6.2, AAV1 and AAV6 (Figures 19 and 23). In addition, dopaminergic neurons in substantia nigra were transduced by AAVrh.10 (Figure 23). Transduced cells in the CNS included GFAP-positive astrocytes with small cell bodies and highly ramified processes (Figure 23). The calbindin-D28K immunostaining confirmed the identity of a number of transduced cells in the cerebellum as Purkinje cells, with EGFP expression in both cell body and their tree-like processes (Figure 23). The rAAVs proficient in transducing Purkinje cells include: rAAVrh.10, rAAV9, rAAVrh.39, rAAV7, rAAV6.2 and rAAVrh.43. rAAV1 and rAAV6 transduced a portion of Purkinje cells with relatively low EGFP intensity (Figure 19). Transduction of motor neurons was confirmed by the presence of large EGFP+/ChAT+ cells in the ventral spinal cord for several rAAV vectors (Figure 23). rAAVrh.10, rAAV9, rAAV7, rAAVrh.39 showed comparable efficiency transduction of motor neurons (Figure 21).

IV administration of AAV vectors mediated robust transduction in ventricles and brain blood vessels

[0142] EGFP expression was observed in the choroid plexus cells in lateral, 3rd and 4th ventricles of the animals infused with rAAVrh.39, rAAVrh.10, rAAVrh.43, rAAV7 and rAAV9 (ranked by transduction efficiency, Table 5 and Figures 19 and 24). EGFP expression in different ventricles of the same mouse brain was similar (Figure 24). Ependymal cells lining the ventricles were also transduced. An observation regarding the distribution of EGFP-positive cells was the apparent gradient with the highest number of transduced cells in peri-ventricular regions and progressively lower numbers with increasing distance to the ventricles. This was apparent in areas around the 3rd and 4th ventricles than the lateral ventricles (Figure 24). Extensive EGFP signal was also found with blood vessels throughout mouse brain and spinal cord. This was verified by dual immunofluorescent staining with antibodies directed to EGFP and a blood vessel endothelium specific marker, CD34 (Figures 27a and 27b). Unlike the rAAV transduction profiles in different regions of the brain parenchyma, the EGFP transduction of the blood vessels throughout the CNS was relatively uniform for any given vector. However, transduction of blood vessels was influenced by the particular rAAV used. A majority of rAAVs mediated moderate (e.g., rAAV6) to highly efficient (e.g. rAAVrh.10) blood vessel transduction in the CNS.

IV injection of AAV vectors did not cause microgliosis

[0143] Brain sections were also stained with antibody against Iba-1 to label microglial cells. The Iba-1-positive cells in the sections from mice received rAAVrh.10 was no more than those in naive or PBS-injected mice (Figure 28). This result indicated that intravascularly delivered rAAVs do not cause sustained inflammation in the CNS of mice 3 weeks after the injection of PI neonates.

Discussion of Results

[0144] In this study, the CNS transduction profile was evaluated for 10 different rAAV vectors delivered by intravascular infusion in neonatal mice. Most of the rAAVs can cross the BBB and mediate gene transfer to the neonatal mouse CNS with varying degrees of efficiency (Figures 19-21 and Table 5). After systemic administration, rAAVrh.10, rAAVrh.39, rAAVrh.43, and rAAV9 are the effective rAAVs with similar transduction capabilities and cellular tropism, as assessed by overall EGFP expression in the CNS. Specifically, a number of regions in the mouse CNS, including striatum, hippocampus, cortex, hypothalamus, cerebellum, medulla, and cervical spinal cord, revealed substantial EGFP expression. In addition, rAAV6.2 and rAAV7 were also effective. AAV1 and AAV6, achieved CNS transduction (Table 5). Native EGFP expression was detectable in brain and spinal cord sections for most of the rAAVs without immunostaining (Figure 29).

[0145] This example has clinical significance for gene therapy of CNS-related disorders, including for young patients. For a variety of neurological diseases, early treatment during infancy may be necessary to prevent irreversible CNS injury. The capacity of rAAVs to transduce large numbers of neuronal cells in different regions is relevant for treating neurological diseases such as spinal muscular atrophies, neuronal ceroid lipofuscinoses, and spinocerebellar degenerations. The efficiency of some rAAV vectors in transducing Purkinje and granule layer cells indicates that the vectors may be used for treating spinocerebellar ataxias. Transduction of astrocytes by rAAVs expressing secreted neurotrophic factors may be also beneficial for a number of neurodegenerative diseases such as Canavan's disease and amyotrophic lateral sclerosis. The vascular transduction in the CNS may be relevant for treating brain ischemia and stroke. The clinical application of intravascular rAAV-mediated gene delivery may also extend to the peripheral nervous system (PNS). Efficient transduction of DRG provides new therapeutic strategies for patients suffering from chronic pain.

[0146] Systemic gene delivery to the CNS is also useful as a method to manipulate gene expression in research. Effective and stable transgene expression in the CNS by intravenous administration of rAAVs may be applied to establish somatic transgenic animal models, which is a potentially cheaper, faster and simpler method than conventional transgenesis. Somatic CNS gene knock-down animal models may also be created using the method described herein.

[0147] Some rAAVs indeed demonstrated unique transduction profiles in the CNS. For instance, rAAV1 displayed transduced granule cells in the cerebellum, while rAAV6 and rAAV6.2 transduced Purkinje cells, and others transduced both types of cells (Figure 9). This indicates that once across the BBB, the rAAVs have distinct tropisms, which can be attributed to the capsid because that the vector genome used in all vectors was the same.

[0148] AAV serotypes disclosed herein can efficiently transduce brain capillary endothelial cells, neurons and astrocytes. This indicates that these vectors may extravasate from the circulation and reach the CNS parenchyma, possibly by crossing the BBB. AAV may cross the endothelial barrier by a transcytosis pathway. In this study, choroid plexuses and their surrounding parenchymal tissue were efficiently transduced. In addition, there was an apparent gradient of EGFP intensity from peri-ventricular (higher) to deep parenchymal (lower) tissue. These observations indicate that AAV may enter the neonatal mouse CNS through the choroid plexus, followed by widespread distribution via CSF and/or interstitial fluid flow to transduce neuronal and glial cells.

[0149] Neuronal- or glial-specific promoters, such as synapsin-1, and GFAP promoters may be used to restrict gene expression to a specific cell type. A further method to achieve targeted CNS gene delivery is to utilize RNA interference to detarget the peripheral tissues by post-transcriptional regulatory mechanisms. By adding microRNA binding sites into the 3' end of the transgene cassettes, transgene expression after systemic administration of AAV vectors may be reduced or eliminated in tissues such as liver, heart and skeletal muscle, while maintaining CNS transduction.

Materials And Methods

AAV production

[0150] ScAAV vectors were produced by trans-encapsidation of rAAV vector genome flanking by inverted terminal repeats (ITRs) from AAV2 with the capsids of different AAVs using the method transient transfection of 293 cells and CsCl gradient sedimentation as previously described. Vector preparations were titrated by quantitative PCR. Purity of vectors was assessed by 4-12% SDS-acrylamide gel electrophoresis and silver staining (Invitrogen, Carlsbad, CA). Morphological integrity of each vector used in the study was examined by transmission electron microscopy of negative stained recombinant AAV virions. The expression of EGFP in the scAAV vector genome is directed by a hybrid CMV enhancer/chicken β -actin promoter.

Neonatal mouse injections

[0151] Wild-type C57BL/6 mice littermates were used. Mice breeding were conducted using programmatic timing method. Pregnant mice were monitored daily from embryonic day 17 to 21 to ensure the newborn pups could be dosed with vectors on P1. The mother (singly housed) of each litter to be injected was removed from the cage. Vectors were diluted to concentration of 4×10^{12} GCs/mL in PBS and 100 μ l of solution was subsequently drawn into 31G insulin syringes (BD Ultra-Fine II U-100 Insulin Syringes). P1 pups of C57BL/6 mice were anesthetized using isoflurane and rested on ice. For intravenous injections, a dissection microscope was used to visualize the temporal vein (located just anterior to the ear). The needle was inserted into the vein and the plunger was manually depressed. Correct injection was verified by noting blanching of the vein. Each pup received 4×10^{11} GCs of different scAAVCBEGFP vectors (rAAV1, rAAV2, rAAV5, rAAV6, rAAV6.2, rAAV7, rAAV9, rAAVrh.10, rAAVrh.39, rAAVrh.43; n=6-8 mice per group) via the superficial temporal vein. After the injection pups were carefully cleaned, rubbed with their original bedding, and then returned to their original cage. The mother was then reintroduced to the cage after brief nose numbing using ethanol pads.

Histological processing

[0152] The study animals were anesthetized 21 days post-injection, then transcardially perfused with 15 mL of cold PBS followed by 15 mL of fixation solution containing 4% paraformaldehyde (v/v) with 0.2% of glutaraldehyde (v/v) in PBS. Then the whole carcasses were post-fixed in fixation solution for 5 days. Spinal cords and brains were extracted under a bright-field dissecting microscope, rinsed in PBS, and then cryoprotected in 30% sucrose (w/v) in PBS at 4 °C. Once the tissues sank to the bottom of the sucrose solution, they were embedded in Tissue-Tek OCT compound (Sakura Finetek, Torrance, CA) and frozen in a dry ice/ethanol bath. The tissue blocks were stored at -80 °C until sectioning. Serial 40 μ m floating sections of the entire brain were cut in a Cryostat (Thermo Microm HM 550). For the spinal cord, 3 mm length sections were taken from cervical, thoracic and lumbar regions, and then serial 40 μ m transverse sections prepared as above.

Immunostaining and microscopy imaging analysis

[0153] Brain and spinal cord sections were stained as floating sections in 12-well plates. Sections were washed 3 times in PBS for 5 min each time, and then incubated in blocking solution containing 1% Triton-X100 (v/v) (Fisher, Pittsburgh, PA), 5% dry-milk (w/v) and 10% goat serum (v/v) (Invitrogen) for 2h at room temperature. Then the sections were incubated with primary antibodies diluted in blocking solution at 4°C overnight. The following day tissue sections were washed twice in 0.05% Tween-20 (v/v) in PBS (PBST) and once with PBS, with each washing step lasting 10 min. Afterwards sections were incubated with appropriate secondary antibodies in blocking solution at room temperature for 2 h. Sections were washed again as above before mounting on glass slides. Vectashield with DAPI (Vector Laboratories, Burlingame, CA) was used to coverslip all slides, and then they were analyzed using a fluorescent inverted microscope (Nikon Eclipse Ti) or a Leica TSC-SP2 AOBS confocal microscope equipped with a 63 \times oil lens and a DM-IRE2 inverted microscope. The primary antibodies used in this study were as follows: rabbit anti-GFP (Invitrogen), goat anti-ChAT and mouse anti-NeuN (both from Millipore, Billerica, MA), mouse anti-GFAP (Cell signaling, Danvers, MA), rat anti-CD34 (Abcam, Cambridge, MA), mouse anti-Calbindin D-28k (Sigma, St Louis, MO) and rabbit anti-DARPP (Abcam, Cam-

bridge, MA). The secondary antibodies used in the study included: DyLight 488 AffiniPure Donkey Anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA); DyLight 549 AffiniPure Donkey Anti-Goat IgG (Jackson ImmunoResearch); DyLight 549 Affinipure Goat Anti-Rat IgG (Jackson ImmunoResearch); DyLight 594 AffiniPure Goat Anti-Mouse IgG (Jackson ImmunoResearch); goat anti-rabbit IgG-Alexa fluoro 488 (Invitrogen) and goat anti-mouse IgG-Alexa fluoro 568 (Invitrogen).

Semi-quantitative and quantitative comparison of EGFP transduction by different vectors

[0154] To generate a quantifiable and comparable data format, a semi-quantitative scoring system was developed to estimate transduction efficiency of different rAAV vectors in different regions of the mouse CNS. Briefly, regions with no EGFP positive cells were marked as (-). Regions with very few EGFP positive cells were scored (+), regions with some EGFP positive cells were ranked as (++) , regions with many EGFP positive cells were marked as (+++). Finally, regions filled with EGFP positive cells were marked as (++++).

[0155] Next, 12 sub-anatomically and functionally important regions in the brain as well as cervical, thoracic and lumbar sections of the spinal cord were selected for quantitative analysis of images that were taken on a Nikon Eclipse Ti inverted microscope equipped with a Retiga 2000-RV CCD cooled camera. Nikon NIS elements AR software v. 3.2 was used for intensity quantification. Prior to quantification, optimal light source intensity and exposure times were obtained by plotting an intensity/exposure time curve using fluorescence reference slides (Ted Pella, prod. 2273). It was found that the intensity and exposure times had linear correlation. In addition, overexposure and extreme underexposure distorts the linear correlation. The maximum intensity (ND1) and a 20ms exposure were used for all sections to avoid overexposure. For quantification, fixed region of interest (ROI) was used to quantify the brightest area of any given brain region. A mean intensity (total intensity/size of ROI) was obtained for each region of all serotypes.

Table 5. Transduction characteristics of AAV serotypes following intravascular injections into neonatal mouse brain

	Olfactory Bulb		Striatum		Hippocampus		Cortex		Thalamus		Hypothalamus		Cerebellum		Medulla		Cervical		Thoracic		Lumbar		Choroid Plexus	
	score	n	score	n	score	n	score	n	score	n	score	n	score	n	score	n	score	n	score	n	score	n	score	n
AAV1	+	3	++	3	++	3	++	3	+	3	+++	3	+++	3	+++	3	+++	3	+++	3	+	3	+++	3
AAV2	-	3	-	3	+	3	+	3	+	3	+	3	+	3	+	3	+	3	-	3	-	3	++	3
AAV5	-	3	-	3	-	3	+	3	-	3	+	3	-	3	-	3	-	3	-	3	-	3	-	3
AAV6	+	3	+	3	++	3	++	3	+	3	+++	2	++	3	++	3	++	3	+	3	+	3	+++	3
AAV6.2	-	3	+++	2	++	3	++	3	+	3	++++	3	++	3	++	3	++	3	++	3	+	3	++++	3
AAV7	+++	1	+++	3	+++	2	++	3	+	3	++++	3	+++	1	++	3	++	3	+	3	+	3	++++	3
AAV9	+++	2	+++	3	++	3	+++	1	+	3	++++	1	+++	1	++	3	++++	1	++	3	+	3	++++	3
rh10	+++	1	+++	1	+++	3	+++	2	++	2	+++	3	+++	1	+++	3	+++	1	++	3	+	3	+++	3
rh39	++	2	++	2			++	1	+	1			++	2			++	2						
	+++	1	+++	2	+++	3	+++	1	+	3	+++	3	+++	1	+++	1	+++	1	+++	3	+	3	+++	3
rh13	++	2	+++	1			++	2					++	2	+++	2	+++	2						
	++	3	+++	3	+++	3	+++	3	+	3	+++	1	++	3	+++	1	+++	2	+++	3	+	3	+++	3
											+++	2			+++	2	+++	1						

Scoring: (-) no transduction, (+) very few positive cells, (++) some positive cells, (+++) many positive cells, and (++++) region is almost saturated with EGFP-positive cells. The number of animals (n) with the particular score is given to the right of the score.

Example 10: Evaluation of an rAAV Based Treatment in a Canavan Disease Model Introduction to the Example

[0156] CD is a rare and fatal childhood leukodystrophy caused by autosomal recessive mutations in the aspartoacylase

gene (*ASPA*) [as established by G.G.'s graduate work (12)]. *ASPA* deficiency in CD patients leads to elevated N-Acetyl-Aspartic Acid (NAA) in urine (a hallmark of CD) and spongy degeneration of white matter throughout the CNS, producing severe psychomotor retardation and early death. An *ASPA*^{-/-} mouse model mimics the neuropathology and clinical manifestations seen in CD patients, i.e., spongy degeneration of white matter, motor deficits, developmental delays, and early death (within 3 weeks after birth).

[0157] In this study, i.v. deliverable rAAVs were used to target the CNS globally to treat diffused WM degeneration in CD mice. Single i.v. injections of *ASPA* vector to the neonatal CD mice corrected metabolic defect, psychomotor malfunction and other disease phenotypes, and prolonged survival. While untreated CD mice started showing growth retardation, psychomotor malfunction in the 2nd wk after birth and uniformly died soon after weaning, the treated mice began to gain weight 2 wks after vector injection and nearly caught up with their heterozygous littermates within 7 -8 weeks. Unlike CD mice, the mobility of the treated animals was similar to Wt littermates. Data from rotarod test on the treated mice showed no significant differences in the latency time among the treated CD mice and their age-matched Wt littermates, indicating that gene therapy corrected the ataxia, a typical neuromuscular symptom of CD. Biochemical characterization indicated reduction of NAA levels in the urine samples and restoration of *ASPA* activity in their brain and kidney tissues. Mitigation of the biochemical and clinical phenotypes was well correlated with globally ameliorated histopathology in not only the brain, spinal cord but also in the peripheral tissues such as kidney, indicating that CD is not just a CNS disorder.

Results

[0158] In CD mice were dosed at P1 (facial vein, 4x10¹¹ GCs) with AAV9*ASPA*. The mice were monitored for growth, gait, motor function on rotarod, NAA levels in urine and *ASPA* activities in brain. The results showed that i) Untreated CD mice started losing weight at the 2nd week and died in the 3rd week after birth; ii) The treated animals recovered their capacity to grow in the 5th week and caught up with *ASPA*^{+/-} animal by the 10th week; iii). Gene therapy completely corrected gait of CD mice as well as motor function of the CD mice treated at P1 (Figure 30A) as measured by rotarod test; iv). Gene therapy restored the vision of CD mice. The electroretinography (ERG) tests on the eyes of the CD mice showed non-recordable responses to light, while well-defined ERG responses were readily detectable in the treated CD mice (Figure 30B). These data indicate a severer retinopathy and loss of vision in CD mice and gene therapy can mitigate the retinopathy and restore the vision of CD mice; v). Gene therapy clearly improved metabolic defects of NAA as the NAA levels in the treated CD mice approach those in the control mice (Figure 30C); and vi) correction of NAA metabolism is well correlated with restoration of *ASPA* expression (Figure 30E) and activities (Figure 30D) in the brain of the treated CD mice.

[0159] To determine if the phenotypic corrections are correlated with alleviated neuropathology as well as in situ expression of *ASPA* in the brain sections of the treated CD mice, brain sections were analyzed at 3 months after gene therapy for neuropathology and *ASPA* immunohistochemistry. While the untreated mouse brain shows marked vacuolation that diffusely involves all regions of the brain and spinal cord, the vacuolation in both brain and spinal cord of the treated animal appears more patchy and variable with generally smaller-sized vacuoles. Some areas of the cerebral cortex show almost no vacuolation (Figure 31A). In addition, avidin-biotin complex (ABC) system was used to stain brain sections to detect *ASPA* expression in the cerebral cortex in situ (Figure 31B). To generate quantitative measurements on the improvement of neuropathology in the treated CD mice, the "vacuoles" in the brain and spinal cord sections caused by the white matter degeneration in the CD mice were quantified before and after gene therapy treatment. For this quantitative analysis, a Nikon Eclipse Ti inverted microscope and Nikon NIS elements AR software V.3.2 were used. Vacuoles that were > 3,000 pixels, 1,000 - 3,000 pixels and 100- 1,000 pixels were defined as large, medium and small vacuoles respectively. Among the 5 brain regions evaluated in this experiment, the olfactory bulb had the most dramatic mitigation in the white matter degeneration after gene therapy (Figure 32A). For the other 3 regions, while the large vacuoles were completely eliminated and the numbers of medium vacuoles were remarkably reduced, the reduction in the numbers of small vacuoles (<100 um) was not as significant in this experiment (Figure 32A). The same analysis on the spinal cord sections revealed a similar trend (Figure 32B).

[0160] Histopathology of the kidneys in the CD mice were evaluated. The glomeruli showed normal structure but were associated with dilation of Bowman's spaces. The renal tubular epithelium was diffusely attenuated (or atrophic) in association with enlargement of the tubular lumens (Figure 33A). In contrast, the treated CD mouse had normal glomeruli. Renal tubular epithelial cells were well-stained and normal in volume (Figure 33B). These results indicate the involvement of kidney in the pathophysiology of CD and kidney as a peripheral target for CD gene therapy. This result also indicates renal tropism of AAV vectors as a consideration for selection of a vector for CD gene therapy. Two vectors, rAAV9 and rh.10 were evaluated for efficiency of kidney transduction after IV delivery to 10 week old C57BL/6 mice. The results indicate the use of rAAVrh.10 (Figure 33D) as a useful vector for CD gene therapy because it transduces kidney efficiently in addition to its efficient CNS transduction (Figure 33C).

NUCLEIC ACID AND AMINO ACID SEQUENCES

[0161]

5 >gij9632548|ref|NP_049542.1| capsid protein [Adeno-associated virus - 1]
(SEQ ID NO: 1)

10 MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLG
PFNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADADEFQERLQEDTS
FGGNLGRAVFQAKKRVLEPLGLVEEGAKTAPGKKRPVEQSPQEPDSSSGIGKTGQQP
AKKRLNFGQTGDSESVDPDQPLGEPPATPAAVGPTTMASGGGAPMADNNEGADGV
GNASGNWHCDSTWLGDRVITSTRTWALPTYNNHLYKQISSASTGASNDNHYFGYS
15 TPWGYFDNRFHCHFSRDPWQRLINNNWGFRPKRLNFKLFNIQVKEVTTNDGVTIA
NNLTSTVQVFSDEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRS
SFYCLEYFPSQMLRTGNNFTFSYTFEEVFPFHSSYAHSQSLDRLMNPLIDQYLYLNRT
QNGSGSAQNKDLLFSRGPAGMSVQPKNWLPGPCYRQQRVSKTKTDNNNSNFTWT
GASKYNLNGRESIINPGTAMASHKDDDEDKFFPMSGVMIFGKESAGASNTALDNVMIT
20 DEEEIKATNPVATERFGTVAVNFQSSSTDPATGDVHAMGALPGMVWQDRDVYLQG
PIWAKIPHTDGHFHPSPLMGGFGLKNPPPQILIKNTPVPANPPAEFSATKFASFITQYST
GQVSVEIEWELQKENS KRWNPEVQYTSNYAKSANVDFTVDNNGLYTEPRPIGTRYL
TRPL

25 >gij110645923|ref|YP-680426.1| major coat protein VP1 [Adeno-associated virus - 2]
(SEQ ID NO: 2)

30 MAADGYLPDWLEDTLSEGIRQWWKLKPGPPPKPAERHKDDSRGLVLPGYKYLGPF
NGLDKGEPVNEADAAALEHDKAYDRQLDSGDNPYLKYNHADAEFQERLKEDTSFG
GNLGRAVFQAKKRVLEPLGLVEEPVKTAPGKKRPVEHSPVEPDSSSGTGKAGQQPA
RKRLNFGQTGDADSVDPDQPLGQPPAAPSGLGTNTMATGSGAPMADNNEGADGVG
NSSGNWHCDSTWMGDRVITSTRTWALPTYNNHLYKQISSQSGASNDNHYFGYSTP
WG YFDNRFHCHFSRDPWQRLINNNWGFRPKRLNFKLFNIQVKEVTQNDGTTTIAN
35 NLTSTVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMVPQYGYLTLNNGSQAVGRS
SFYCLEYFPSQMLRTGNNFTFSYTFEDVFPFHSSYAHSQSLDRLMNPLIDQYLYLSRT
NTPSGTTTTQSRLQFSQAGASDIRDQSRNWLPGPCYRQQRVSKTSADNNNSEYSWTG
ATKYHLNGRDSL VNPGPAMASHKDDEEKFFPQSGVLIFGKQGSEKTNVDIEKVMITD
EEEIRTTNPVATEQYGSVSTNLQRGNRQAATADVNTQGVLPGMVWQDRDVYLQGPI
40 WAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPSTTFSAAKFASFITQYSTG
QVSVEIEWELQKENS KRWNPEIQYTSNYNKS VNVDFTVD TNNGVYSEPRPIGTRYLTR
NL

45 >gij51593838|ref|YP_068409.1| capsid protein [Adeno-associated virus - 5]
(SEQ ID NO: 3)

50

55

MSFVDHPPDWLEEVGEGLEFLGLEAGPPKPKPNQQHQDQARGLVLPGYNYLGPGN
 GLDRGEPVNRADDEVAREHDISYNEQLEAGDNPYLKYNHADADEFQEKLADDTSFGGN
 LGKAVFQAKKRVLEPFGLVEEGAKTAPTGKRIDHFPKRKKARTEEDSKPSTSSDAE
 5 AGPSGSQQLQIPAQPASSLGADTMSAGGGGGLGDNNQGADGVGNASGDWHCDSTW
 MGDRVVTKSTRTWLPSYNNHQYREIKSGSVDGSNANAYFGYSTPWGYFDFNRFHS
 HWSRPDWQRLINNYWGFRPRSLRVKIFNIQVKEVTVQDSTTTIANNLTSTVQVFTDD
 DYQLPYVVGNGTEGCLPAFPPQVFTLPQYGYATLNRDNTENPTERSSFFCLEYFPSK
 MLRTGNNFEFTYNFEEVPFHSSFAPSQNLFKLANPLVDQYLRFVSTNNTGGVQFNK
 10 NLAGRYANTYKNWFPGPMGRTQGWNLGSVGNRASVSATFATNRMELEGASYQVPP
 QPNGMTNNLQGSNTYALENTMIFNSQPANPGTTATYLEGNMLITSESETQPVNRVAY
 NVGGQMATNNQSSTTAPATGTYNLQEIVPGSVWMERDVYLQGPWAKIPETGAHFH
 PSPAMGGFGLKHPPPMMLIKNTPVGNITSFSDVPVSSFITQYSTGQVTVEMEWELKK
 ENSKRWNPEIQYTNNYNDPQFVDFAPDSTGEYRTTRPIGTRYLTRPL

>gij2766607|gb|AAB95450.1| capsid protein VP1 [Adeno-associated virus - 6]
 (SEQ ID NO: 4)

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYL
 PFNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADADEFQERLQEDTS
 FGGNLGRAVFQAKKRVLEPFGLVEEGAKTAPGKKRPVEQSPQEPDSSSGIGKTGQQP
 AKKRLNFGQTGDSESVDPQPLGEPPATPAAVGPPTMASGGGAPMADNNEGADGV
 GNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSASTGASNDNHYFGYS
 20 TPWGYFDFNRFHCHFSRPDWQRLINNNWGFRPKRLNFKLFNIQVKEVTTNDGVTTIA
 NNLSTVQVFSDEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRS
 SFYCLEYFPSQMLRTGNNFTFSYTFEDVPFHSSY AHSQSLDRLMNPLIDQYLYLNRT
 QNQS GSAQNKDLLFSRGSPAGMSVQPKNWLPGPCYRQQRVSKTKTDNNNSNFTWT
 GASKYNLNGRESIINPGTAMASHKDDKDKFFPMSGVMIFGKESAGASNTALDNVMIT
 25 DEEEIKATNPVATERFGTVAVNLQSSSTDPATGDVHVMGALPGMVWQDRDVYLQG
 PIWAKIPHDTGHHFSPMLMGGFGLKHPPPPQILIKNTPVPANPPAEFSATKFASFITQYST
 GQVSVEIEWELQKENS KRWNPEVQYTSNYAKSANVDFTVDNNGLYTEPRPIGTRYL
 TRPL

>gij171850125|gb|ACB55302.1| capsid protein VP1 [Adeno-associated virus - 6.2]
 (SEQ ID NO: 5)

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYL
 PFNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADADEFQERLQEDTS
 FGGNLGRAVFQAKKRVLEPLGLVEEGAKTAPGKKRPVEQSPQEPDSSSGIGKTGQQP
 AKKRLNFGQTGDSESVDPQPLGEPPATPAAVGPPTMASGGGAPMADNNEGADGV
 GNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSASTGASNDNHYFGYS
 TPWGYFDFNRFHCHFSRPDWQRLINNNWGFRPKRLNFKLFNIQVKEVTTNDGVTTIA
 40 NNLSTVQVFSDEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRS
 SFYCLEYFPSQMLRTGNNFTFSYTFEDVPFHSSY AHSQSLDRLMNPLIDQYLYLNRT
 QNQS GSAQNKDLLFSRGSPAGMSVQPKNWLPGPCYRQQRVSKTKTDNNNSNFTWT
 GASKYNLNGRESIINPGTAMASHKDDKDKFFPMSGVMIFGKESAGASNTALDNVMIT
 DEEEIKATNPVATERFGTVAVNLQSSSTDPATGDVHVMGALPGMVWQDRDVYLQG
 45 PIWAKIPHDTGHHFSPMLMGGFGLKHPPPPQILIKNTPVPANPPAEFSATKFASFITQYST
 GQVSVEIEWELQKENS KRWNPEVQYTSNYAKSANVDFTVDNNGLYTEPRPIGTRYL
 TRPL

>gij22652861|gb|AAN03855.1|AF513851_2 capsid protein [Adeno-associated virus - 7]
 (SEQ ID NO: 6)

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDNGRGLVLPGYKYL
 PFNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADADEFQERLQEDTS
 FGGNLGRAVFQAKKRVLLEPLGLVEEGAKTAPAKKRPVEPSQSPDSSTGIGKKGQQ
 5 PARKRLNFGQTGDSESVDPQPLGEPPAAPSSVSGTVAAGGGAPMADNNEGADGV
 GNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSETAGSTNDNTYFGYS
 TPWGYFDNRFHCHFSRPDWQRLINNNWGFPRPKLRFKLFNIQVKEVTNDGVTIA
 NNLSTIQVFSDEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQSVGRSS
 FYCLEYFPSQMLRTGNNFEFSYSFEDVPFHSSYAHSQSLDRLMNPLIDQYLYLARTQ
 10 SNPGGTAGNRELQFYQGGPSTMAEQAKNWLPGPCFRQQRVSKTLDQNNNSNFAWT
 GATKYHLNGRNSLVNPGVAMATHKDDERFFPSSGVLIFGKTGATNKTTLENVLMT
 NEEERPTNPVATEEYGIVSSNLQAANTAAQTQVVNNQALPGMVWQNRDVYLQGP
 IWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPANPPEVFTPAKFASFITQYSTG
 15 QVSVEIEWELQKENS KRWNPEIQYTSNFEKQTGVDFAVDSQGVYSEPRPIGTRYLTR
 NL

>g|22652864|gb|AAN03857.1|AF513852_2 capsid protein [Adeno-associated virus - 8]
 (SEQ ID NO: 7)

MAADGYLPDWLEDNLSEGIREWWALKPGAPKPKANQQKQDDGRGLVLPGYKYL
 PFNGLDKGEPVNAADAAALEHDKAYDQQLQAGDNPYLRYNHADADEFQERLQEDTS
 FGGNLGRAVFQAKKRVLLEPLGLVEEGAKTAPGKKRPVEPSQSPDSSTGIGKKGQQ
 20 PARKRLNFGQTGDSESVDPQPLGEPPAAPSGVGPNTMAAGGGAPMADNNEGADG
 VGSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGATNDNTYFG
 YSTPWGYFDNRFHCHFSRPDWQRLINNNWGFPRKLSFKLFNIQVKEVTQNEGKT
 IANNLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGR
 SSFYCLEYFPSQMLRTGNNFQFTYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYLSR
 25 TQTTGGTANTQTLGFSQGGPNTMANQAKNWLPGPCYRQQRVSTTTGQNNNSNFAW
 TAGTKYHLNGRNSLANPGIAMATHKDDERFFPSNGILIFGKQNAARDNADYSDVM
 LTSEEEIKTTNPVATEEYGIVADNLQQQNTAPQIGTVNSQALPGMVWQNRDVYLQ
 30 GPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFNQSKLNSFITQYS

TGQVSVEIEWELQKENS KRWNPEIQYTSNYYKSTSVDFAVNTEGVYSEPRPIGTRYL
 TRNL

>g|46487805|gb|AAS99264.1| capsid protein VP1 [Adeno-associated virus 9]
 (SEQ ID NO: 8)

MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYL
 PGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADADEFQERLKEDTS
 45 FGGNLGRAVFQAKKRLLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQP
 AKKRLNFGQTGDTESVDPQPIGEPPAAPSGVGSLTMAAGGGAPVADNNEGADGVG
 SSSGNWHCDSQWLGDVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYST
 PWGYFDNRFHCHFSRPDWQRLINNNWGFPRKRLNFKLFNIQVKEVTDNNGVKIA
 NNLSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRS
 50 SFYCLEYFPSQMLRTGNNFQFSYEFENVFPFHSSYAHSQSLDRLMNPLIDQYLYLSKT
 INSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGA
 SSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDNVDADKVMITN
 EEEIKTTNPVATESYQQVATNHQSAQAQAQTGWVQNQGILPGMVWQDRDVYLQGP
 55 IWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYST
 GQVSVEIEWELQKENS KRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLT
 RNL

>g|29650526|gb|AAO88201.1| capsid protein [Non-human primate Adeno-associated virus]

(SEQ ID NO: 9 rh-10)

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYL
 5 PFNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADADEFQERLQEDTS
 FGGNLGRAVFQAKKRVLEPLGLVEEGAKTAPGKKRPVEPSQSPDSSTGIGKKGQQ
 PAKKRLNFGQTGDSESVDPDQPIGEPPAGPSGLSGTMAAGGGAPMADNNEGADGV
 GSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGY
 STPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTQNEGTKTI
 10 ANNLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGR
 SSFYCLEYFPSQMLRTGNNFEFSYQFEDVPFHSSYAHQSQSLDRLMNPLIDQYLYLSR
 TQSTGGTAGTQQLLFSQAGPNNMSAQAKNWLPGPCYRQQRVSTTLSQNNNSNFAW
 TGATKYHLNGRDSL VNPGVAMATHKDDEERFFPSSGVL MFGKQGAGKDNVDYSSV
 MLTSEEEIKTTNPVATEQYGVVADNLQQNAAPIVGAVNSQGALPGMVWQNRDVY
 15 LQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFSQAKLASFIT
 QYSTGQVSVEIEWELQKENS KRWNPEIQYTSNY YKSTNVDFAVNTDGTYSEPRPIGT
 RYLTRNL

>gi|171850147|gb|ACB55313.1| capsid protein VP1 [Adeno-associated virus - rh.39]

(SEQ ID NO: 10)

MAADGYLPDWLEDNLSEGIREWWALKPGAPKPKANQQKQDDGRGLVLPGYKYL
 25 PFNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADADEFQERLQEDTS
 FGGNLGRAVFQAKKRVLEPLGLVEEAAKTAPGKKRPVEPSQSPDSSTGIGKKGQQ
 PAKKRLNFGQTGDSESVDPDQPIGEPPAGPSGLSGTMAAGGGAPMADNNEGADGV
 GSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGY
 STPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLSFKLFNIQVKEVTQNEGTKTI
 ANNLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGR
 30 SSFYCLEYFPSQMLRTGNNFEFSYTFEDVPFHSSYAHQSQSLDRLMNPLIDQYLYLSR
 TQSTGGTQGTQQLLFSQAGPANMSAQAKNWLPGPCYRQQRVSTTLSQNNNSNFAW

TGATKYHLNGRDSL VNPGVAMATHKDDEERFFPSSGVL MFGKQGAGRDNVDYSSV
 35 MLTSEEEIKTTNPVATEQYGVVADNLQQNTGPIVGNVNSQGALPGMVWQNRDVY
 LQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFSQAKLASFIT
 QYSTGQVSVEIEWELQKENS KRWNPEIQYTSNY YKSTNVDFAVNTEGTYSEPRPIGT
 RYLTRNL

>gi|46487767|gb|AAS99245.1| capsid protein VP1 [Adeno-associated virus rh.43]

(SEQ ID NO: 11)

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYL
 45 PFNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADADEFQERLQEDTS
 FGGNLGRAVFQAKKRVLEPLGLVEEGAKTAPGKKRPVEQSPQEPDSSSGIGKKGQQP
 ARKRLNFGQTGDSESVDPDQPLGEPPAAPSGVGPNTMAAGGGAPMADNNEGADGV
 GSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGATNDNTYFGY
 STPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLSFKLFNIQVKEVTQNEGTKTI
 50 ANNLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGR
 SSFYCLEYFPSQMLRTGNNFQFTYTFEDVPFHSSYAHQSQSLDRLMNPLIDQYLYLSR
 TQTTGGTANTQTLGFSQGGPNTMANQAKNWLPGPCYRQQRVSTTTGQNNNSNFAW
 TAGTKYHLNGRNSLANPGIAMATHKDDEERFFPVTGSCFWQQNAARDNADYSDVM
 LTSEEEIKTTNPVATEEYGVVADNLQQNTAPQIGTVNSQGALPGMVWQNRDVYLQ
 55 GPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFNQSKLNSFITQYS
 TGQVSVEIEWELQKENS KRWNPEIQYTSNY YKSTSVDFAVNTEGVYSEPRPIGTRYL
 TRNL

>capsid protein VP1 [Adeno-associated virus] CSp3
(SEQ ID NO: 12)

MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYL
PGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADADEFQERLKEDTS
FGGNLGRAVFQAKKRILLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQP
AKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGS LTASGGGAPVADNNEGADGVGS
SSGNWHCDSQWLGD RVITTSTRTWALPTYNNHLYKRISNSTSGGSSNDNAYFGYSTP
WGYFDENRFHCHFSRDPWQRLINNNWGRPKRLNFKLFNIRVKEVTDNNGVKITIN
NLTSTVQVFTDSQYLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSS
FYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYLSKTI
NGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTRNNNSEFAWPGAS
SWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDNVDADKVMITNE
EEIKTTNPVATESYGQVATNHQSAQAQAQTGWVQNQGILPGMVWQDRDVYLQGP
WAKIPHTDGNFHPSPLMGGFGVKHPPQILIKNTVPADPPTAFNKDKLNSFITQYST
QQVSVEIEWELQKENS KRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLT
RNL

>gi|189339202|ref|NP_001121557.1| aspartoacylase [Homo sapiens]
(SEQ ID NO: 13)

MTSCHIAEEHIQKVAIFGGTHGNELTG VFLVKHWLENGAEIQR TGLEV KPFITNPRAV
KKCTRYIDCDLNRIFDLENLGKKMSEDLPEYVRR AQEINH LFGPKDSEDSYDIIFDLH
NTTSNMGCTLILED SRNNFLIQMFHYIKTSLAPLPCYVYLIEHPSLKYATTRSI AKYPV
GIEVGPQPQGVLRADILDQMRKMIKHALDFIHHFNEGKEFP PCAIEVYKII EKVDYPR
DENG EIAAIIHPNLQDQDWKPLHPGDP MFLTLDGKTIPLGGDCTVYPV FVNEAAYYE
KKEAFAKTTKLTLNAKSIRCCLH

>gi|189339201:92-1033 Homo sapiens aspartoacylase (Canavan disease) (ASPA), transcript variant 2, mRNA
(SEQ ID NO: 14)

ATGACTTCTTGTCACATTGCTGAAGAACATATACAAAAGGTTGCTATCTTTGGAG
GAACCCATGGGAATGAGCTAACCGGAGTATTTCTGGTTAAGCATTGGCTAGAGA
ATGGCGCTGAGATTCAGAGAACAGGGCTGGAGGTAAAACCATTTATTACTAACC
CCAGAGCAGTGAAGAAGTGTACCAGATATATTGACTGTGACCTGAATCGCATTTT
TGACCTTGAAAATCTTG GCAAAAAAATGTCAGAAGATTTGCCATATGAAGTGAG
AAGGGCTCAAGAAATAAATCATTTATTTGGTCCAAAAGACAGTGAAGATTCCTAT
GACATTATTTTTGACCTTCACAACACCACCTCTAACATGGGGTGCACTCTTATTCT
TGAGGATTCCAGGAATAACTTTTTAATTCAGATGTTTCATTACATTAAGACTTCTC
TGGCTCCACTACCCTGCTACGTTTATCTGATTGAGCATCCTTCCCTCAAATATGCG
ACCACTCGTTCCATAGCCAAGTATCCTGTGGGTATAGAAGTTGGTCCTCAGCCTC
AAGGGGTCTGAGAGCTGATATCTTGGATCAAATGAGAAAAATGATTAAACATG
CTCTTGATTTTATACATCATTTCAATGAAGGAAAAGAATTTCCCTCCCTGCGCCATT
GAGGTCTATAAAATTATAGAGAAAGTTGATTACCCCCGGGATGAAAATGGAGAA
ATTGCTGCTATCATCCATCCTAATCTGCAGGATCAAGACTGGAAACCACTGCATC
CTGGGGATCCCATGTTTTTA ACTCTTGATGGGAAGACGATCCCCTG GGGCGGAGA
CTGTACCGTGTACCCCGTGT TTTGTGAATGAGGCCGCATATTACGAAAAGAAAGA
AGCTTTTGCAAAGACA ACTAACTAACGCTCAATGCAAAAAGTATTGCTGCTGT
TTACATTAG

>gi|31560279|ref|NP_075602.2| aspartoacylase [Mus Musculus]
(SEQ ID NO: 15)

MTSCVAKEPIKKIAIFGGTHGNELTGVFLVTHWLRNGTEVHRAGLDVKPFITNPRAV
 EKCTRYIDCDLNRVFDLENLSKEMSEDLPYEVRRRAQEINHLEFGPKNSDDAYDLVFDL
 HNTTSNMGCTLILEDNRNDFLIQMFHYIKTCMAPLPCSVYLIEHPSLKYATTRSIKYP
 VGIEVGPQPHGVLRADILDQMRKMIKHALDFIQHFNEGKEFPFPCSIDVYKIMEKVDYP
 RNESGDMAAAVIHPNLQDQDWKPLHPGDPVVFVSLDGKVIPLGGDCTVYPVFNAAAY
 YEKKEAFAKTTKLTLSAKSIRSTLH

>gij142354273:148-1086 Mus musculus aspartoacylase (Aspa), mRNA
 (SEQ ID NO: 16)

ATGACCTCTTGTGTTGCTAAAGAACCTATTAAGAAGATTGCCATCTTTGGAGGGA
 CTCATGGAAATGAACTGACCGGAGTGTTTCTAGTTACTCACTGGCTAAGGAATGG
 CACTGAAGTTCACAGAGCAGGGCTGGACGTGAAGCCATTACCAATCCAAG
 GGCGGTGGAGAAGTGCACCAGATACATTGACTGTGACCTGAATCGTGTTTTTGAC
 CTTGAAAATCTTAGCAAAGAGATGTCTGAAGACTTGCCATATGAAGTGAGAAGG
 GCTCAAGAAATAAATCATTTATTTGGTCCAAAAAATAGTGATGATGCCTATGACC
 TTGTTTTTGACCTTCACAACACCACTTCTAACATGGGTTGCACTCTTATTCTTGAG
 GATTCCAGGAATGACTTTTTAATTCAGATGTTTCACTATATTAAGACTTGCATGGC
 TCCATTACCCTGCTCTGTTTATCTCATTGAGCATCCTTCACTCAAATATGCAACCA
 CTCGTTCCATTGCCAAGTATCCTGTTGGTATAGAAGTTGGTCCTCAGCCTCACGGT
 GTCCTTAGAGCTGATATTTTAGACCAAATGAGAAAAATGATAAAACATGCTCTTG
 ATTTTATACAGCATTTCAATGAAGGAAAAGAATTTCCCTCCCTGTTCTATTGACGTC
 TATAAAATAATGGAGAAAGTTGATTATCCAAGGAATGAAAGTGGAGACATGGCT
 GCTGTTATTCATCCTAATCTGCAGGATCAAGACTGGAAACCATTGCACCCTGGAG

ATCCTGTGTTTGTGTCTCTTGATGGAAAAGTTATTCCACTGGGTGGAGACTGTAC
 CGTGTAACCCAGTGTTTGTGAATGAAGCTGCATATTATGAAAAAAGAAGCATT
 GCAAAGACAACAAAACCTAACACTCAGCGCAAAAAGCATCCGCTCCACTTTGCAC
 TAA

>gij48762945:149-613 Homo sapiens superoxide dismutase 1, soluble (SOD1), mRNA
 (SEQ ID NO: 17)

ATGGCGACGAAGGCCGTGTGCGTGCTGAAGGGCGACGGCCCAGTGCAGGGCATC
 ATCAATTTTCGAGCAGAAGGAAAGTAATGGACCAGTGAAGGTGTGGGAAGCATT
 AAAGGACTGACTGAAGGCCCTGCATGGATTCCATGTTTCATGAGTTTGAGATAATA
 CAGCAGGCTGTACCAGTGCAGGTCCTCACTTTAATCCTCTATCCAGAAAACACGG
 TGGGCCAAAGGATGAAGAGAGGCATGTTGGAGACTTGGGCAATGTGACTGCTGA
 CAAAGATGGTGTGGCCGATGTGTCTATTGAAGATTCTGTGATCTCACTCTCAGGA
 GACCATTGCATCATTGGCCGCACACTGGTGGTCCATGAAAAAGCAGATGACTTG
 GGCAAAGGTGGAAATGAAGAAAGTACAAAGACAGGAAACGCTGGAAGTCGTTT
 GGCTTGTGGTGTAATTGGGATCGCCCAATAA

>gij4507149|ref|NP_000445.1| superoxide dismutase [Homo sapiens]
 (SEQ ID NO: 18)

MATKAVCVLKGDPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTA
 GCTSAGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLGDHCII
 GRTLTVVHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ

>gij45597446:117-581 Mus musculus superoxide dismutase 1, soluble (Sod1), mRNA
 (SEQ ID NO: 19)

EP 3 567 106 A1

5
10
ATGGCGATGAAAGCGGTGTGCGTGCTGAAGGGCGACGGTCCGGTGCAGGGAACC
ATCCACTTCGAGCAGAAGGCAAGCGGTGAACCAGTTGTGTTGTCAGGACAAATT
ACAGGATTAAGTGAAGGCCAGCATGGGTTCCACGTCCATCAGTATGGGGACAAT
ACACAAGGCTGTACCAGTGCAGGACCTCATTTTAATCCTCACTCTAAGAAACATG
GTGGCCCGGGCGGATGAAGAGAGGCATGTTGGAGACCTGGGCAATGTGACTGCTG
GAAAGGACGGTGTGGCCAATGTGTCCATTGAAGATCGTGTGATCTCACTCTCAGG
AGAGCATTCCATCATTGGCCGTACAATGGTGGTCCATGAGAAACAAGATGACTT
GGGCAAAGGTGGAAATGAAGAAAGTACAAAGACTGGAAATGCTGGGAGCCGCT
TGGCCTGTGGAGTGATTGGGATTGCGCAGTAA

>gij45597447|ref|NP_035564.1| superoxide dismutase [Mus musculus]
(SEQ ID NO: 20)

15
MAMKAVCVLKGDGPVQGTIHFEQKASGEPVVLSGQITGLTEGQHGFHVHQYGDNT
QGCTSAGPHFNPHSKKHGGPADEERHVGDLGNVTAGKDGVANVSIEDRVISLSGEH
SIIGRTMVVHEKQDDLKGKGGNEESTKTGNAGSRLACGVIGIAQ

20
>pAAVscCB6 EGFPmir SOD5 (direct) 5243bp (SEQ ID NO: 21)

25
CTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCG
ACCTTTGGTCGCCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGTAG
CCATGCTCTAGGAAGATCAATTCAATTCACGCGTCGACATTGATTATTGACTAGT
TATTAATAGTAATCAATTACGGGGGTCATTAGTTCATAGCCCATATATGGAGTTCC
GCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCG
CCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTC

30

35

40

45

50

55

CATTGACGTCAATGGGTGGATATTTACGGTAAACTGCCCACTTGGCAGTACATCA
 AGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCC
 GCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACA
 TCTACGTATTAGTCATCGCTATTACCATGTCGAGGCCACGTTCTGCTTCACTCTCC
 5 CCATCTCCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTAAATTATTTT
 GTGCAGCGATGGGGGCGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGG
 GCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGC
 GCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGGCGGGCGGGCGGCCCTATA
 10 AAAAGCGAAGCGCGCGGGCGGGGAGCAAGCTCTAGCCTCGAGAATTCACGCG
 TGGTACCTCTAGAGCAGAGCTCGTTTAGTGAACCGTCAGTTCGAAATCGCCACCA
 TGGTGAGCAAGGGCGAGGAGCTGTTACCGGGGTGGTGCCCATCTGGTTCGAGC
 TGGACGGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCG
 ATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCC
 15 CGTGCCCTGGCCACCCTCGTGACCACCCTGACCTACGGCGTGCACTGCTTCAGC
 CGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCGAAG
 GCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCC
 GCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGG
 GCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAAC
 20 ACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGG
 TGAACCTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACC
 ACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACC
 ACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATC
 ACATGGTCCTGCTGGAGTTCGTGACCGCCCGGGATCACTCTCGGCATGGACGA
 25 GCTGTACAAGTAAGTAACAGGTAAGTGCGATCGCTAATGCGGGAAGCTCTTAT
 TCGGGTGAGATGGGCTGGGGCACCATCTGGGGACCCTGACGTGAAGTTTGTCACT
 GACTGGAGAAGTTCGGTTTGTCTGTGTGCGGGGGCGGCAGTTATGGCGGTGCCG
 TTGGGCAGTGCACCCGTACCTTTGGGAGCGCGCGCCCTCGTCGTGCTGACGTC
 ACCCGTTCTGTTGGTACCTGCTGTTGACAGTGAGCGACGCAATGTGACTTCGCTG
 30 ACAAAGCTGTGAAGCCACAGATGGGCTTTGTCAGCAGTCACATTGCGCTGCCTAC
 TGCCTCGGACTTCAAGGGCTCGAGAATTCAGGGTGGGGCCACCTGCCGGTAGGT
 GTGCGGTAGGCTTTTCTCCGTGCGAGGACGACAGGGTTCGGGCCTAGGGTAGGCTC
 TCCTGAATCGACAGGCGCCGACCTCTGGCGGCCGCAACAACGCGTTCCTGACC
 ATTCATCCTCTTTCTTTTTCCTGACGGCTTGTGGAAGAAATGGGATCCGATCTTTT
 35 TCCCTCTGCCAAAAATTATGGGGACATCATGAAGCCCCCTTGAGCATCTGACTTCT
 GGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTGTGTCT
 CTCCTCGGCCTAGGTAGATAAGTAGCATGGCGGGTTAATCATTAACTACAAGG
 AACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGA
 40 GGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGT
 GAGCGAGCGAGCGCGCAGCCTTAATTAACCTAATTCAGTGGCCGTCTGTTTACAA
 CGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGACGACATC
 CCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCA
 ACAGTTGCGCAGCCTGAATGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAG
 45 CGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTA
 GCGCCCGCTCCTTTTCGCTTTCTTCCCTTCTTTCTCGCCACGTTCCGCGGCTTTCC
 CGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGC
 ACCTCGACCCCCAAAAAAGTTGATTAGGGTGATGGTTACGTTAGTGGGCCATCGCC
 CTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGAC
 50 TCTTGTTCCAACTGGAACAACACTCAACCTATCTCGGTCTATTCTTTTGATTTA

TAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAA
 AATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTAGGTGGCACTTTT
 CGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTCTAAATACATTCAAATA
 5 TGTATCCGCTCATGAGACAATAACCCGTGATAAATGCTTCAATAATATTGAAAAAG
 GAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTTCGGGCAT
 TTTGCCTTCCTGTTTTTGTCTACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGA
 AGATCAGTTGGGTGCACGAGTGGGTACATCGAACTGGATCTCAACAGCGGTAA
 10 GATCCTTGAGAGTTTTTCGCCCCGAAGAACGTTTTTCCAATGATGAGCACTTTTAA
 GTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCG
 GTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGA
 AAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAAC
 CATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA
 GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCCTTGATCGT
 15 TGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATG
 CCTGTAGCAATGGCAACAACGTTGCGCAAACCTATTAACCTGGCGAACTACTTACT
 TAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGAC
 CACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCC
 GGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCC
 20 TCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGA
 AATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAG
 ACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACCTTCATTTTTAATTTAAA
 AGGATCTAGGTGAAGATCCTTTTTTGATAATCTCATGACCAAAATCCCTTAACGTG
 AGTTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAAGATCAAAGGATCTTCTTG
 25 AGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTA
 CCAGCGGTGGTTTTGTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAA
 CTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTT
 AGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATC
 30 CTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACT
 CAAGACGATAGTTACCGGATAAGGCGCAGCGGTTCGGGCTGAACGGGGGGTTTCGT
 GCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGC
 GTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATC
 CGGTAAGCGGCAGGGTTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGA
 35 AACGCTGGTATCTTTATAGTCCTGTTCGGGTTTCGCCACCTCTGACTTGAGCGTCG
 ATTTTTGTGATGCTCGTCAGGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGC
 GGCTTTTACGGTTCCTGGCCTTTTGTCTGGCCTTTTGTCTCATATGTTCTTCTGCTG
 GTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACC
 GCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGA
 40 AGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCAATTAATGC
 AGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATT
 AATGTGAGTTAGCTCACTCATTAGGCACCCAGGCTTTACACTTTATGCTTCCGG
 CTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTACACAGGAAACAGCTA
 TGACCATGATTACGCCAGATTTAATTAAGGCCTTAATTAGG

>sod1mir1 (direct) 108bp
 (SEQ ID NO: 22)

TGCTGTTGACAGTGAGCGACATCATCAATTTTCCGAGCAGAACTGTGAAGCCACA
 GATGGGTTCTGCTCGAAATTGATGATGCTGCCTACTGCCTCGGACTTCAAGGG

>sodlmir2 (direct) 106bp
 (SEQ ID NO: 23)

TGCTGTTGACAGTGAGCGACGCATTAAAGGATCCTGACTGACTGTGAAGCCACA
 GATGGGTCAGTCAGTCCTTTAATGCGCTGCCTACTGCCTCGGACTTCAAGGG

EP 3 567 106 A1

>sodlmir3 (direct) 108bp
(SEQ ID NO: 24)

5 TGCTGTTGACAGTGAGCGACTGCATGGATTCTCCATGTTTCATCTGTGAAGCCACA
GATGGGATGAACATGGAATCCATGCAGCTGCCTACTGCCTCGGACTTCAAGGG

>sodlmir4 (direct) 106bp
(SEQ ID NO: 25)

10 TGCTGTTGACAGTGAGCGACAAGGATGAAGATCGAGGCATGCTGTGAAGCCACA
GATGGGCATGCCTCTCTTCATCCTTGCTGCCTACTGCCTCGGACTTCAAGGG

15 >sod1mir5 (direct) 110bp
(SEQ ID NO: 26)

20 TGCTGTTGACAGTGAGCGACGCAATGTGACTTCGCTGACAAAGCTGTGAAGCCA
CAGATGGGCTTTGTCAGCAGTCACATTGCGCTGCCTACTGCCTCGGACTTCAAGG
G

>sodlmir6 (direct) 108bp
(SEQ ID NO: 27)

25 TGCTGTTGACAGTGAGCGACCGATGTGTCTATCTTGAAGATTCTGTGAAGCCACA
GATGGGAATCTTCAATAGACACATCGGCTGCCTACTGCCTCGGACTTCAAGGG

30 >sodlmir7 (direct) 106bp
(SEQ ID NO: 28)

35 TGCTGTTGACAGTGAGCGACGGTGGAATGATCAGAAAGTACTGTGAAGCCACA
GATGGGTACTTTCTTCATTTCCACCGCTGCCTACTGCCTCGGACTTCAAGGG

>sodlmir8 (direct) 110bp
(SEQ ID NO: 29)

40 TGCTGTTGACAGTGAGCGACGCTGTAGAAATTCGTATCCTGATCTGTGAAGCCAC
AGATGGGATCAGGATACATTTCTACAGCGCTGCCTACTGCCTCGGACTTCAAGGG

>sodlmir9 (direct) 106bp
(SEQ ID NO: 30)

45 TGCTGTTGACAGTGAGCGAGGTATTAAGTTGTCAGAATTTAGTGAAGCCACAGA
TGTAATTCTGACAAGTTTAATACCCTGCCTACTGCCTCGGACTTCAAGGG

50 >pAAVscCB6 EGFPmir scr (1820bp - 1925bp, direct) 106bp
(SEQ ID NO: 31)

55 TGCTGTTGACAGTGAGCGACGATGCTCTAATCGGTTCTATCAAGTGAAGCCACAG
ATGTTGATAGAACCTTAGAGCATCGCTGCCTACTGCCTCGGACTTCAAGGG

[0162] This invention is not limited in its application to the details of construction and the arrangement of components

set forth in this description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of "including," "comprising," or "having," "containing," "involving," and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

[0163] Having thus described several aspects of at least one embodiment of this invention, it is to be appreciated various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the spirit and scope of the invention. Accordingly, the foregoing description and drawings are by way of example only.

Embodiments of the invention will now be described in the following numbered paragraphs:

1. A method for delivering a transgene to CNS tissue in a subject, the method comprising:
administering an effective amount of a rAAV by intrathecal administration, wherein the rAAV comprises (i) a capsid protein comprising a sequence as set forth in SEQ ID NO: 9 and (ii) a nucleic acid comprising a promoter operably linked with a transgene.

2. The method of paragraph 1 further comprising administering an effective amount of the rAAV by intracerebral administration.

3. A method for delivering a transgene to central nervous system (CNS) tissue in a subject, the method comprising:
administering an effective amount of a rAAV by intrathecal administration and by intracerebral administration, wherein the rAAV infects cells of CNS tissue in the subject and comprises a nucleic acid comprising a promoter operably linked with a transgene.

4. The method of paragraph 2 or 3, wherein the intracerebral administration is an intraventricular administration.

5. The method of any one of paragraphs 1 to 4, wherein the intrathecal administration is in the lumbar region of the subject

6. The method of paragraph 4 or 5, wherein the intraventricular administration is an administration into a ventricular region of the forebrain of the subject.

7. The method of any one of paragraphs 1 to 6, wherein the dose of the rAAV for intrathecal administration is in a range of 10^{10} genome copies to 10^{11} genome copies.

8. The method of any one of paragraphs 2 to 6, wherein the dose of the rAAV for intracerebral administration is in a range of 10^{10} genome copies to 10^{11} genome copies.

9. The method of any one of paragraphs 1 to 8, wherein the transgene is a CNS-associated gene.

10. The method of paragraph 9, wherein the CNS-associated gene is neuronal apoptosis inhibitory protein (NAIP), nerve growth factor (NGF), glial-derived growth factor (GDNF), brain-derived growth factor (BDNF), ciliary neurotrophic factor (CNTF), tyrosine hydroxylase (TH), GTP-cyclohydrolase (GTPCH), amino acid decarboxylase (AADC) or aspartoacylase (ASPA).

11. The method of any one of paragraphs 1 to 8, wherein the transgene encodes an inhibitory RNA that binds specifically to SOD1 mRNA and inhibits expression of SOD1 in the subject.

12. The method of paragraph 11, wherein the inhibitory RNA is an antisense RNA, a shRNA or a miRNA.

13. The method of paragraph 11, wherein the inhibitory RNA has a sequence as set forth in SEQ ID NO: 26.

14. A nucleic acid comprising a sequence as set forth in SEQ ID NO: 26.

15. A recombinant AAV comprising the nucleic acid of paragraph 14.

16. The recombinant AAV of paragraph 15 further comprising a capsid protein comprising a sequence as set forth in SEQ ID NO: 9.

17. A method for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof, the method comprising: administering an effective amount of a rAAV to CNS tissue of the subject, wherein the rAAV comprises (i) a capsid protein comprising a sequence as set forth in SEQ ID NO: 9 and (ii) a nucleic acid comprising a promoter operably linked with a region encoding an inhibitory RNA that binds specifically to SOD1 mRNA and inhibits expression of SOD1 in the subject.

18. The method of paragraph 17, wherein the inhibitory RNA is an antisense RNA, a shRNA or a miRNA.

19. The method of paragraph 18, wherein the inhibitory RNA has a sequence as set forth in SEQ ID NO: 26.

20. A method for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof, the method comprising: administering an effective amount of a rAAV to the subject, wherein the rAAV comprises a nucleic acid comprising a promoter operably linked with a region encoding a sequence as set forth in SEQ ID NO: 26 and wherein the rAAV infects cells of CNS tissue in the subject.

21. A method for delivering a transgene to a CNS tissue in a subject, the method comprising: administering to a subject an effective amount of a rAAV that comprises (i) a capsid protein having a sequence as set forth in any one of SEQ ID NO: 10 to 12 and (ii) a nucleic acid comprising a promoter operably linked with a transgene.

22. The method of paragraph 21, wherein the transgene encodes a reporter protein.

23. The method of paragraph 22, wherein the reporter protein is a fluorescent protein, an enzyme that catalyzes a reaction yielding a detectable product, or a cell surface antigen.

24. The method of paragraph 23, wherein the enzyme is a luciferase, a beta-glucuronidase, a chloramphenicol acetyltransferase, an aminoglycoside phosphotransferase, an aminocyclitol phosphotransferase, or a Puromycin N-acetyl-transferase.

25. The method of paragraph 21, wherein the transgene is a CNS-associated gene.

26. The method of paragraph 25, wherein the CNS-associated gene is neuronal apoptosis inhibitory protein (NAIP), nerve growth factor (NGF), glial-derived growth factor (GDNF), brain-derived growth factor (BDNF), ciliary neurotrophic factor (CNTF), tyrosine hydroxylase (TH), GTP-cyclohydrolase (GTPCH), amino acid decarboxylase (AADC) or aspartoacylase (ASPA).

27. A rAAV that comprises (i) a capsid protein having a sequence as set forth in any one of SEQ ID NO: 10 to 12 and (ii) a nucleic acid comprising a promoter operably linked with a CNS-associated gene.

28. The rAAV of paragraph 25 or 27, wherein mRNA expressed from the CNS-associated gene comprises a miRNA binding site of a miRNA that is preferentially expressed in non-CNS tissue.

29. The rAAV of paragraph 27 or 28, wherein mRNA expressed from the CNS-associated gene does not comprise a miRNA binding site of a miRNA that is preferentially expressed in CNS tissue.

30. The rAAV of any one of paragraphs 27 to 28, wherein the promoter is a CNS tissue specific promoter.

31. The rAAV of any one of paragraphs 27 to 30, wherein the promoter is a promoter of a gene selected from: neuronal nuclei (NeuN), glial fibrillary acidic protein (GFAP), adenomatous polyposis coli (APC), and ionized calcium-binding adapter molecule 1 (Iba-1).

32. The rAAV of any one of paragraphs 27 to 31, wherein the CNS-associated gene is neuronal apoptosis inhibitory protein (NAIP), nerve growth factor (NGF), glial-derived growth factor (GDNF), brain-derived growth factor (BDNF), ciliary neurotrophic factor (CNTF), tyrosine hydroxylase (TH), GTP-cyclohydrolase (GTPCH), amino acid decarboxylase (AADC) or aspartoacylase (ASPA).

33. A composition comprising the rAAV of any one of paragraphs 27 to 32.

34. The composition of paragraph 33 further comprising a pharmaceutically acceptable carrier.

35. A kit comprising a container housing the composition of paragraph 33 or 34.

36. The kit of paragraph 35, wherein the container is a sealed vial or ampule.

37. The kit of paragraph 35, wherein the container is a syringe.

38. An isolated mammalian cell comprising a nucleic acid encoding a capsid protein having a sequence as set forth in SEQ ID NO: 10 to 12 and a rAAV vector comprising a nucleic acid encoding a CNS-disease associated gene.

39. The isolated mammalian cell of paragraph 38 further comprising an AAV helper function vector.

40. The isolated mammalian cell of paragraph 38 or 39 further comprising an accessory function vector.

41. The isolated mammalian cell of any one of paragraphs 38 to 40, wherein the CNS-associated gene is neuronal apoptosis inhibitory protein (NAIP), nerve growth factor (NGF), glial-derived growth factor (GDNF), brain-derived growth factor (BDNF), ciliary neurotrophic factor (CNTF), tyrosine hydroxylase (TH), GTP-cyclohydrolase (GTPCH), amino acid decarboxylase (AADC) or aspartoacylase (ASPA).

42. A method for treating Canavan disease in a subject in need thereof, the method comprising: administering an effective amount of a rAAV to CNS tissue of the subject, wherein the rAAV comprises (i) a capsid protein other than a capsid protein of AAV serotype 2 and (ii) a nucleic acid comprising a promoter operably linked with a region encoding aspartoacylase (ASPA).

43. A method for treating Canavan disease in a subject in need thereof, the method comprising: administering an effective amount of a rAAV to CNS tissue of the subject by a route other than intracerebral administration, wherein the rAAV comprises a nucleic acid comprising a promoter operably linked with a region encoding aspartoacylase (ASPA).

44. A method for treating Canavan disease in a subject in need thereof, the method comprising:

administering an effective amount of a rAAV to CNS tissue of the subject, wherein the rAAV comprises a nucleic acid comprising a promoter operably linked with a region encoding aspartoacylase (ASPA), and

evaluating kidney function in the subject at least once after the administration.

45. A method for treating Canavan disease in a subject in need thereof, the method comprising:

administering an effective amount of a rAAV to CNS tissue of the subject, wherein the rAAV comprises a nucleic acid comprising a promoter operably linked with a region encoding aspartoacylase (ASPA), and

evaluating vision of the subject at least once after the administration.

46. The method of any one of paragraphs 42 to 45, wherein the rAAV has a capsid protein having an amino acid sequence as set forth in SEQ ID NO: 8 or 9.

47. The method of any one of paragraphs 44 to 46, wherein administering is performed intrathecally or intracerebrally.

48. The method of any one of paragraphs 42 to 46, wherein administering is performed intravascularly.

49. The method of paragraph 48, wherein the nucleic acid expresses an aspartoacylase (ASPA) mRNA comprising one or more miRNA binds sites for one or more miRNAs that are more abundant in one or more non-CNS tissues in comparison to a CNS tissue.

50. The method of paragraph 49, wherein the one or more miRNAs that are more abundant in one or more non-CNS tissues in comparison to the CNS tissue are at least twofold more abundant.

51. The method of paragraph 49 or 50, wherein the one or more non-CNS tissue is not kidney tissue or retinal tissue.

52. A method for delivering a transgene to central nervous system (CNS) tissue in a subject, the method comprising:

administering an effective amount of a rAAV comprising a transgene to a subject, wherein the rAAV comprises a capsid protein of a AAV serotype selected from the group consisting of: AAV1, AAV2, AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, rh.IO, rh.39, rh.43 and CSp3, and

wherein:

(a) if the AAV serotype is AAV1, the administration route is not intracerebral, intramuscular, intranerve, or intraventricular and/or the subject is not a mouse, rat or feline;

(b) if the AAV serotype is AAV2, the administration route is not intracerebral or intraventricular administration and/or the subject is not a rat, mouse, feline, marmoset, or macaque;

(c) if the AAV serotype is AAV5, the administration route is not intracerebral or intraventricular administration and/or the subject is not a rat, mouse, or marmoset;

(d) if the AAV serotype is AAV6, the subject is not a mouse;

(e) if the AAV serotype is AAV7, the administration route is not intracerebral administration and/or the subject is not a mouse or macaque;

(f) if the AAV serotype is AAV8, the administration route is not intracerebral, intraperitoneal, or intravascular administration and/or the subject is not a mouse or macaque;

(g) if the AAV serotype is AAV9, the administration route is not intracerebral or intravascular administration and/or the subject is not a rat or mouse; and (h) if the AAV serotype is AAVrh.IO, the administration route is not intracerebral or intravascular administration and/or the subject is not a rat or mouse.

53. The method of paragraph 52, wherein the AAV serotype is selected from AAV1, AAV6, AAV7, rh.39, rh.43, and CSp3, and the administration route is intravascular administration.

54. The method of paragraph 52, wherein the AAV serotype is AAV7 and the administration route is intravascular administration.

55. The method of paragraph 52, wherein the CNS tissue is selected from cortex, hippocampus, thalamus, hypothalamus, cerebellum, brain stem, cervical spinal cord, thoracic spinal cord, and lumbar spinal cord.

[0164] It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the following paragraphs.

EP 3 567 106 A1

SEQUENCE LISTING

<110> University of Massachusetts

<120> CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF

<130> WOLBR/P52496EPdiv3

<150> 61/327,627

<151> 2010-04-23

<160> 64

<170> PatentIn version 3.5

<210> 1

<211> 736

<212> PRT

<213> Adeno associated virus 1

<400> 1

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
145 150 155 160

Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr

EP 3 567 106 A1

	165					170					175					
5	Gly	Asp	Ser	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Leu	Gly	Glu	Pro	Pro
				180					185					190		
10	Ala	Thr	Pro	Ala	Ala	Val	Gly	Pro	Thr	Thr	Met	Ala	Ser	Gly	Gly	Gly
			195					200					205			
15	Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Asn	Ala
	210						215					220				
20	Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Thr	Trp	Leu	Gly	Asp	Arg	Val	Ile
	225					230					235					240
25	Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	Leu
					245					250					255	
30	Tyr	Lys	Gln	Ile	Ser	Ser	Ala	Ser	Thr	Gly	Ala	Ser	Asn	Asp	Asn	His
				260					265					270		
35	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	Phe
			275					280					285			
40	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	Asn
		290					295					300				
45	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	Gln
	305					310					315					320
50	Val	Lys	Glu	Val	Thr	Thr	Asn	Asp	Gly	Val	Thr	Thr	Ile	Ala	Asn	Asn
					325					330					335	
55	Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Ser	Asp	Ser	Glu	Tyr	Gln	Leu	Pro
				340					345					350		
60	Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	Ala
			355					360					365			
65	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	Gly
		370					375					380				
70	Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	Pro
	385					390					395					400
75	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Thr	Phe	Ser	Tyr	Thr	Phe
					405					410					415	

EP 3 567 106 A1

	Glu	Glu	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	Asp	
				420					425					430			
5	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Asn	Arg	
			435					440					445				
	Thr	Gln	Asn	Gln	Ser	Gly	Ser	Ala	Gln	Asn	Lys	Asp	Leu	Leu	Phe	Ser	
10		450					455					460					
	Arg	Gly	Ser	Pro	Ala	Gly	Met	Ser	Val	Gln	Pro	Lys	Asn	Trp	Leu	Pro	
	465					470					475					480	
15																	
	Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Lys	Thr	Lys	Thr	Asp	Asn	
					485					490					495		
	Asn	Asn	Ser	Asn	Phe	Thr	Trp	Thr	Gly	Ala	Ser	Lys	Tyr	Asn	Leu	Asn	
20				500					505					510			
	Gly	Arg	Glu	Ser	Ile	Ile	Asn	Pro	Gly	Thr	Ala	Met	Ala	Ser	His	Lys	
			515					520					525				
25																	
	Asp	Asp	Glu	Asp	Lys	Phe	Phe	Pro	Met	Ser	Gly	Val	Met	Ile	Phe	Gly	
		530					535					540					
	Lys	Glu	Ser	Ala	Gly	Ala	Ser	Asn	Thr	Ala	Leu	Asp	Asn	Val	Met	Ile	
30		545				550					555					560	
	Thr	Asp	Glu	Glu	Glu	Ile	Lys	Ala	Thr	Asn	Pro	Val	Ala	Thr	Glu	Arg	
35					565					570					575		
	Phe	Gly	Thr	Val	Ala	Val	Asn	Phe	Gln	Ser	Ser	Ser	Thr	Asp	Pro	Ala	
				580					585					590			
40																	
	Thr	Gly	Asp	Val	His	Ala	Met	Gly	Ala	Leu	Pro	Gly	Met	Val	Trp	Gln	
			595					600					605				
	Asp	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His	
45		610					615					620					
	Thr	Asp	Gly	His	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu	
50		625				630					635					640	
	Lys	Asn	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro	Ala	
					645					650					655		
55																	
	Asn	Pro	Pro	Ala	Glu	Phe	Ser	Ala	Thr	Lys	Phe	Ala	Ser	Phe	Ile	Thr	
				660					665					670			

EP 3 567 106 A1

	Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	Leu	Gln	
			675					680					685				
5	Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Val	Gln	Tyr	Thr	Ser	Asn	
		690					695					700					
10	Tyr	Ala	Lys	Ser	Ala	Asn	Val	Asp	Phe	Thr	Val	Asp	Asn	Asn	Gly	Leu	
	705					710					715					720	
15	Tyr	Thr	Glu	Pro	Arg	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg	Pro	Leu	
					725					730					735		
20	<210> 2 <211> 735 <212> PRT <213> Adeno associated virus 2 <400> 2																
25	Met	Ala	Ala	Asp	Gly	Tyr	Leu	Pro	Asp	Trp	Leu	Glu	Asp	Thr	Leu	Ser	
	1				5					10					15		
30	Glu	Gly	Ile	Arg	Gln	Trp	Trp	Lys	Leu	Lys	Pro	Gly	Pro	Pro	Pro	Pro	
				20					25					30			
35	Lys	Pro	Ala	Glu	Arg	His	Lys	Asp	Asp	Ser	Arg	Gly	Leu	Val	Leu	Pro	
			35					40					45				
40	Gly	Tyr	Lys	Tyr	Leu	Gly	Pro	Phe	Asn	Gly	Leu	Asp	Lys	Gly	Glu	Pro	
		50					55					60					
45	Val	Asn	Glu	Ala	Asp	Ala	Ala	Ala	Leu	Glu	His	Asp	Lys	Ala	Tyr	Asp	
	65					70					75					80	
50	Arg	Gln	Leu	Asp	Ser	Gly	Asp	Asn	Pro	Tyr	Leu	Lys	Tyr	Asn	His	Ala	
					85					90					95		
55	Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Lys	Glu	Asp	Thr	Ser	Phe	Gly	Gly	
				100					105						110		
60	Asn	Leu	Gly	Arg	Ala	Val	Phe	Gln	Ala	Lys	Lys	Arg	Val	Leu	Glu	Pro	
			115					120					125				
65	Leu	Gly	Leu	Val	Glu	Glu	Pro	Val	Lys	Thr	Ala	Pro	Gly	Lys	Lys	Arg	
		130					135					140					
70	Pro	Val	Glu	His	Ser	Pro	Val	Glu	Pro	Asp	Ser	Ser	Ser	Gly	Thr	Gly	
	145					150					155					160	

EP 3 567 106 A1

	Lys	Ala	Gly	Gln	Gln	Pro	Ala	Arg	Lys	Arg	Leu	Asn	Phe	Gly	Gln	Thr	
					165					170					175		
5	Gly	Asp	Ala	Asp	Ser	Val	Pro	Asp	Pro	Gln	Pro	Leu	Gly	Gln	Pro	Pro	
				180					185					190			
	Ala	Ala	Pro	Ser	Gly	Leu	Gly	Thr	Asn	Thr	Met	Ala	Thr	Gly	Ser	Gly	
10			195					200					205				
	Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Asn	Ser	
		210					215					220					
15	Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Thr	Trp	Met	Gly	Asp	Arg	Val	Ile	
	225					230					235					240	
	Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	Leu	
20					245					250					255		
	Tyr	Lys	Gln	Ile	Ser	Ser	Gln	Ser	Gly	Ala	Ser	Asn	Asp	Asn	His	Tyr	
				260					265					270			
25	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	Phe	His	
			275					280					285				
	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	Asn	Trp	
30		290					295					300					
	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	Gln	Val	
35	305					310					315					320	
	Lys	Glu	Val	Thr	Gln	Asn	Asp	Gly	Thr	Thr	Thr	Ile	Ala	Asn	Asn	Leu	
					325					330					335		
40	Thr	Ser	Thr	Val	Gln	Val	Phe	Thr	Asp	Ser	Glu	Tyr	Gln	Leu	Pro	Tyr	
				340					345					350			
	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	Ala	Asp	
45			355					360					365				
	Val	Phe	Met	Val	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	Gly	Ser	
		370					375					380					
50	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	Pro	Ser	
	385					390					395					400	
	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Thr	Phe	Ser	Tyr	Thr	Phe	Glu	
55					405					410					415		

EP 3 567 106 A1

	Asp	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	Asp	Arg	
				420					425					430			
5	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Ser	Arg	Thr	
			435					440					445				
10	Asn	Thr	Pro	Ser	Gly	Thr	Thr	Thr	Gln	Ser	Arg	Leu	Gln	Phe	Ser	Gln	
		450					455					460					
15	Ala	Gly	Ala	Ser	Asp	Ile	Arg	Asp	Gln	Ser	Arg	Asn	Trp	Leu	Pro	Gly	
	465					470					475					480	
20	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Lys	Thr	Ser	Ala	Asp	Asn	Asn	
					485					490					495		
25	Asn	Ser	Glu	Tyr	Ser	Trp	Thr	Gly	Ala	Thr	Lys	Tyr	His	Leu	Asn	Gly	
				500					505					510			
30	Arg	Asp	Ser	Leu	Val	Asn	Pro	Gly	Pro	Ala	Met	Ala	Ser	His	Lys	Asp	
			515					520					525				
35	Asp	Glu	Glu	Lys	Phe	Phe	Pro	Gln	Ser	Gly	Val	Leu	Ile	Phe	Gly	Lys	
		530					535					540					
40	Gln	Gly	Ser	Glu	Lys	Thr	Asn	Val	Asp	Ile	Glu	Lys	Val	Met	Ile	Thr	
	545					550					555					560	
45	Asp	Glu	Glu	Glu	Ile	Arg	Thr	Thr	Asn	Pro	Val	Ala	Thr	Glu	Gln	Tyr	
					565					570					575		
50	Gly	Ser	Val	Ser	Thr	Asn	Leu	Gln	Arg	Gly	Asn	Arg	Gln	Ala	Ala	Thr	
				580					585					590			
55	Ala	Asp	Val	Asn	Thr	Gln	Gly	Val	Leu	Pro	Gly	Met	Val	Trp	Gln	Asp	
			595					600					605				
60	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His	Thr	
		610					615					620					
65	Asp	Gly	His	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu	Lys	
	625					630					635					640	
70	His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro	Ala	Asn	
					645					650					655		
75	Pro	Ser	Thr	Thr	Phe	Ser	Ala	Ala	Lys	Phe	Ala	Ser	Phe	Ile	Thr	Gln	

EP 3 567 106 A1

	660	665	670
5	Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys 675 680 685		
10	Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr 690 695 700		
15	Asn Lys Ser Val Asn Val Asp Phe Thr Val Asp Thr Asn Gly Val Tyr 705 710 715 720		
20	Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu 725 730 735		
	<210> 3		
	<211> 724		
	<212> PRT		
	<213> Adeno associated virus 5		
	<400> 3		
25	Met Ser Phe Val Asp His Pro Pro Asp Trp Leu Glu Glu Val Gly Glu 1 5 10 15		
30	Gly Leu Arg Glu Phe Leu Gly Leu Glu Ala Gly Pro Pro Lys Pro Lys 20 25 30		
35	Pro Asn Gln Gln His Gln Asp Gln Ala Arg Gly Leu Val Leu Pro Gly 35 40 45		
40	Tyr Asn Tyr Leu Gly Pro Gly Asn Gly Leu Asp Arg Gly Glu Pro Val 50 55 60		
45	Asn Arg Ala Asp Glu Val Ala Arg Glu His Asp Ile Ser Tyr Asn Glu 65 70 75 80		
50	Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala Asp 85 90 95		
55	Ala Glu Phe Gln Glu Lys Leu Ala Asp Asp Thr Ser Phe Gly Gly Asn 100 105 110		
	Leu Gly Lys Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro Phe 115 120 125		
	Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Thr Gly Lys Arg Ile 130 135 140		
	Asp Asp His Phe Pro Lys Arg Lys Lys Ala Arg Thr Glu Glu Asp Ser		

EP 3 567 106 A1

	145		150		155		160
5	Lys	Pro	Ser	Thr	Ser	Ser	Gln
				165			175
					170		
	Gln	Leu	Gln	Ile	Pro	Ala	Gln
10				180			185
							190
	Met	Ser	Ala	Gly	Gly	Gly	Gly
			195			200	
							205
15	Asp	Gly	Val	Gly	Asn	Ala	Ser
		210				215	
							220
	Met	Gly	Asp	Arg	Val	Val	Thr
20	225					230	
							235
	Ser	Tyr	Asn	Asn	His	Gln	Tyr
					245		
							250
25							255
	Gly	Ser	Asn	Ala	Asn	Ala	Tyr
				260			Phe
							265
							270
30	Phe	Asp	Phe	Asn	Arg	Phe	His
			275				280
							285
	Arg	Leu	Ile	Asn	Asn	Tyr	Trp
35		290				295	
							300
	Lys	Ile	Phe	Asn	Ile	Gln	Val
	305					310	
							315
40							320
	Thr	Thr	Ile	Ala	Asn	Asn	Leu
					325		
							330
							335
45	Asp	Asp	Tyr	Gln	Leu	Pro	Tyr
				340			345
							350
	Leu	Pro	Ala	Phe	Pro	Pro	Gln
50			355				360
							365
	Ala	Thr	Leu	Asn	Arg	Asp	Asn
						375	
							380
55	Phe	Phe	Cys	Leu	Glu	Tyr	Phe
	385					390	
							395
							400

EP 3 567 106 A1

	Asn	Phe	Glu	Phe	Thr	Tyr	Asn	Phe	Glu	Glu	Val	Pro	Phe	His	Ser	Ser	
					405					410					415		
5	Phe	Ala	Pro	Ser	Gln	Asn	Leu	Phe	Lys	Leu	Ala	Asn	Pro	Leu	Val	Asp	
				420					425					430			
10	Gln	Tyr	Leu	Tyr	Arg	Phe	Val	Ser	Thr	Asn	Asn	Thr	Gly	Gly	Val	Gln	
			435					440					445				
15	Phe	Asn	Lys	Asn	Leu	Ala	Gly	Arg	Tyr	Ala	Asn	Thr	Tyr	Lys	Asn	Trp	
	450						455					460					
20	Phe	Pro	Gly	Pro	Met	Gly	Arg	Thr	Gln	Gly	Trp	Asn	Leu	Gly	Ser	Gly	
	465					470					475					480	
25	Val	Asn	Arg	Ala	Ser	Val	Ser	Ala	Phe	Ala	Thr	Thr	Asn	Arg	Met	Glu	
					485					490					495		
30	Leu	Glu	Gly	Ala	Ser	Tyr	Gln	Val	Pro	Pro	Gln	Pro	Asn	Gly	Met	Thr	
				500					505					510			
35	Asn	Asn	Leu	Gln	Gly	Ser	Asn	Thr	Tyr	Ala	Leu	Glu	Asn	Thr	Met	Ile	
			515					520					525				
40	Phe	Asn	Ser	Gln	Pro	Ala	Asn	Pro	Gly	Thr	Thr	Ala	Thr	Tyr	Leu	Glu	
	530						535					540					
45	Gly	Asn	Met	Leu	Ile	Thr	Ser	Glu	Ser	Glu	Thr	Gln	Pro	Val	Asn	Arg	
	545					550					555					560	
50	Val	Ala	Tyr	Asn	Val	Gly	Gly	Gln	Met	Ala	Thr	Asn	Asn	Gln	Ser	Ser	
				565						570					575		
55	Thr	Thr	Ala	Pro	Ala	Thr	Gly	Thr	Tyr	Asn	Leu	Gln	Glu	Ile	Val	Pro	
				580					585					590			
60	Gly	Ser	Val	Trp	Met	Glu	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	
			595					600					605				
65	Ala	Lys	Ile	Pro	Glu	Thr	Gly	Ala	His	Phe	His	Pro	Ser	Pro	Ala	Met	
	610						615					620					
70	Gly	Gly	Phe	Gly	Leu	Lys	His	Pro	Pro	Pro	Met	Met	Leu	Ile	Lys	Asn	
	625					630					635					640	
75	Thr	Pro	Val	Pro	Gly	Asn	Ile	Thr	Ser	Phe	Ser	Asp	Val	Pro	Val	Ser	
					645					650					655		

EP 3 567 106 A1

Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Thr Val Glu Met Glu
660 665 670

5 Trp Glu Leu Lys Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln
675 680 685

10 Tyr Thr Asn Asn Tyr Asn Asp Pro Gln Phe Val Asp Phe Ala Pro Asp
690 695 700

Ser Thr Gly Glu Tyr Arg Thr Thr Arg Pro Ile Gly Thr Arg Tyr Leu
705 710 715 720

15 Thr Arg Pro Leu

20 <210> 4
<211> 736
<212> PRT
<213> Adeno associated virus 6

25 <400> 4

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15

30 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
35 35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60

40 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80

45 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
100 105 110

50 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125

55 Phe Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140

EP 3 567 106 A1

	Pro	Val	Glu	Gln	Ser	Pro	Gln	Glu	Pro	Asp	Ser	Ser	Ser	Gly	Ile	Gly	145	150	155	160
5	Lys	Thr	Gly	Gln	Gln	Pro	Ala	Lys	Lys	Arg	Leu	Asn	Phe	Gly	Gln	Thr		165	170	175
10	Gly	Asp	Ser	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Leu	Gly	Glu	Pro	Pro		180	185	190
	Ala	Thr	Pro	Ala	Ala	Val	Gly	Pro	Thr	Thr	Met	Ala	Ser	Gly	Gly	Gly		195	200	205
15	Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Asn	Ala		210	215	220
20	Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Thr	Trp	Leu	Gly	Asp	Arg	Val	Ile	225	230	235	240
	Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	Leu		245	250	255
25	Tyr	Lys	Gln	Ile	Ser	Ser	Ala	Ser	Thr	Gly	Ala	Ser	Asn	Asp	Asn	His		260	265	270
30	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	Phe		275	280	285
	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	Asn		290	295	300
35	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	Gln	305	310	315	320
40	Val	Lys	Glu	Val	Thr	Thr	Asn	Asp	Gly	Val	Thr	Thr	Ile	Ala	Asn	Asn		325	330	335
45	Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Ser	Asp	Ser	Glu	Tyr	Gln	Leu	Pro		340	345	350
	Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	Ala		355	360	365
50	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	Gly		370	375	380
55	Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	Pro	385	390	395	400

EP 3 567 106 A1

	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Thr	Phe	Ser	Tyr	Thr	Phe	
					405					410					415		
5	Glu	Asp	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	Asp	
				420					425					430			
10	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Asn	Arg	
			435					440					445				
15	Thr	Gln	Asn	Gln	Ser	Gly	Ser	Ala	Gln	Asn	Lys	Asp	Leu	Leu	Phe	Ser	
			450				455					460					
20	Arg	Gly	Ser	Pro	Ala	Gly	Met	Ser	Val	Gln	Pro	Lys	Asn	Trp	Leu	Pro	
	465					470					475					480	
25	Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Lys	Thr	Lys	Thr	Asp	Asn	
					485					490					495		
30	Asn	Asn	Ser	Asn	Phe	Thr	Trp	Thr	Gly	Ala	Ser	Lys	Tyr	Asn	Leu	Asn	
				500					505					510			
35	Gly	Arg	Glu	Ser	Ile	Ile	Asn	Pro	Gly	Thr	Ala	Met	Ala	Ser	His	Lys	
			515					520					525				
40	Asp	Asp	Lys	Asp	Lys	Phe	Phe	Pro	Met	Ser	Gly	Val	Met	Ile	Phe	Gly	
		530					535					540					
45	Lys	Glu	Ser	Ala	Gly	Ala	Ser	Asn	Thr	Ala	Leu	Asp	Asn	Val	Met	Ile	
	545					550					555					560	
50	Thr	Asp	Glu	Glu	Glu	Ile	Lys	Ala	Thr	Asn	Pro	Val	Ala	Thr	Glu	Arg	
					565					570					575		
55	Phe	Gly	Thr	Val	Ala	Val	Asn	Leu	Gln	Ser	Ser	Ser	Thr	Asp	Pro	Ala	
				580					585					590			
60	Thr	Gly	Asp	Val	His	Val	Met	Gly	Ala	Leu	Pro	Gly	Met	Val	Trp	Gln	
			595					600					605				
65	Asp	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His	
		610					615					620					
70	Thr	Asp	Gly	His	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu	
	625					630					635					640	
75	Lys	His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro	Ala	

EP 3 567 106 A1

	645	650	655
5	Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr 660 665 670		
10	Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln 675 680 685		
15	Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn 690 695 700		
20	Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu 705 710 715 720		
25	Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu 725 730 735		
30	<210> 5 <211> 736 <212> PRT <213> Adeno associated virus 6.2 <400> 5		
35	Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15		
40	Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30		
45	Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45		
50	Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60		
55	Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80		
	Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala 85 90 95		
	Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110		
	Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125		
	Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg		

EP 3 567 106 A1

	130					135						140					
5	Pro	Val	Glu	Gln	Ser	Pro	Gln	Glu	Pro	Asp	Ser	Ser	Ser	Gly	Ile	Gly	
	145					150					155					160	
	Lys	Thr	Gly	Gln	Gln	Pro	Ala	Lys	Lys	Arg	Leu	Asn	Phe	Gly	Gln	Thr	
10					165					170					175		
	Gly	Asp	Ser	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Leu	Gly	Glu	Pro	Pro	
				180					185					190			
15	Ala	Thr	Pro	Ala	Ala	Val	Gly	Pro	Thr	Thr	Met	Ala	Ser	Gly	Gly	Gly	
			195					200					205				
	Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Asn	Ala	
20		210					215					220					
	Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Thr	Trp	Leu	Gly	Asp	Arg	Val	Ile	
	225					230					235					240	
25																	
	Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	Leu	
					245					250					255		
30	Tyr	Lys	Gln	Ile	Ser	Ser	Ala	Ser	Thr	Gly	Ala	Ser	Asn	Asp	Asn	His	
				260					265					270			
	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	Phe	
35			275					280					285				
	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	Asn	
		290					295					300					
40																	
	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	Gln	
	305					310					315					320	
45	Val	Lys	Glu	Val	Thr	Thr	Asn	Asp	Gly	Val	Thr	Thr	Ile	Ala	Asn	Asn	
					325					330					335		
	Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Ser	Asp	Ser	Glu	Tyr	Gln	Leu	Pro	
50				340					345					350			
	Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	Ala	
			355					360					365				
55																	
	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	Gly	
		370					375					380					

EP 3 567 106 A1

	Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	Pro	385	390	395	400
5	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Thr	Phe	Ser	Tyr	Thr	Phe	405	410		415
10	Glu	Asp	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	Asp	420	425		430
	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Asn	Arg	435	440	445	
15	Thr	Gln	Asn	Gln	Ser	Gly	Ser	Ala	Gln	Asn	Lys	Asp	Leu	Leu	Phe	Ser	450	455	460	
20	Arg	Gly	Ser	Pro	Ala	Gly	Met	Ser	Val	Gln	Pro	Lys	Asn	Trp	Leu	Pro	465	470	475	480
	Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Lys	Thr	Lys	Thr	Asp	Asn	485	490		495
25	Asn	Asn	Ser	Asn	Phe	Thr	Trp	Thr	Gly	Ala	Ser	Lys	Tyr	Asn	Leu	Asn	500	505		510
30	Gly	Arg	Glu	Ser	Ile	Ile	Asn	Pro	Gly	Thr	Ala	Met	Ala	Ser	His	Lys	515	520		525
35	Asp	Asp	Lys	Asp	Lys	Phe	Phe	Pro	Met	Ser	Gly	Val	Met	Ile	Phe	Gly	530	535	540	
	Lys	Glu	Ser	Ala	Gly	Ala	Ser	Asn	Thr	Ala	Leu	Asp	Asn	Val	Met	Ile	545	550	555	560
40	Thr	Asp	Glu	Glu	Glu	Ile	Lys	Ala	Thr	Asn	Pro	Val	Ala	Thr	Glu	Arg	565	570		575
45	Phe	Gly	Thr	Val	Ala	Val	Asn	Leu	Gln	Ser	Ser	Ser	Thr	Asp	Pro	Ala	580	585		590
	Thr	Gly	Asp	Val	His	Val	Met	Gly	Ala	Leu	Pro	Gly	Met	Val	Trp	Gln	595	600	605	
50	Asp	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His	610	615	620	
55	Thr	Asp	Gly	His	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu	625	630	635	640

EP 3 567 106 A1

	Lys	His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro	Ala	
					645					650					655		
5	Asn	Pro	Pro	Ala	Glu	Phe	Ser	Ala	Thr	Lys	Phe	Ala	Ser	Phe	Ile	Thr	
				660					665					670			
10	Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	Leu	Gln	
			675					680					685				
15	Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Val	Gln	Tyr	Thr	Ser	Asn	
		690					695					700					
20	Tyr	Ala	Lys	Ser	Ala	Asn	Val	Asp	Phe	Thr	Val	Asp	Asn	Asn	Gly	Leu	
	705					710					715					720	
25	Tyr	Thr	Glu	Pro	Arg	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg	Pro	Leu	
					725					730					735		
	<210>	6															
	<211>	737															
	<212>	PRT															
	<213>	Adeno associated virus	7														
	<400>	6															
30	Met	Ala	Ala	Asp	Gly	Tyr	Leu	Pro	Asp	Trp	Leu	Glu	Asp	Asn	Leu	Ser	
	1				5					10					15		
35	Glu	Gly	Ile	Arg	Glu	Trp	Trp	Asp	Leu	Lys	Pro	Gly	Ala	Pro	Lys	Pro	
				20					25					30			
40	Lys	Ala	Asn	Gln	Gln	Lys	Gln	Asp	Asn	Gly	Arg	Gly	Leu	Val	Leu	Pro	
			35					40					45				
45	Gly	Tyr	Lys	Tyr	Leu	Gly	Pro	Phe	Asn	Gly	Leu	Asp	Lys	Gly	Glu	Pro	
		50					55					60					
50	Val	Asn	Ala	Ala	Asp	Ala	Ala	Ala	Leu	Glu	His	Asp	Lys	Ala	Tyr	Asp	
	65					70					75					80	
55	Gln	Gln	Leu	Lys	Ala	Gly	Asp	Asn	Pro	Tyr	Leu	Arg	Tyr	Asn	His	Ala	
					85					90					95		
60	Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Gln	Glu	Asp	Thr	Ser	Phe	Gly	Gly	
				100					105					110			
65	Asn	Leu	Gly	Arg	Ala	Val	Phe	Gln	Ala	Lys	Lys	Arg	Val	Leu	Glu	Pro	
			115					120					125				

EP 3 567 106 A1

	Leu	Gly	Leu	Val	Glu	Glu	Gly	Ala	Lys	Thr	Ala	Pro	Ala	Lys	Lys	Arg	
	130						135					140					
5	Pro	Val	Glu	Pro	Ser	Pro	Gln	Arg	Ser	Pro	Asp	Ser	Ser	Thr	Gly	Ile	
	145					150					155					160	
	Gly	Lys	Lys	Gly	Gln	Gln	Pro	Ala	Arg	Lys	Arg	Leu	Asn	Phe	Gly	Gln	
10					165					170					175		
	Thr	Gly	Asp	Ser	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Leu	Gly	Glu	Pro	
				180					185					190			
15	Pro	Ala	Ala	Pro	Ser	Ser	Val	Gly	Ser	Gly	Thr	Val	Ala	Ala	Gly	Gly	
			195					200					205				
	Gly	Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Asn	
20		210					215					220					
	Ala	Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Thr	Trp	Leu	Gly	Asp	Arg	Val	
	225					230					235					240	
25	Ile	Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	
					245					250					255		
	Leu	Tyr	Lys	Gln	Ile	Ser	Ser	Glu	Thr	Ala	Gly	Ser	Thr	Asn	Asp	Asn	
30				260					265					270			
	Thr	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	
35			275					280					285				
	Phe	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	
	290						295					300					
40	Asn	Trp	Gly	Phe	Arg	Pro	Lys	Lys	Leu	Arg	Phe	Lys	Leu	Phe	Asn	Ile	
	305					310					315					320	
	Gln	Val	Lys	Glu	Val	Thr	Thr	Asn	Asp	Gly	Val	Thr	Thr	Ile	Ala	Asn	
45					325					330					335		
	Asn	Leu	Thr	Ser	Thr	Ile	Gln	Val	Phe	Ser	Asp	Ser	Glu	Tyr	Gln	Leu	
50				340					345					350			
	Pro	Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	
			355					360					365				
55	Ala	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	
	370						375					380					

EP 3 567 106 A1

	Gly	Ser	Gln	Ser	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	385	390	395	400
5	Pro	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Glu	Phe	Ser	Tyr	Ser	405	410	415	
10	Phe	Glu	Asp	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	420	425	430	
15	Asp	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Ala	435	440	445	
20	Arg	Thr	Gln	Ser	Asn	Pro	Gly	Gly	Thr	Ala	Gly	Asn	Arg	Glu	Leu	Gln	450	455	460	
25	Phe	Tyr	Gln	Gly	Gly	Pro	Ser	Thr	Met	Ala	Glu	Gln	Ala	Lys	Asn	Trp	465	470	475	480
	Leu	Pro	Gly	Pro	Cys	Phe	Arg	Gln	Gln	Arg	Val	Ser	Lys	Thr	Leu	Asp	485	490	495	
30	Gln	Asn	Asn	Asn	Ser	Asn	Phe	Ala	Trp	Thr	Gly	Ala	Thr	Lys	Tyr	His	500	505	510	
35	Leu	Asn	Gly	Arg	Asn	Ser	Leu	Val	Asn	Pro	Gly	Val	Ala	Met	Ala	Thr	515	520	525	
40	His	Lys	Asp	Asp	Glu	Asp	Arg	Phe	Phe	Pro	Ser	Ser	Gly	Val	Leu	Ile	530	535	540	
	Phe	Gly	Lys	Thr	Gly	Ala	Thr	Asn	Lys	Thr	Thr	Leu	Glu	Asn	Val	Leu	545	550	555	560
45	Met	Thr	Asn	Glu	Glu	Glu	Ile	Arg	Pro	Thr	Asn	Pro	Val	Ala	Thr	Glu	565	570	575	
50	Glu	Tyr	Gly	Ile	Val	Ser	Ser	Asn	Leu	Gln	Ala	Ala	Asn	Thr	Ala	Ala	580	585	590	
	Gln	Thr	Gln	Val	Val	Asn	Asn	Gln	Gly	Ala	Leu	Pro	Gly	Met	Val	Trp	595	600	605	
55	Gln	Asn	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	610	615	620	
	His	Thr	Asp	Gly	Asn	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly				

625	630										635										640									
Leu	Lys	His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro															
				645					650					655																
Ala	Asn	Pro	Pro	Glu	Val	Phe	Thr	Pro	Ala	Lys	Phe	Ala	Ser	Phe	Ile															
			660					665					670																	
Thr	Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	Leu															
		675					680					685																		
Gln	Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Ile	Gln	Tyr	Thr	Ser															
	690					695					700																			
Asn	Phe	Glu	Lys	Gln	Thr	Gly	Val	Asp	Phe	Ala	Val	Asp	Ser	Gln	Gly															
705					710					715					720															
Val	Tyr	Ser	Glu	Pro	Arg	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg	Asn															
				725					730					735																
Leu																														
<210>	7																													
<211>	738																													
<212>	PRT																													
<213>	Adeno associated virus	8																												
<400>	7																													
Met	Ala	Ala	Asp	Gly	Tyr	Leu	Pro	Asp	Trp	Leu	Glu	Asp	Asn	Leu	Ser															
1				5					10					15																
Glu	Gly	Ile	Arg	Glu	Trp	Trp	Ala	Leu	Lys	Pro	Gly	Ala	Pro	Lys	Pro															
			20					25					30																	
Lys	Ala	Asn	Gln	Gln	Lys	Gln	Asp	Asp	Gly	Arg	Gly	Leu	Val	Leu	Pro															
		35					40					45																		
Gly	Tyr	Lys	Tyr	Leu	Gly	Pro	Phe	Asn	Gly	Leu	Asp	Lys	Gly	Glu	Pro															
	50					55					60																			
Val	Asn	Ala	Ala	Asp	Ala	Ala	Ala	Leu	Glu	His	Asp	Lys	Ala	Tyr	Asp															
65					70					75					80															
Gln	Gln	Leu	Gln	Ala	Gly	Asp	Asn	Pro	Tyr	Leu	Arg	Tyr	Asn	His	Ala															
				85					90					95																
Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Gln	Glu	Asp	Thr	Ser	Phe	Gly	Gly															

EP 3 567 106 A1

	100		105		110												
5	Asn	Leu	Gly	Arg	Ala	Val	Phe	Gln	Ala	Lys	Lys	Arg	Val	Leu	Glu	Pro	
			115					120					125				
	Leu	Gly	Leu	Val	Glu	Glu	Gly	Ala	Lys	Thr	Ala	Pro	Gly	Lys	Lys	Arg	
10		130					135					140					
	Pro	Val	Glu	Pro	Ser	Pro	Gln	Arg	Ser	Pro	Asp	Ser	Ser	Thr	Gly	Ile	
	145					150					155					160	
15	Gly	Lys	Lys	Gly	Gln	Gln	Pro	Ala	Arg	Lys	Arg	Leu	Asn	Phe	Gly	Gln	
					165					170					175		
	Thr	Gly	Asp	Ser	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Leu	Gly	Glu	Pro	
20				180					185					190			
	Pro	Ala	Ala	Pro	Ser	Gly	Val	Gly	Pro	Asn	Thr	Met	Ala	Ala	Gly	Gly	
			195					200					205				
25	Gly	Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Ser	
	210						215					220					
30	Ser	Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Thr	Trp	Leu	Gly	Asp	Arg	Val	
	225					230					235					240	
	Ile	Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	
35					245					250					255		
	Leu	Tyr	Lys	Gln	Ile	Ser	Asn	Gly	Thr	Ser	Gly	Gly	Ala	Thr	Asn	Asp	
				260					265					270			
40	Asn	Thr	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	
			275					280					285				
45	Arg	Phe	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	
		290					295					300					
	Asn	Asn	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Ser	Phe	Lys	Leu	Phe	Asn	
50	305					310					315					320	
	Ile	Gln	Val	Lys	Glu	Val	Thr	Gln	Asn	Glu	Gly	Thr	Lys	Thr	Ile	Ala	
					325					330					335		
55	Asn	Asn	Leu	Thr	Ser	Thr	Ile	Gln	Val	Phe	Thr	Asp	Ser	Glu	Tyr	Gln	
				340					345					350			

EP 3 567 106 A1

	Leu	Pro	Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	
			355					360					365				
5	Pro	Ala	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	
		370					375					380					
10	Asn	Gly	Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	
	385					390					395					400	
	Phe	Pro	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Gln	Phe	Thr	Tyr	
					405					410					415		
15	Thr	Phe	Glu	Asp	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	
				420					425					430			
20	Leu	Asp	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	
		435						440					445				
	Ser	Arg	Thr	Gln	Thr	Thr	Gly	Gly	Thr	Ala	Asn	Thr	Gln	Thr	Leu	Gly	
		450					455					460					
25	Phe	Ser	Gln	Gly	Gly	Pro	Asn	Thr	Met	Ala	Asn	Gln	Ala	Lys	Asn	Trp	
	465					470					475					480	
30	Leu	Pro	Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Thr	Thr	Thr	Gly	
					485					490						495	
35	Gln	Asn	Asn	Asn	Ser	Asn	Phe	Ala	Trp	Thr	Ala	Gly	Thr	Lys	Tyr	His	
				500					505					510			
	Leu	Asn	Gly	Arg	Asn	Ser	Leu	Ala	Asn	Pro	Gly	Ile	Ala	Met	Ala	Thr	
			515					520					525				
40	His	Lys	Asp	Asp	Glu	Glu	Arg	Phe	Phe	Pro	Ser	Asn	Gly	Ile	Leu	Ile	
		530					535					540					
45	Phe	Gly	Lys	Gln	Asn	Ala	Ala	Arg	Asp	Asn	Ala	Asp	Tyr	Ser	Asp	Val	
	545					550					555					560	
	Met	Leu	Thr	Ser	Glu	Glu	Glu	Ile	Lys	Thr	Thr	Asn	Pro	Val	Ala	Thr	
					565					570					575		
50	Glu	Glu	Tyr	Gly	Ile	Val	Ala	Asp	Asn	Leu	Gln	Gln	Gln	Asn	Thr	Ala	
				580					585					590			
55	Pro	Gln	Ile	Gly	Thr	Val	Asn	Ser	Gln	Gly	Ala	Leu	Pro	Gly	Met	Val	
			595					600					605				

EP 3 567 106 A1

	Trp	Gln	Asn	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	
	610						615					620					
5	Pro	His	Thr	Asp	Gly	Asn	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	
	625					630					635					640	
	Gly	Leu	Lys	His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	
10					645					650					655		
	Pro	Ala	Asp	Pro	Pro	Thr	Thr	Phe	Asn	Gln	Ser	Lys	Leu	Asn	Ser	Phe	
				660					665					670			
15	Ile	Thr	Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	
			675					680					685				
	Leu	Gln	Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Ile	Gln	Tyr	Thr	
20		690					695					700					
	Ser	Asn	Tyr	Tyr	Lys	Ser	Thr	Ser	Val	Asp	Phe	Ala	Val	Asn	Thr	Glu	
25	705					710					715					720	
	Gly	Val	Tyr	Ser	Glu	Pro	Arg	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg	
					725					730					735		
30	Asn	Leu															
	<210>	8															
35	<211>	736															
	<212>	PRT															
	<213>	Adeno associated virus	9														
	<400>	8															
40	Met	Ala	Ala	Asp	Gly	Tyr	Leu	Pro	Asp	Trp	Leu	Glu	Asp	Asn	Leu	Ser	
	1				5					10					15		
	Glu	Gly	Ile	Arg	Glu	Trp	Trp	Ala	Leu	Lys	Pro	Gly	Ala	Pro	Gln	Pro	
45				20					25					30			
	Lys	Ala	Asn	Gln	Gln	His	Gln	Asp	Asn	Ala	Arg	Gly	Leu	Val	Leu	Pro	
50			35					40					45				
	Gly	Tyr	Lys	Tyr	Leu	Gly	Pro	Gly	Asn	Gly	Leu	Asp	Lys	Gly	Glu	Pro	
		50					55					60					
55	Val	Asn	Ala	Ala	Asp	Ala	Ala	Ala	Leu	Glu	His	Asp	Lys	Ala	Tyr	Asp	
	65					70					75					80	

EP 3 567 106 A1

	Gln	Gln	Leu	Lys	Ala	Gly	Asp	Asn	Pro	Tyr	Leu	Lys	Tyr	Asn	His	Ala	
					85					90					95		
5	Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Lys	Glu	Asp	Thr	Ser	Phe	Gly	Gly	
				100					105					110			
10	Asn	Leu	Gly	Arg	Ala	Val	Phe	Gln	Ala	Lys	Lys	Arg	Leu	Leu	Glu	Pro	
			115					120					125				
15	Leu	Gly	Leu	Val	Glu	Glu	Ala	Ala	Lys	Thr	Ala	Pro	Gly	Lys	Lys	Arg	
		130					135					140					
20	Pro	Val	Glu	Gln	Ser	Pro	Gln	Glu	Pro	Asp	Ser	Ser	Ala	Gly	Ile	Gly	
	145					150					155					160	
25	Lys	Ser	Gly	Ala	Gln	Pro	Ala	Lys	Lys	Arg	Leu	Asn	Phe	Gly	Gln	Thr	
					165					170					175		
30	Gly	Asp	Thr	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Ile	Gly	Glu	Pro	Pro	
				180					185					190			
35	Ala	Ala	Pro	Ser	Gly	Val	Gly	Ser	Leu	Thr	Met	Ala	Ser	Gly	Gly	Gly	
			195					200					205				
40	Ala	Pro	Val	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Ser	Ser	
		210					215					220					
45	Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Gln	Trp	Leu	Gly	Asp	Arg	Val	Ile	
	225					230					235					240	
50	Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	Leu	
					245					250					255		
55	Tyr	Lys	Gln	Ile	Ser	Asn	Ser	Thr	Ser	Gly	Gly	Ser	Ser	Asn	Asp	Asn	
				260					265					270			
60	Ala	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	
			275					280					285				
65	Phe	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	
		290					295					300					
70	Asn	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	
	305					310					315					320	
75	Gln	Val	Lys	Glu	Val	Thr	Asp	Asn	Asn	Gly	Val	Lys	Thr	Ile	Ala	Asn	
					325					330					335		

EP 3 567 106 A1

	Asn	Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Thr	Asp	Ser	Asp	Tyr	Gln	Leu	
				340					345					350			
5	Pro	Tyr	Val	Leu	Gly	Ser	Ala	His	Glu	Gly	Cys	Leu	Pro	Pro	Phe	Pro	
			355					360					365				
10	Ala	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asp	
		370					375					380					
15	Gly	Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	
	385					390					395					400	
20	Pro	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Gln	Phe	Ser	Tyr	Glu	
				405						410					415		
25	Phe	Glu	Asn	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	
				420					425					430			
30	Asp	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Ser	
			435					440					445				
35	Lys	Thr	Ile	Asn	Gly	Ser	Gly	Gln	Asn	Gln	Gln	Thr	Leu	Lys	Phe	Ser	
	450						455					460					
40	Val	Ala	Gly	Pro	Ser	Asn	Met	Ala	Val	Gln	Gly	Arg	Asn	Tyr	Ile	Pro	
	465					470					475					480	
45	Gly	Pro	Ser	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Thr	Thr	Val	Thr	Gln	Asn	
				485						490					495		
50	Asn	Asn	Ser	Glu	Phe	Ala	Trp	Pro	Gly	Ala	Ser	Ser	Trp	Ala	Leu	Asn	
				500					505					510			
55	Gly	Arg	Asn	Ser	Leu	Met	Asn	Pro	Gly	Pro	Ala	Met	Ala	Ser	His	Lys	
			515					520					525				
60	Glu	Gly	Glu	Asp	Arg	Phe	Phe	Pro	Leu	Ser	Gly	Ser	Leu	Ile	Phe	Gly	
		530					535					540					
65	Lys	Gln	Gly	Thr	Gly	Arg	Asp	Asn	Val	Asp	Ala	Asp	Lys	Val	Met	Ile	
	545					550					555					560	
70	Thr	Asn	Glu	Glu	Glu	Ile	Lys	Thr	Thr	Asn	Pro	Val	Ala	Thr	Glu	Ser	
					565					570					575		
75	Tyr	Gly	Gln	Val	Ala	Thr	Asn	His	Gln	Ser	Ala	Gln	Ala	Gln	Ala	Gln	

EP 3 567 106 A1

	580		585		590
5	Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln	595	600	605	
10	Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His	610	615	620	
15	Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Met	625	630	635	640
20	Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala	645	650	655	
25	Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr	660	665	670	
30	Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln	675	680	685	
35	Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn	690	695	700	
40	Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val	705	710	715	720
45	Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu	725	730	735	
50	<210> 9				
	<211> 738				
	<212> PRT				
	<213> Adeno associated virus rh.10				
55	<400> 9				
	Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser	1	5	10	15
	Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro	20	25	30	
	Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro	35	40	45	
	Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro	50	55	60	
	Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp				

EP 3 567 106 A1

	65					70						75				80
5	Gln	Gln	Leu	Lys	Ala	Gly	Asp	Asn	Pro	Tyr	Leu	Arg	Tyr	Asn	His	Ala
					85					90					95	
10	Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Gln	Glu	Asp	Thr	Ser	Phe	Gly	Gly
				100					105					110		
15	Asn	Leu	Gly	Arg	Ala	Val	Phe	Gln	Ala	Lys	Lys	Arg	Val	Leu	Glu	Pro
			115					120					125			
20	Leu	Gly	Leu	Val	Glu	Glu	Gly	Ala	Lys	Thr	Ala	Pro	Gly	Lys	Lys	Arg
		130					135					140				
25	Pro	Val	Glu	Pro	Ser	Pro	Gln	Arg	Ser	Pro	Asp	Ser	Ser	Thr	Gly	Ile
	145					150					155					160
30	Gly	Lys	Lys	Gly	Gln	Gln	Pro	Ala	Lys	Lys	Arg	Leu	Asn	Phe	Gly	Gln
					165					170					175	
35	Thr	Gly	Asp	Ser	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Ile	Gly	Glu	Pro
				180					185					190		
40	Pro	Ala	Gly	Pro	Ser	Gly	Leu	Gly	Ser	Gly	Thr	Met	Ala	Ala	Gly	Gly
			195					200					205			
45	Gly	Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Ser
		210					215					220				
50	Ser	Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Thr	Trp	Leu	Gly	Asp	Arg	Val
	225					230					235					240
55	Ile	Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His
					245					250					255	
60	Leu	Tyr	Lys	Gln	Ile	Ser	Asn	Gly	Thr	Ser	Gly	Gly	Ser	Thr	Asn	Asp
				260					265					270		
65	Asn	Thr	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn
			275					280					285			
70	Arg	Phe	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn
		290					295					300				
75	Asn	Asn	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn
	305					310					315					320

EP 3 567 106 A1

	Ile	Gln	Val	Lys	Glu	Val	Thr	Gln	Asn	Glu	Gly	Thr	Lys	Thr	Ile	Ala	
					325					330					335		
5	Asn	Asn	Leu	Thr	Ser	Thr	Ile	Gln	Val	Phe	Thr	Asp	Ser	Glu	Tyr	Gln	
				340					345					350			
10	Leu	Pro	Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	
			355					360					365				
15	Pro	Ala	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	
		370					375					380					
20	Asn	Gly	Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	
		385				390					395					400	
25	Phe	Pro	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Glu	Phe	Ser	Tyr	
				405						410					415		
30	Gln	Phe	Glu	Asp	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	
				420					425					430			
35	Leu	Asp	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	
			435					440					445				
40	Ser	Arg	Thr	Gln	Ser	Thr	Gly	Gly	Thr	Ala	Gly	Thr	Gln	Gln	Leu	Leu	
		450					455					460					
45	Phe	Ser	Gln	Ala	Gly	Pro	Asn	Asn	Met	Ser	Ala	Gln	Ala	Lys	Asn	Trp	
	465					470					475					480	
50	Leu	Pro	Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Thr	Thr	Leu	Ser	
				485						490					495		
55	Gln	Asn	Asn	Asn	Ser	Asn	Phe	Ala	Trp	Thr	Gly	Ala	Thr	Lys	Tyr	His	
				500					505					510			
60	Leu	Asn	Gly	Arg	Asp	Ser	Leu	Val	Asn	Pro	Gly	Val	Ala	Met	Ala	Thr	
			515					520					525				
65	His	Lys	Asp	Asp	Glu	Glu	Arg	Phe	Phe	Pro	Ser	Ser	Gly	Val	Leu	Met	
		530					535					540					
70	Phe	Gly	Lys	Gln	Gly	Ala	Gly	Lys	Asp	Asn	Val	Asp	Tyr	Ser	Ser	Val	
	545					550					555					560	
75	Met	Leu	Thr	Ser	Glu	Glu	Glu	Ile	Lys	Thr	Thr	Asn	Pro	Val	Ala	Thr	
				565						570					575		

EP 3 567 106 A1

	Glu	Gln	Tyr	Gly	Val	Val	Ala	Asp	Asn	Leu	Gln	Gln	Gln	Asn	Ala	Ala	
				580					585					590			
5	Pro	Ile	Val	Gly	Ala	Val	Asn	Ser	Gln	Gly	Ala	Leu	Pro	Gly	Met	Val	
			595					600					605				
10	Trp	Gln	Asn	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	
		610					615					620					
15	Pro	His	Thr	Asp	Gly	Asn	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	
	625					630					635					640	
20	Gly	Leu	Lys	His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	
					645					650					655		
25	Pro	Ala	Asp	Pro	Pro	Thr	Thr	Phe	Ser	Gln	Ala	Lys	Leu	Ala	Ser	Phe	
				660					665					670			
30	Ile	Thr	Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	
			675					680					685				
35	Leu	Gln	Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Ile	Gln	Tyr	Thr	
		690					695					700					
40	Ser	Asn	Tyr	Tyr	Lys	Ser	Thr	Asn	Val	Asp	Phe	Ala	Val	Asn	Thr	Asp	
	705					710					715					720	
45	Gly	Thr	Tyr	Ser	Glu	Pro	Arg	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg	
					725					730					735		
50	Asn Leu																
55	<210> 10																
	<211> 738																
	<212> PRT																
	<213> Adeno associated virus rh.39																
	<400> 10																
60	Met	Ala	Ala	Asp	Gly	Tyr	Leu	Pro	Asp	Trp	Leu	Glu	Asp	Asn	Leu	Ser	
	1				5					10					15		
65	Glu	Gly	Ile	Arg	Glu	Trp	Trp	Ala	Leu	Lys	Pro	Gly	Ala	Pro	Lys	Pro	
				20					25					30			
70	Lys	Ala	Asn	Gln	Gln	Lys	Gln	Asp	Asp	Gly	Arg	Gly	Leu	Val	Leu	Pro	
			35					40					45				

EP 3 567 106 A1

	Gly	Tyr	Lys	Tyr	Leu	Gly	Pro	Phe	Asn	Gly	Leu	Asp	Lys	Gly	Glu	Pro	
	50						55					60					
5	Val	Asn	Ala	Ala	Asp	Ala	Ala	Ala	Leu	Glu	His	Asp	Lys	Ala	Tyr	Asp	
	65					70					75					80	
	Gln	Gln	Leu	Lys	Ala	Gly	Asp	Asn	Pro	Tyr	Leu	Arg	Tyr	Asn	His	Ala	
10					85					90					95		
	Asp	Ala	Glu	Phe	Gln	Glu	Arg	Leu	Gln	Glu	Asp	Thr	Ser	Phe	Gly	Gly	
				100					105					110			
15	Asn	Leu	Gly	Arg	Ala	Val	Phe	Gln	Ala	Lys	Lys	Arg	Val	Leu	Glu	Pro	
			115					120					125				
	Leu	Gly	Leu	Val	Glu	Glu	Ala	Ala	Lys	Thr	Ala	Pro	Gly	Lys	Lys	Arg	
20		130					135					140					
	Pro	Val	Glu	Pro	Ser	Pro	Gln	Arg	Ser	Pro	Asp	Ser	Ser	Thr	Gly	Ile	
	145					150					155					160	
25	Gly	Lys	Lys	Gly	Gln	Gln	Pro	Ala	Lys	Lys	Arg	Leu	Asn	Phe	Gly	Gln	
					165					170					175		
	Thr	Gly	Asp	Ser	Glu	Ser	Val	Pro	Asp	Pro	Gln	Pro	Ile	Gly	Glu	Pro	
30				180					185					190			
	Pro	Ala	Gly	Pro	Ser	Gly	Leu	Gly	Ser	Gly	Thr	Met	Ala	Ala	Gly	Gly	
35			195					200					205				
	Gly	Ala	Pro	Met	Ala	Asp	Asn	Asn	Glu	Gly	Ala	Asp	Gly	Val	Gly	Ser	
		210					215					220					
40	Ser	Ser	Gly	Asn	Trp	His	Cys	Asp	Ser	Thr	Trp	Leu	Gly	Asp	Arg	Val	
	225					230					235					240	
	Ile	Thr	Thr	Ser	Thr	Arg	Thr	Trp	Ala	Leu	Pro	Thr	Tyr	Asn	Asn	His	
45					245					250					255		
	Leu	Tyr	Lys	Gln	Ile	Ser	Asn	Gly	Thr	Ser	Gly	Gly	Ser	Thr	Asn	Asp	
				260					265					270			
50	Asn	Thr	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	
			275					280					285				
55	Arg	Phe	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	
		290					295					300					

EP 3 567 106 A1

	Asn	Asn	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Ser	Phe	Lys	Leu	Phe	Asn	305	310	315	320
5	Ile	Gln	Val	Lys	Glu	Val	Thr	Gln	Asn	Glu	Gly	Thr	Lys	Thr	Ile	Ala		325	330	335
10	Asn	Asn	Leu	Thr	Ser	Thr	Ile	Gln	Val	Phe	Thr	Asp	Ser	Glu	Tyr	Gln		340	345	350
15	Leu	Pro	Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe		355	360	365
20	Pro	Ala	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn		370	375	380
25	Asn	Gly	Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr		385	390	395
30	Phe	Pro	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Glu	Phe	Ser	Tyr		405	410	415
35	Thr	Phe	Glu	Asp	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser		420	425	430
40	Leu	Asp	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu		435	440	445
45	Ser	Arg	Thr	Gln	Ser	Thr	Gly	Gly	Thr	Gln	Gly	Thr	Gln	Gln	Leu	Leu		450	455	460
50	Phe	Ser	Gln	Ala	Gly	Pro	Ala	Asn	Met	Ser	Ala	Gln	Ala	Lys	Asn	Trp		465	470	475
55	Leu	Pro	Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Thr	Thr	Leu	Ser		485	490	495
	Gln	Asn	Asn	Asn	Ser	Asn	Phe	Ala	Trp	Thr	Gly	Ala	Thr	Lys	Tyr	His		500	505	510
	Leu	Asn	Gly	Arg	Asp	Ser	Leu	Val	Asn	Pro	Gly	Val	Ala	Met	Ala	Thr		515	520	525
	His	Lys	Asp	Asp	Glu	Glu	Arg	Phe	Phe	Pro	Ser	Ser	Gly	Val	Leu	Met		530	535	540
	Phe	Gly	Lys	Gln	Gly	Ala	Gly	Arg	Asp	Asn	Val	Asp	Tyr	Ser	Ser	Val				

EP 3 567 106 A1

	545		550		555		560									
5	Met	Leu	Thr	Ser	Glu	Glu	Glu	Ile	Lys	Thr	Thr	Asn	Pro	Val	Ala	Thr
				565					570						575	
10	Glu	Gln	Tyr	Gly	Val	Val	Ala	Asp	Asn	Leu	Gln	Gln	Thr	Asn	Thr	Gly
				580					585					590		
15	Pro	Ile	Val	Gly	Asn	Val	Asn	Ser	Gln	Gly	Ala	Leu	Pro	Gly	Met	Val
			595					600					605			
20	Trp	Gln	Asn	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile
		610					615					620				
25	Pro	His	Thr	Asp	Gly	Asn	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe
	625					630					635					640
30	Gly	Leu	Lys	His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val
				645						650					655	
35	Pro	Ala	Asp	Pro	Pro	Thr	Thr	Phe	Ser	Gln	Ala	Lys	Leu	Ala	Ser	Phe
				660					665					670		
40	Ile	Thr	Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu
		675					680						685			
45	Leu	Gln	Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Ile	Gln	Tyr	Thr
	690						695					700				
50	Ser	Asn	Tyr	Tyr	Lys	Ser	Thr	Asn	Val	Asp	Phe	Ala	Val	Asn	Thr	Glu
	705					710					715					720
55	Gly	Thr	Tyr	Ser	Glu	Pro	Arg	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg
				725						730					735	
	Asn	Leu														
	<210>	11														
	<211>	736														
	<212>	PRT														
	<213>	Adeno associated virus rh.43														
	<400>	11														
	Met	Ala	Ala	Asp	Gly	Tyr	Leu	Pro	Asp	Trp	Leu	Glu	Asp	Asn	Leu	Ser
	1				5					10					15	
	Glu	Gly	Ile	Arg	Glu	Trp	Trp	Asp	Leu	Lys	Pro	Gly	Ala	Pro	Lys	Pro

EP 3 567 106 A1

	20	25	30
5	Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45		
10	Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60		
15	Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80		
20	Gln Gln Leu Glu Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala 85 90 95		
25	Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110		
30	Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125		
35	Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140		
40	Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly 145 150 155 160		
45	Lys Lys Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln Thr 165 170 175		
50	Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro 180 185 190		
55	Ala Ala Pro Ser Gly Val Gly Pro Asn Thr Met Ala Ala Gly Gly Gly 195 200 205		
	Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser 210 215 220		
	Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile 225 230 235 240		
	Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu 245 250 255		
	Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ala Thr Asn Asp Asn 260 265 270		

EP 3 567 106 A1

	Thr	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	
			275					280					285				
5	Phe	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	
		290					295					300					
10	Asn	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Ser	Phe	Lys	Leu	Phe	Asn	Ile	
	305					310					315					320	
15	Gln	Val	Lys	Glu	Val	Thr	Gln	Asn	Glu	Gly	Thr	Lys	Thr	Ile	Ala	Asn	
					325					330					335		
20	Asn	Leu	Thr	Ser	Thr	Ile	Gln	Val	Phe	Thr	Asp	Ser	Glu	Tyr	Gln	Leu	
				340					345					350			
25	Pro	Tyr	Val	Leu	Gly	Ser	Ala	His	Gln	Gly	Cys	Leu	Pro	Pro	Phe	Pro	
			355					360					365				
30	Ala	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asn	
		370					375					380					
35	Gly	Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	
	385					390					395					400	
40	Pro	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Gln	Phe	Thr	Tyr	Thr	
				405						410					415		
45	Phe	Glu	Asp	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	
				420					425					430			
50	Asp	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Ser	
			435					440					445				
55	Arg	Thr	Gln	Thr	Thr	Gly	Gly	Thr	Ala	Asn	Thr	Gln	Thr	Leu	Gly	Phe	
		450				455						460					
60	Ser	Gln	Gly	Gly	Pro	Asn	Thr	Met	Ala	Asn	Gln	Ala	Lys	Asn	Trp	Leu	
	465					470					475					480	
65	Pro	Gly	Pro	Cys	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Thr	Thr	Thr	Gly	Gln	
				485						490					495		
70	Asn	Asn	Asn	Ser	Asn	Phe	Ala	Trp	Thr	Ala	Gly	Thr	Lys	Tyr	His	Leu	
				500					505					510			
75	Asn	Gly	Arg	Asn	Ser	Leu	Ala	Asn	Pro	Gly	Ile	Ala	Met	Ala	Thr	His	
		515						520					525				

EP 3 567 106 A1

	Lys	Asp	Asp	Glu	Glu	Arg	Phe	Phe	Pro	Val	Thr	Gly	Ser	Cys	Phe	Trp	
	530						535					540					
5	Gln	Gln	Asn	Ala	Ala	Arg	Asp	Asn	Ala	Asp	Tyr	Ser	Asp	Val	Met	Leu	
	545					550					555					560	
10	Thr	Ser	Glu	Glu	Glu	Ile	Lys	Thr	Thr	Asn	Pro	Val	Ala	Thr	Glu	Glu	
					565					570					575		
15	Tyr	Gly	Ile	Val	Ala	Asp	Asn	Leu	Gln	Gln	Gln	Asn	Thr	Ala	Pro	Gln	
				580					585					590			
20	Ile	Gly	Thr	Val	Asn	Ser	Gln	Gly	Ala	Leu	Pro	Gly	Met	Val	Trp	Gln	
			595					600					605				
25	Asn	Arg	Asp	Val	Tyr	Leu	Gln	Gly	Pro	Ile	Trp	Ala	Lys	Ile	Pro	His	
	610						615					620					
30	Thr	Asp	Gly	Asn	Phe	His	Pro	Ser	Pro	Leu	Met	Gly	Gly	Phe	Gly	Leu	
	625					630					635					640	
35	Lys	His	Pro	Pro	Pro	Gln	Ile	Leu	Ile	Lys	Asn	Thr	Pro	Val	Pro	Ala	
					645					650					655		
40	Asp	Pro	Pro	Thr	Thr	Phe	Asn	Gln	Ser	Lys	Leu	Asn	Ser	Phe	Ile	Thr	
				660					665					670			
45	Gln	Tyr	Ser	Thr	Gly	Gln	Val	Ser	Val	Glu	Ile	Glu	Trp	Glu	Leu	Gln	
			675					680					685				
50	Lys	Glu	Asn	Ser	Lys	Arg	Trp	Asn	Pro	Glu	Ile	Gln	Tyr	Thr	Ser	Asn	
	690						695					700					
55	Tyr	Tyr	Lys	Ser	Thr	Ser	Val	Asp	Phe	Ala	Val	Asn	Thr	Glu	Gly	Val	
	705					710					715					720	
60	Tyr	Ser	Glu	Pro	Arg	Pro	Ile	Gly	Thr	Arg	Tyr	Leu	Thr	Arg	Asn	Leu	
					725					730					735		
65	<210>	12															
70	<211>	736															
75	<212>	PRT															
80	<213>	Adeno associated virus	CSp3														
85	<400>	12															
90	Met	Ala	Ala	Asp	Gly	Tyr	Leu	Pro	Asp	Trp	Leu	Glu	Asp	Asn	Leu	Ser	
	1				5					10					15		

EP 3 567 106 A1

	Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Gln Pro	20	25	30
5	Lys Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val Leu Pro	35	40	45
10	Gly Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro	50	55	60
15	Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp	65	70	75
20	Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala	85	90	95
25	Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp Thr Ser Phe Gly Gly	100	105	110
30	Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Leu Leu Glu Pro	115	120	125
35	Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg	130	135	140
40	Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ala Gly Ile Gly	145	150	155
45	Lys Ser Gly Ala Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr	165	170	175
50	Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro	180	185	190
55	Ala Ala Pro Ser Gly Val Gly Ser Leu Thr Ile Ala Ser Gly Gly Gly	195	200	205
	Ala Pro Val Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser	210	215	220
	Ser Gly Asn Trp His Cys Asp Ser Gln Trp Leu Gly Asp Arg Val Ile	225	230	235
	Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu	245	250	255
	Tyr Lys Arg Ile Ser Asn Ser Thr Ser Gly Gly Ser Ser Asn Asp Asn	260	265	270

EP 3 567 106 A1

	Ala	Tyr	Phe	Gly	Tyr	Ser	Thr	Pro	Trp	Gly	Tyr	Phe	Asp	Phe	Asn	Arg	
			275					280					285				
5	Phe	His	Cys	His	Phe	Ser	Pro	Arg	Asp	Trp	Gln	Arg	Leu	Ile	Asn	Asn	
		290					295					300					
10	Asn	Trp	Gly	Phe	Arg	Pro	Lys	Arg	Leu	Asn	Phe	Lys	Leu	Phe	Asn	Ile	
	305					310					315					320	
15	Arg	Val	Lys	Glu	Val	Thr	Asp	Asn	Asn	Gly	Val	Lys	Thr	Ile	Thr	Asn	
				325						330					335		
20	Asn	Leu	Thr	Ser	Thr	Val	Gln	Val	Phe	Thr	Asp	Ser	Asp	Tyr	Gln	Leu	
				340					345					350			
25	Pro	Tyr	Val	Leu	Gly	Ser	Ala	His	Glu	Gly	Cys	Leu	Pro	Pro	Phe	Pro	
			355					360					365				
30	Ala	Asp	Val	Phe	Met	Ile	Pro	Gln	Tyr	Gly	Tyr	Leu	Thr	Leu	Asn	Asp	
	370						375					380					
35	Gly	Ser	Gln	Ala	Val	Gly	Arg	Ser	Ser	Phe	Tyr	Cys	Leu	Glu	Tyr	Phe	
	385					390					395					400	
40	Pro	Ser	Gln	Met	Leu	Arg	Thr	Gly	Asn	Asn	Phe	Gln	Phe	Ser	Tyr	Glu	
				405						410					415		
45	Phe	Glu	Asn	Val	Pro	Phe	His	Ser	Ser	Tyr	Ala	His	Ser	Gln	Ser	Leu	
				420					425					430			
50	Asp	Arg	Leu	Met	Asn	Pro	Leu	Ile	Asp	Gln	Tyr	Leu	Tyr	Tyr	Leu	Ser	
			435					440					445				
55	Lys	Thr	Ile	Asn	Gly	Ser	Gly	Gln	Asn	Gln	Gln	Thr	Leu	Lys	Phe	Ser	
	450						455					460					
60	Val	Ala	Gly	Pro	Ser	Asn	Met	Ala	Val	Gln	Gly	Arg	Asn	Tyr	Ile	Pro	
	465					470					475					480	
65	Gly	Pro	Ser	Tyr	Arg	Gln	Gln	Arg	Val	Ser	Thr	Thr	Val	Thr	Arg	Asn	
					485					490					495		
70	Asn	Asn	Ser	Glu	Phe	Ala	Trp	Pro	Gly	Ala	Ser	Ser	Trp	Ala	Leu	Asn	
			500						505					510			
75	Gly	Arg	Asn	Ser	Leu	Met	Asn	Pro	Gly	Pro	Ala	Met	Ala	Ser	His	Lys	

EP 3 567 106 A1

	515	520	525
5	Glu Gly Glu Asp Arg Phe Phe Pro Leu Ser Gly Ser Leu Ile Phe Gly 530 535 540		
10	Lys Gln Gly Thr Gly Arg Asp Asn Val Asp Ala Asp Lys Val Met Ile 545 550 555 560		
15	Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Ser 565 570 575		
20	Tyr Gly Gln Val Ala Thr Asn His Gln Ser Ala Gln Ala Gln Ala Gln 580 585 590		
25	Thr Gly Trp Val Gln Asn Gln Gly Ile Leu Pro Gly Met Val Trp Gln 595 600 605		
30	Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His 610 615 620		
35	Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Val 625 630 635 640		
40	Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala 645 650 655		
45	Asp Pro Pro Thr Ala Phe Asn Lys Asp Lys Leu Asn Ser Phe Ile Thr 660 665 670		
50	Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln 675 680 685		
55	Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn 690 695 700		
	Tyr Tyr Lys Ser Asn Asn Val Glu Phe Ala Val Asn Thr Glu Gly Val 705 710 715 720		
	Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu 725 730 735		
	<210> 13 <211> 313 <212> PRT <213> Homo sapiens		
	<400> 13		
	Met Thr Ser Cys His Ile Ala Glu Glu His Ile Gln Lys Val Ala Ile		

EP 3 567 106 A1

	1		5					10					15			
5	Phe	Gly	Gly	Thr	His	Gly	Asn	Glu	Leu	Thr	Gly	Val	Phe	Leu	Val	Lys
				20					25					30		
10	His	Trp	Leu	Glu	Asn	Gly	Ala	Glu	Ile	Gln	Arg	Thr	Gly	Leu	Glu	Val
			35					40					45			
15	Lys	Pro	Phe	Ile	Thr	Asn	Pro	Arg	Ala	Val	Lys	Lys	Cys	Thr	Arg	Tyr
		50					55					60				
20	Ile	Asp	Cys	Asp	Leu	Asn	Arg	Ile	Phe	Asp	Leu	Glu	Asn	Leu	Gly	Lys
	65					70					75					80
25	Lys	Met	Ser	Glu	Asp	Leu	Pro	Tyr	Glu	Val	Arg	Arg	Ala	Gln	Glu	Ile
					85					90					95	
30	Asn	His	Leu	Phe	Gly	Pro	Lys	Asp	Ser	Glu	Asp	Ser	Tyr	Asp	Ile	Ile
				100					105					110		
35	Phe	Asp	Leu	His	Asn	Thr	Thr	Ser	Asn	Met	Gly	Cys	Thr	Leu	Ile	Leu
			115					120					125			
40	Glu	Asp	Ser	Arg	Asn	Asn	Phe	Leu	Ile	Gln	Met	Phe	His	Tyr	Ile	Lys
		130					135					140				
45	Thr	Ser	Leu	Ala	Pro	Leu	Pro	Cys	Tyr	Val	Tyr	Leu	Ile	Glu	His	Pro
	145					150					155					160
50	Ser	Leu	Lys	Tyr	Ala	Thr	Thr	Arg	Ser	Ile	Ala	Lys	Tyr	Pro	Val	Gly
					165					170					175	
55	Ile	Glu	Val	Gly	Pro	Gln	Pro	Gln	Gly	Val	Leu	Arg	Ala	Asp	Ile	Leu
				180					185					190		
60	Asp	Gln	Met	Arg	Lys	Met	Ile	Lys	His	Ala	Leu	Asp	Phe	Ile	His	His
			195					200					205			
65	Phe	Asn	Glu	Gly	Lys	Glu	Phe	Pro	Pro	Cys	Ala	Ile	Glu	Val	Tyr	Lys
		210					215					220				
70	Ile	Ile	Glu	Lys	Val	Asp	Tyr	Pro	Arg	Asp	Glu	Asn	Gly	Glu	Ile	Ala
	225					230					235					240
75	Ala	Ile	Ile	His	Pro	Asn	Leu	Gln	Asp	Gln	Asp	Trp	Lys	Pro	Leu	His
				245						250					255	

EP 3 567 106 A1

Pro Gly Asp Pro Met Phe Leu Thr Leu Asp Gly Lys Thr Ile Pro Leu
260 265 270

5 Gly Gly Asp Cys Thr Val Tyr Pro Val Phe Val Asn Glu Ala Ala Tyr
275 280 285

10 Tyr Glu Lys Lys Glu Ala Phe Ala Lys Thr Thr Lys Leu Thr Leu Asn
290 295 300

Ala Lys Ser Ile Arg Cys Cys Leu His
305 310

15 <210> 14
<211> 942
<212> DNA
<213> Homo sapiens

20 <400> 14
atgacttctt gtcacattgc tgaagaacat atacaaaagg ttgctatctt tggaggaacc 60
catgggaatg agctaaccgg agtatttctg gttaagcatt ggctagagaa tggcgctgag 120
25 attcagagaa cagggctgga ggtaaaacca tttattacta accccagagc agtgaagaag 180
tgtaccagat atattgactg tgacctgaat cgcatttttg accttgaaaa tcttggtgcaa 240
aaaatgtcag aagatttgcc atatgaagtg agaagggctc aagaaataaa tcatttatctt 300
30 ggtccaaaag acagtgaaga ttcctatgac attatttttg accttcacaa caccacctct 360
aacatggggg gcactcttat tcttgaggat tccaggaata actttttaat tcagatgttt 420
cattacatta agacttctct ggctccacta ccctgctacg tttatctgat tgagcatcct 480
35 tccctcaa atgcgaccac tcgttccata gccagtatc ctgtgggtat agaagttggg 540
cctcagcctc aaggggttct gagagctgat atcttggatc aaatgagaaa aatgattaaa 600
catgctcttg attttataca tcatttcaat gaaggaaaag aatttcctcc ctgcgccatt 660
40 gaggtctata aaattataga gaaagttgat tccccccggg atgaaaatgg agaaattgct 720
gctatcatcc atcctaattc gcaggatcaa gactggaaac cactgcatcc tggggatccc 780
atgtttttta ctcttgatgg gaagacgatc ccactgggag gagactgtac cgtgtacccc 840
45 gtgtttgtga atgaggccgc atattacgaa aagaaagaag cttttgcaaa gacaactaaa 900
ctaacgctca atgcaaaaag tattcgctgc tgtttacatt ag 942

50 <210> 15
<211> 312
<212> PRT
<213> Mus Musculus

55 <400> 15

Met Thr Ser Cys Val Ala Lys Glu Pro Ile Lys Lys Ile Ala Ile Phe

EP 3 567 106 A1

	1		5		10		15									
5	Gly	Gly	Thr	His	Gly	Asn	Glu	Leu	Thr	Gly	Val	Phe	Leu	Val	Thr	His
				20					25					30		
10	Trp	Leu	Arg	Asn	Gly	Thr	Glu	Val	His	Arg	Ala	Gly	Leu	Asp	Val	Lys
			35					40					45			
15	Pro	Phe	Ile	Thr	Asn	Pro	Arg	Ala	Val	Glu	Lys	Cys	Thr	Arg	Tyr	Ile
		50					55					60				
20	Asp	Cys	Asp	Leu	Asn	Arg	Val	Phe	Asp	Leu	Glu	Asn	Leu	Ser	Lys	Glu
	65					70					75					80
25	Met	Ser	Glu	Asp	Leu	Pro	Tyr	Glu	Val	Arg	Arg	Ala	Gln	Glu	Ile	Asn
					85					90					95	
30	His	Leu	Phe	Gly	Pro	Lys	Asn	Ser	Asp	Asp	Ala	Tyr	Asp	Leu	Val	Phe
				100					105					110		
35	Asp	Leu	His	Asn	Thr	Thr	Ser	Asn	Met	Gly	Cys	Thr	Leu	Ile	Leu	Glu
			115					120					125			
40	Asp	Ser	Arg	Asn	Asp	Phe	Leu	Ile	Gln	Met	Phe	His	Tyr	Ile	Lys	Thr
		130					135					140				
45	Cys	Met	Ala	Pro	Leu	Pro	Cys	Ser	Val	Tyr	Leu	Ile	Glu	His	Pro	Ser
	145					150					155				160	
50	Leu	Lys	Tyr	Ala	Thr	Thr	Arg	Ser	Ile	Ala	Lys	Tyr	Pro	Val	Gly	Ile
				165						170					175	
55	Glu	Val	Gly	Pro	Gln	Pro	His	Gly	Val	Leu	Arg	Ala	Asp	Ile	Leu	Asp
				180				185						190		
60	Gln	Met	Arg	Lys	Met	Ile	Lys	His	Ala	Leu	Asp	Phe	Ile	Gln	His	Phe
			195					200					205			
65	Asn	Glu	Gly	Lys	Glu	Phe	Pro	Pro	Cys	Ser	Ile	Asp	Val	Tyr	Lys	Ile
		210					215					220				
70	Met	Glu	Lys	Val	Asp	Tyr	Pro	Arg	Asn	Glu	Ser	Gly	Asp	Met	Ala	Ala
	225					230					235				240	
75	Val	Ile	His	Pro	Asn	Leu	Gln	Asp	Gln	Asp	Trp	Lys	Pro	Leu	His	Pro
					245					250					255	

EP 3 567 106 A1

Gly Asp Pro Val Phe Val Ser Leu Asp Gly Lys Val Ile Pro Leu Gly
260 265 270

5 Gly Asp Cys Thr Val Tyr Pro Val Phe Val Asn Glu Ala Ala Tyr Tyr
275 280 285

10 Glu Lys Lys Glu Ala Phe Ala Lys Thr Thr Lys Leu Thr Leu Ser Ala
290 295 300

Lys Ser Ile Arg Ser Thr Leu His
305 310

15 <210> 16
<211> 939
<212> DNA
<213> Mus Musculus

20 <400> 16
atgacctctt gtgttgctaa agaacctatt aagaagattg ccatctttgg agggactcat 60
ggaaatgaac tgaccggagt gtttctagtt actcactggc taaggaatgg cactgaagtt 120
25 cacagagcag ggctggacgt gaagccattc attaccaatc caagggcggt ggagaagtgc 180
accagatata ttgactgtga cctgaatcgt gtttttgacc ttgaaaatct tagcaaagag 240
atgtctgaag acttgccata tgaagtgaga agggctcaag aaataaatca tttatttggt 300
30 ccaaaaaata gtgatgatgc ctatgacctt gtttttgacc ttcacaacac cacttctaac 360
atgggttgca ctcttattct tgaggattcc aggaatgact ttttaattca gatgtttcac 420
tatattaaga cttgcatggc tccattaccc tgctctgttt atctcattga gcatccttca 480
35 ctcaaatatg caaccactcg ttccattgcc aagtatcctg ttggtataga agttggctcct 540
cagcctcacg gtgtccttag agctgatatt ttagacccaa tgagaaaaat gataaaacat 600
gctcttgatt ttatacagca tttcaatgaa ggaaaagaat ttcctccctg ttctattgac 660
40 gtctataaaa taatggagaa agttgattat ccaaggaatg aaagtggaga catggctgct 720
gttattcatc ctaatctgca ggatcaagac tggaaaccat tgcaccctgg agatcctgtg 780
45 tttgtgtctc ttgatggaaa agttattcca ctgggtggag actgtaccgt gtaccagtg 840
tttgtgaatg aagctgcata ttatgaaaaa aaagaagcat ttgcaaagac aacaaaacta 900
acactcagcg caaaaagcat ccgctccact ttgactaa 939

50 <210> 17
<211> 465
<212> DNA
<213> Homo sapiens

55 <400> 17
atggcgacga aggccgtgtg cgtgctgaag ggcgacggcc cagtgcaggg catcatcaat 60

EP 3 567 106 A1

ttcgagcaga aggaaagtaa tggaccagtg aaggtgtggg gaagcattaa aggactgact 120
gaaggcctgc atggattcca tgttcatgag tttggagata atacagcagg ctgtaccagt 180
5 gcaggtcctc actttaatcc tctatccaga aaacacggtg ggccaaagga tgaagagagg 240
catgttggag acttgggcaa tgtgactgct gacaaagatg gtgtggccga tgtgtctatt 300
gaagattctg tgatctcact ctcaggagac cattgcatca ttggccgcac actggtggtc 360
10 catgaaaaag cagatgactt gggcaaaggt ggaaatgaag aaagtacaaa gacaggaaac 420
gctggaagtc gtttggcttg tgggtgaatt gggatcgccc aataa 465

15 <210> 18
<211> 154
<212> PRT
<213> Homo sapiens

20 <400> 18

Met Ala Thr Lys Ala Val Cys Val Leu Lys Gly Asp Gly Pro Val Gln
1 5 10 15

25 Gly Ile Ile Asn Phe Glu Gln Lys Glu Ser Asn Gly Pro Val Lys Val
20 25 30

Trp Gly Ser Ile Lys Gly Leu Thr Glu Gly Leu His Gly Phe His Val
35 40 45

30 His Glu Phe Gly Asp Asn Thr Ala Gly Cys Thr Ser Ala Gly Pro His
50 55 60

35 Phe Asn Pro Leu Ser Arg Lys His Gly Gly Pro Lys Asp Glu Glu Arg
65 70 75 80

40 His Val Gly Asp Leu Gly Asn Val Thr Ala Asp Lys Asp Gly Val Ala
85 90 95

Asp Val Ser Ile Glu Asp Ser Val Ile Ser Leu Ser Gly Asp His Cys
100 105 110

45 Ile Ile Gly Arg Thr Leu Val Val His Glu Lys Ala Asp Asp Leu Gly
115 120 125

50 Lys Gly Gly Asn Glu Glu Ser Thr Lys Thr Gly Asn Ala Gly Ser Arg
130 135 140

Leu Ala Cys Gly Val Ile Gly Ile Ala Gln
145 150

55 <210> 19

EP 3 567 106 A1

<211> 465
<212> DNA
<213> Mus Musculus

5 <400> 19
atggcgatga aagcgggtgtg cgtgctgaag ggcgacggtc cgggtgcaggg aaccatccac 60
ttcgagcaga aggcaagcgg tgaaccagtt gtgttgtcag gacaaattac aggattaact 120
10 gaaggccagc atgggttcca cgtccatcag tatggggaca atacacaagg ctgtaccagt 180
gcaggacctc attttaatcc tcaactctaag aaacatggtg gcccggcgga tgaagagagg 240
catgttggag acctgggcaa tgtgactgct ggaaaggacg gtgtggccaa tgtgtccatt 300
15 gaagatcgtg tgatctcact ctcaaggagag cattccatca ttggccgtac aatggtggtc 360
catgagaaac aagatgactt gggcaaaggt ggaaatgaag aaagtacaaa gactggaaat 420
gctgggagcc gcttggcctg tggagtgatt gggattgcgc agtaa 465

20 <210> 20
<211> 154
<212> PRT
<213> Mus Musculus

25 <400> 20
Met Ala Met Lys Ala Val Cys Val Leu Lys Gly Asp Gly Pro Val Gln
1 5 10 15
30 Gly Thr Ile His Phe Glu Gln Lys Ala Ser Gly Glu Pro Val Val Leu
20 25 30
35 Ser Gly Gln Ile Thr Gly Leu Thr Glu Gly Gln His Gly Phe His Val
35 40 45
His Gln Tyr Gly Asp Asn Thr Gln Gly Cys Thr Ser Ala Gly Pro His
50 55 60
40 Phe Asn Pro His Ser Lys Lys His Gly Gly Pro Ala Asp Glu Glu Arg
65 70 75 80
45 His Val Gly Asp Leu Gly Asn Val Thr Ala Gly Lys Asp Gly Val Ala
85 90 95
Asn Val Ser Ile Glu Asp Arg Val Ile Ser Leu Ser Gly Glu His Ser
100 105 110
50 Ile Ile Gly Arg Thr Met Val Val His Glu Lys Gln Asp Asp Leu Gly
115 120 125
55 Lys Gly Gly Asn Glu Glu Ser Thr Lys Thr Gly Asn Ala Gly Ser Arg
130 135 140

EP 3 567 106 A1

Leu Ala Cys Gly Val Ile Gly Ile Ala Gln
145 150

5 <210> 21
<211> 5243
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Synthetic Oligonucleotide

<400> 21
ctgcgcgctc gctcgctcac tgaggccgcc cgggcaaagc ccgggcgctcg ggcgaccttt 60
15 ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg gagtgtagcc atgctctagg 120
aagatcaatt caattcacgc gtcgacattg attattgact agttattaat agtaatcaat 180
20 tacgggggtca ttagttcata gcccatatat ggagttccgc gttacataac ttacggtaaa 240
tggcccgccct ggctgaccgc ccaacgacct ccgccattg acgtcaataa tgacgtatgt 300
tcccatagta acgccaatag ggactttcca ttgacgtcaa tgggtggata ttacggtaa 360
25 actgcccact tggcagtaca tcaagtgtat catatgccaa gtacgcccc tattgacgtc 420
aatgacggta aatggcccg ctaggcattat gccagtaga tgacctatg ggactttcct 480
acttggcagt acatctacgt attagtcac gctattacca tgtcgaggcc acgttctgct 540
30 tcaactctccc catctcccc ccctccccac cccaatttt gtattttattt attttttaat 600
tattttgtgc agcgatgggg gcgggggggg ggggcgcgcg ccaggcgggg cggggcgggg 660
cgaggggchg ggcgggcgga ggcggagagg tgcggcgga gccaatcaga gcggcgcgct 720
35 ccgaaagttt ctttttatgg cgaggcggg gcggcgcgcg ccctataaaa agcgaagcgc 780
gcggcgggcg ggagcaagct ctagcctcga gaattcacgc gtggtacct tagagcagag 840
40 ctcgtttagt gaaccgtcag ttcgaaatcg ccaccatggg gagcaaggcg gaggagctgt 900
tcaccggggg ggtgcccatc ctggtcgagc tggacggcga cgtaaacggc cacaagttca 960
gctgttccgg cgagggcgag ggcgatgcca cctacggcaa gctgaccctg aagttcatct 1020
45 gcaccaccgg caagctgccc gtgccttggc ccaccctcgt gaccaccctg acctacggcg 1080
tgcagtgtct cagccgctac cccgaccaca tgaagcagca cgacttcttc aagtccgcca 1140
tgcccgaagg ctacgtccag gagcgacca tcttcttcaa ggacgacggc aactacaaga 1200
50 cccgcgccga ggtgaagttc gagggcgaca ccctggtgaa ccgcatcgag ctgaagggca 1260
tcgacttcaa ggaggacggc aacatcctgg ggcacaagct ggagtacaac tacaacagcc 1320
55 acaacgtcta tatcatggcc gacaagcaga agaacggcat caaggtgaac ttcaagatcc 1380
gccacaacat cgaggacggc agcgtgcagc tcgccgacca ctaccagcag aacaccccca 1440

EP 3 567 106 A1

	tcggcgacgg	ccccgtgctg	ctgcccgcaca	accactacct	gagcaccag	tcgcccctga	1500
	gcaaagaccc	caacgagaag	cgcgatcaca	tggtcctgct	ggagttcgtg	accgccgccc	1560
5	ggatcactct	cggcatggac	gagctgtaca	agtaagtaac	aggtaagtgc	gatcgctaata	1620
	gcgggaaagc	tcttattcgg	gtgagatggg	ctggggcacc	atctggggac	cctgacgtga	1680
	agtttgtcac	tgactggaga	actcggtttg	tcgtctgttg	cgggggaggc	agttatggcg	1740
10	gtgccgttgg	gcagtgaccc	cgtacctttg	ggagcgcgag	ccctcgtcgt	gtcgtgacgt	1800
	cacctgttct	gttgggtacct	gctgttgaca	gtgagcgacg	caatgtgact	tcgctgacaa	1860
	agctgtgaag	ccacagatgg	gctttgtcag	cagtcacatt	gcgctgccta	ctgcctcgga	1920
15	cttcaagggc	tcgagaattc	aggggtgggg	cacctgccgg	taggtgtgag	gtaggctttt	1980
	ctccgtcgca	ggacgcaggg	ttcgggccta	gggtaggctc	tcctgaatcg	acaggcgccc	2040
	gacctctggc	ggccgcaaca	acgcgttcct	gaccattcat	cctctttctt	tttctgcag	2100
20	gcttgtggaa	gaaatgggat	ccgatctttt	tcctctgccc	aaaaattatg	gggacatcat	2160
	gaagcccctt	gagcatctga	cttctggcta	ataaaggaaa	tttattttca	ttgcaatagt	2220
25	gtgttggaat	tttttgtgtc	tctcactcgg	cctaggtaga	taagtagcat	ggcgggttaa	2280
	tcattaacta	caaggaaccc	ctagtgatgg	agttggccac	tcctctctcg	cgcgctcgct	2340
	cgtcactga	ggccggggcg	ccaaaggctg	cccgacgccc	gggctttgcc	cgggcggcct	2400
30	cagtgcgcga	gcgagcgcgc	agccttaatt	aacctaatcc	actggccgct	gttttacaac	2460
	gtcgtgactg	ggaaaaccct	ggcgttaccc	aacttaatcg	ccttgacgca	catccccctt	2520
	tcgccagctg	gcgtaatagc	gaagaggccc	gcaccgatcg	cccttcccaa	cagttgcgca	2580
35	gcctgaatgg	cgaatgggac	gcgccctgta	gcggcgcatc	aagcgcgagg	ggtgtggtgg	2640
	ttacgcgcag	cgtgaccgct	acacttgcca	gcgccctagc	gcccgctcct	ttcgctttct	2700
	tccttccctt	tctcgccacg	ttcgccggct	ttccccgtca	agctctaaat	cgggggctcc	2760
40	ctttagggtt	ccgatttagt	gctttacggc	acctcgaccc	caaaaaactt	gattagggtg	2820
	atggttcacg	tagtgggcca	tcgccctgat	agacgggttt	tcgccctttg	acgttggagt	2880
	ccacgttctt	taatagtggg	ctcttggtcc	aaactggaac	aacactcaac	cctatctcgg	2940
45	tctattcttt	tgatttataa	gggattttgc	cgatttcggc	ctattgggta	aaaaatgagc	3000
	tgatttaaca	aaaatttaac	gcgaatttta	acaaaatatt	aacgcttaca	atttaggtgg	3060
	cacttttcgg	ggaaatgtgc	gcggaacccc	tatttggtta	tttttctaaa	tacattcaaa	3120
50	tatgtatccg	ctcatgagac	aataaccctg	ataaatgctt	caataatatt	gaaaaaggaa	3180
	gagtatgagt	attcaacatt	tcctgtgcgc	ccttattccc	ttttttgcgg	cattttgcct	3240
55	tcctgttttt	gctcaccag	aaacgctggg	gaaagtaaaa	gatgctgaag	atcagttggg	3300
	tgcacgagtg	ggttacatcg	aactggatct	caacagcggg	aagatccttg	agagttttcg	3360

EP 3 567 106 A1

	ccccgaagaa	cgtttttccaa	tgatgagcac	ttttaagtt	ctgctatgtg	gcgcggtatt	3420
	atcccgtatt	gacgccgggc	aagagcaact	cggtcgccgc	atacactatt	ctcagaatga	3480
5	cttggttgag	tactcaccag	tcacagaaaa	gcattctacg	gatggcatga	cagtaagaga	3540
	attatgcagt	gctgccataa	ccatgagtga	taacactgcg	gccaacttac	ttctgacaac	3600
	gatcggagga	ccgaaggagc	taaccgcttt	tttgacaaac	atgggggatc	atgtaactcg	3660
10	ccttgatcgt	tggaaccgg	agctgaatga	agccatacca	aacgacgagc	gtgacaccac	3720
	gatgcctgta	gcaatggcaa	caacgttgcg	caaactatta	actggcgaac	tacttactct	3780
	agcttcccgg	caacaattaa	tagactggat	ggaggcggat	aaagttgcag	gaccacttct	3840
15	gcgctcggcc	cttccggctg	gctggtttat	tgctgataaa	tctggagccg	gtgagcgtgg	3900
	gtctcgcggt	atcattgcag	cactggggcc	agatggtaag	ccctcccgtg	tcgtagttat	3960
20	ctacacgacg	gggagtcagg	caactatgga	tgaacgaaat	agacagatcg	ctgagatagg	4020
	tgccctcactg	attaagcatt	ggtaactgtc	agaccaagtt	tactcatata	tactttagat	4080
	tgatttaaaa	cttcattttt	aatttaaaag	gatctaggtg	aagatccttt	ttgataatct	4140
25	catgaccaa	atcccttaac	gtgagttttc	gttccactga	gcgtcagacc	ccgtagaaaa	4200
	gatcaaagga	tcttcttgag	atcctttttt	tctgcgcgta	atctgctgct	tgcaaacaaa	4260
	aaaaccaccg	ctaccagcgg	tggtttggtt	gccggatcaa	gagctaccaa	ctctttttcc	4320
30	gaaggtaact	ggcttcagca	gagcgcagat	accaaatact	gttcttctag	tgtagccgta	4380
	gttaggccac	cacttcaaga	actctgtagc	accgcctaca	tacctcgctc	tgctaatact	4440
35	gttaccagtg	gctgctgcca	gtggcgataa	gtcgtgtctt	accgggttgg	actcaagacg	4500
	atagttaccg	gataaggcgc	agcggtcggg	ctgaacgggg	ggttcgtgca	cacagcccag	4560
	cttgagcga	acgacctaca	ccgaactgag	atacctacag	cgtgagctat	gagaaagcgc	4620
40	cacgcttccc	gaagggagaa	aggcggacag	gtatccggta	agcggcaggg	tcggaacagg	4680
	agagcgcacg	aggagagctt	cagggggaaa	cgcctggtat	ctttatagtc	ctgtcggggt	4740
	tcgccacctc	tgacttgagc	gtcgattttt	gtgatgctcg	tcaggggggc	ggagcctatg	4800
45	gaaaaacgcc	agcaacgcgg	cctttttacg	gttcctggcc	ttttgctggc	cttttgctca	4860
	catgttcttt	cctgcgttat	cccctgattc	tgtggataac	cgtattaccg	cctttgagtg	4920
	agctgatacc	gctcgccgca	gccgaacgac	cgagcgcagc	gagtcagtga	gcgaggaagc	4980
50	ggaagagcgc	ccaatacgca	aaccgcctct	ccccgcgcgt	tgcccgattc	attaatgcag	5040
	ctggcacgac	aggtttcccg	actggaaagc	gggcagtgag	cgcaacgcaa	ttaatgtgag	5100
55	ttagctcact	cattaggcac	cccaggcttt	acactttatg	cttcgggctc	gtatgttgtg	5160
	tggaattgtg	agcggataac	aatttcacac	aggaaacagc	tatgaccatg	attacgccag	5220

atttaattaa ggccttaatt agg

5243

5
 <210> 22
 <211> 108
 <212> DNA
 <213> Artificial Sequence

10
 <220>
 <223> Synthetic Oligonucleotide

15
 <400> 22
 tgctgttgac agtgagcgac atcatcaatt ttccgagcag aactgtgaag ccacagatgg 60
 gttctgctcg aaattgatga tgctgcctac tgcctcggac ttcaaggg 108

20
 <210> 23
 <211> 106
 <212> DNA
 <213> Artificial Sequence

25
 <220>
 <223> Synthetic Oligonucleotide

30
 <400> 23
 tgctgttgac agtgagcgac gcattaaagg atcctgactg actgtgaagc cacagatggg 60
 tcagtcagtc ctttaatgcg ctgcctactg cctcggactt caaggg 106

35
 <210> 24
 <211> 108
 <212> DNA
 <213> Artificial Sequence

40
 <220>
 <223> Synthetic Oligonucleotide

45
 <400> 24
 tgctgttgac agtgagcgac tgcattggatt ctccatgttc atctgtgaag ccacagatgg 60
 gatgaacatg gaatccatgc agctgcctac tgcctcggac ttcaaggg 108

50
 <210> 25
 <211> 106
 <212> DNA
 <213> Artificial Sequence

55
 <220>
 <223> Synthetic Oligonucleotide

50
 <400> 25
 tgctgttgac agtgagcgac aaggatgaag atcgaggcat gctgtgaagc cacagatggg 60
 catgcctctc ttcatccttg ctgcctactg cctcggactt caaggg 106

55
 <210> 26
 <211> 110
 <212> DNA
 <213> Artificial Sequence

EP 3 567 106 A1

<220>
 <223> Synthetic Oligonucleotide

 <400> 26
 5 tgctgttgac agtgagcgac gcaatgtgac ttcgctgaca aagctgtgaa gccacagatg 60
 ggctttgtca gcagtcacat tgcgctgcct actgcctcgg acttcaaggg 110

 <210> 27
 10 <211> 108
 <212> DNA
 <213> Artificial Sequence

 <220>
 15 <223> Synthetic Oligonucleotide

 <400> 27
 tgctgttgac agtgagcgac cgatgtgtct atcttgaaga ttctgtgaag ccacagatgg 60
 20 gaatcttcaa tagacacatc ggctgcctac tgcctcggac ttcaaggg 108

 <210> 28
 <211> 106
 <212> DNA
 25 <213> Artificial Sequence

 <220>
 <223> Synthetic Oligonucleotide

 <400> 28
 30 tgctgttgac agtgagcgac ggtggaaatg atcagaaagt actgtgaagc cacagatggg 60
 tactttcttc atttccaccg ctgcctactg cctcggactt caaggg 106

 <210> 29
 35 <211> 110
 <212> DNA
 <213> Artificial Sequence

 <220>
 40 <223> Synthetic Oligonucleotide

 <400> 29
 tgctgttgac agtgagcgac gctgtagaaa ttcgatcct gatctgtgaa gccacagatg 60
 45 ggatcaggat acatttctac agcgctgcct actgcctcgg acttcaaggg 110

 <210> 30
 <211> 106
 50 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic Oligonucleotide

 <400> 30
 55 tgctgttgac agtgagcgag gtattaaact tgcagaatt tagtgaagcc acagatgtaa 60

EP 3 567 106 A1

attctgacaa gtttaataacc ctgcctactg cctcggactt caaggg 106

5 <210> 31
<211> 106
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Synthetic Oligonucleotide

<400> 31
tgctgttgac agtgagcgac gatgctctaa tcggttctat caagtgaagc cacagatggt 60
gatagaacct tagagcatcg ctgcctactg cctcggactt caaggg 106

15 <210> 32
<211> 28
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Synthetic Oligonucleotide

25 <400> 32
cgaaatacat acttctttac attccatt 28

30 <210> 33
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

35 <400> 33
cgaatggaat gtaaagaagt atgtatatt 28

40 <210> 34
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

45 <400> 34
cgaaacaaac accattgtca cactccatt 29

50 <210> 35
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Oligonucleotide

55 <400> 35
cgaatggagt gtgacaatgg tgtttgatt 29

<210> 36
 <211> 72
 <212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> Synthetic Oligonucleotide
 <400> 36
 10 cgaaatacat acttctttac attccaatac atacttcttt acattccaat acatacttct 60
 ttacattcca tt 72
 <210> 37
 15 <211> 72
 <212> DNA
 <213> Artificial Sequence
 <220>
 20 <223> Synthetic Oligonucleotide
 <400> 37
 cgaatggaat gtaaagaagt atgtattgga atgtaaagaa gtatgtattg gaatgtaaag 60
 25 aagtatgtat tt 72
 <210> 38
 <211> 75
 <212> DNA
 30 <213> Artificial Sequence
 <220>
 <223> Synthetic Oligonucleotide
 <400> 38
 35 cgaaacaaac accattgtca cactccaaca aacaccattg tcacactcca acaaacacca 60
 ttgtcacact ccatt 75
 <210> 39
 40 <211> 75
 <212> DNA
 <213> Artificial Sequence
 <220>
 45 <223> Synthetic Oligonucleotide
 <400> 39
 cgaatggagt gtgacaatgg tgtttggtgg agtgtgacaa tgggtgttgt tggagtgtga 60
 50 caatgggtgtt tgttt 75
 <210> 40
 55 <211> 51
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Oligonucleotide

 <400> 40
 5 cgaatacat acttctttac attccaacaa acaccattgt cacactccat t 51

 <210> 41
 <211> 51
 <212> DNA
 10 <213> Artificial Sequence

 <220>
 <223> Synthetic Oligonucleotide

 <400> 41
 15 cgaatggagt gtgacaatgg tgtttggtgg aatgtaaaga agtatgtatt t 51

 <210> 42
 <211> 173
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic Oligonucleotide

 <400> 42
 25 ttcgaactcg agatacatat ttctttacat tccaatacat acttctttac attccaatac 60
 atacttcttt acattccacc atggactagt acaaacacca ttgtcacact ccaacaaaca 120
 30 ccattgtcac actccaacaa acaccattgt cacactccag cggccgcttc gaa 173

 <210> 43
 <211> 29
 <212> DNA
 35 <213> Artificial Sequence

 <220>
 <223> Synthetic Oligonucleotide

 <400> 43
 40 atcggggcccg actgcagttt cagcgtttg 29

 <210> 44
 <211> 29
 45 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic Oligonucleotide

 <400> 44
 50 cgcggggcccg actttacatt acacacaat 29

 <210> 45
 <211> 29
 55 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Oligonucleotide

 <400> 45
 5 cgcgggcccg actgatgtgt gagagagac 29

 <210> 46
 <211> 29
 10 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic Oligonucleotide

 15 <400> 46
 cgcgggcccg actttcggcc tcccagaggc 29

 <210> 47
 <211> 20
 20 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic Oligonucleotide

 25 <400> 47
 tgaagctgaa gcctgtgatg 20

 <210> 48
 <211> 20
 30 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic Oligonucleotide

 35 <400> 48
 gagcacctga cagcattgaa 20

 <210> 49
 <211> 20
 40 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Synthetic Oligonucleotide

 45 <400> 49
 ctcagcaaca gctcatggaa 20

 <210> 50
 <211> 20
 50 <212> DNA
 <213> Artificial Sequence

 55 <220>
 <223> Synthetic Oligonucleotide

	<400> 50 ttacttctgg caccacacca	20
5	<210> 51 <211> 20 <212> DNA <213> Artificial Sequence	
10	<220> <223> Synthetic Oligonucleotide	
	<400> 51 tggtgtggtg ccagaagtaa	20
15	<210> 52 <211> 20 <212> DNA <213> Artificial Sequence	
20	<220> <223> Synthetic Oligonucleotide	
	<400> 52 caacagatgg ctggcaacta	20
25	<210> 53 <211> 18 <212> DNA <213> Artificial Sequence	
30	<220> <223> Synthetic Oligonucleotide	
	<400> 53 tgggagtggc accttcca	18
35	<210> 54 <211> 20 <212> DNA <213> Artificial Sequence	
40	<220> <223> Synthetic Oligonucleotide	
	<400> 54 cgaccactac cagcagaaca	20
45	<210> 55 <211> 20 <212> DNA <213> Artificial Sequence	
50	<220> <223> Synthetic Oligonucleotide	
	<400> 55 cttgtacagc tcgtccatgc	20

	<210> 56	
	<211> 20	
	<212> DNA	
	<213> Artificial Sequence	
5	<220>	
	<223> Synthetic Oligonucleotide	
	<400> 56	
10	aatggcctca gaatgactgc	20
	<210> 57	
	<211> 20	
	<212> DNA	
15	<213> Artificial Sequence	
	<220>	
	<223> Synthetic Oligonucleotide	
	<400> 57	
20	agtcgctttc acagccaaat	20
	<210> 58	
	<211> 22	
25	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Synthetic Oligonucleotide	
30	<400> 58	
	atgccaacac agtgctgtct gg	22
	<210> 59	
35	<211> 22	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
40	<223> Synthetic Oligonucleotide	
	<400> 59	
	tgcttgctga tccacatctg ct	22
	<210> 60	
45	<211> 22	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
50	<223> Synthetic Oligonucleotide	
	<400> 60	
	tggagtgtga caatggtgtt tg	22
55	<210> 61	

<211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Oligonucleotide

<400> 61
 aactatacaa cctactacct ca 22

<210> 62
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Oligonucleotide

<400> 62
 agcctatcct ggattacttg aa 22

<210> 63
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Oligonucleotide

<400> 63
 acagttcttc aactggcagc tt 22

<210> 64
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Oligonucleotide

<400> 64
 ctctgtatcg ttccaatttt agtata 26

Claims

1. A recombinant adeno-associated virus (rAAV) comprising (i) a capsid protein of a AAV serotype and (ii) a nucleic acid comprising a transgene, wherein the transgene encodes glial-derived growth factor (GDNF), for use as a medicament; wherein the rAAV is to be delivered in an effective amount to central nervous system (CNS) tissue of a subject by intracerebral injection into the putamen of the subject.
2. The rAAV for the use of claim 1 wherein the AAV serotype is AAV2.
3. The rAAV for the use of claim 1 or claim 2 wherein the intracerebral injection includes the use of a stereotactic device to guide the injection.
4. The rAAV for the use of any one of claims 1 to 3 wherein the intracerebral injection includes the use of a catheter

to deliver the rAAV into the putamen of the subject.

5 **5.** The rAAV for the use of any one of claims 1 to 4 wherein the rAAV is formulated in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

6. The rAAV for the use of claim 5, wherein between 100 μ l to 1 ml of the pharmaceutical composition is injected into the putamen of the subject.

10 **7.** The rAAV for the use of any one of claims 1 to 6, wherein the effective amount of the rAAV for intracerebral injection to the subject is in a range of 1×10^{10} genome copies to 1×10^{11} genome copies.

8. The rAAV for the use of any one of claims 1 to 6, wherein the effective amount of the rAAV for intracerebral injection to the subject is in a range of 1×10^{11} genome copies to 1×10^{12} genome copies.

15 **9.** The rAAV for the use of any one of claims 1 to 6, wherein the effective amount of the rAAV for intracerebral injection to the subject is in a range of 1×10^{12} genome copies to 1×10^{13} genome copies.

10. The rAAV for the use of any one of claims 1 to 6, wherein the effective amount of the rAAV for intracerebral injection to the subject is in a range of 1×10^{13} genome copies to 1×10^{14} genome copies.

20 **11.** The rAAV for the use of any one of claims 1 to 10, wherein the rAAV is for use in treating Parkinson's Disease and is to be delivered in an effective amount to central nervous system (CNS) tissue of a subject afflicted with Parkinson's Disease.




Fig. 1-1




Fig. 1-2




Fig. 2-1




Fig. 2-2




Fig. 3




Fig. 4A




Fig. 4B



Fig. 5A




Fig. 5B





Fig. 5C






Fig. 6A




Fig. 6B




Fig. 7A




Fig. 7B




Fig. 8




Fig. 9





Fig. 10






Fig. 12A




Fig. 12B




Fig. 12C




Fig. 13A




Fig. 13B




Fig. 13C




Fig. 13D




Fig. 14A




Fig. 14B




Fig. 14C




Fig. 14D




Fig. 14E




Fig. 15A




Fig. 15B




Fig. 15C




Fig. 15D




Fig. 15E




Fig. 15F




Fig. 16A






Fig. 17A




Fig. 17B




Fig. 18




Fig. 19A-1




Fig. 19A-2




Fig. 19A-3




Fig. 19B




Fig. 20




Fig. 21




Fig. 22




Fig. 23




Fig. 24




Fig. 25A




Fig. 25B




Fig. 26




Fig. 27A




Fig. 27B





Fig. 28






Fig. 30A




Fig. 30B




Fig. 30C




Fig. 30D




Fig. 30E




Fig. 31A




Fig. 31B




Fig. 32A




Fig. 32B




Fig. 33A




Fig. 33B



Fig. 33C




Fig. 33D



EUROPEAN SEARCH REPORT

 Application Number
EP 18 24 8250

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Y,P	WO 2010/129021 A1 (GENZYME CORP [US]; PASSINI MARCO A [US]; SHIHABUDDIN LAMYA [US]; CHENG) 11 November 2010 (2010-11-11) * page 4, line 29 - line 31 * * page 5, line 8 - line 17; figure 2 * -----	1-11	INV. C12N15/00 C12N15/86 A61K48/00
Y	DOLAN SONDHI ET AL: "Enhanced Survival of the LINCL Mouse Following CLN2 Gene Transfer Using the rh.10 Rhesus Macaque-derived Adeno-associated Virus Vector", MOLECULAR THERAPY, vol. 15, no. 3, 19 December 2006 (2006-12-19), pages 481-491, XP055084809, ISSN: 1525-0016, DOI: 10.1038/sj.mt.6300049 * abstract * * figure 1 * * page 484, right-hand column, paragraph 2 * * page 488, left-hand column, paragraphs 2, 3 * * page 488, right-hand column, paragraphs 2, last *	1-11	TECHNICAL FIELDS SEARCHED (IPC) C12N
Y	A S BEUTLER ET AL: "AAV for pain: steps towards clinical translation", GENE THERAPY, vol. 16, no. 4, 1 April 2009 (2009-04-01), pages 461-469, XP055070356, ISSN: 0969-7128, DOI: 10.1038/gt.2009.23 * page 464, right-hand column, last paragraph - page 466, left-hand column, paragraph 2 * * page 462, right-hand column, paragraph 3 * ----- -/--	1-11	
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 13 September 2019	Examiner Rojo Romeo, Elena
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P04C01)



EUROPEAN SEARCH REPORT

 Application Number
 EP 18 24 8250

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Y	TENENBAUM L ET AL: "Recombinant AAV-mediated gene delivery to the central nervous system.", THE JOURNAL OF GENE MEDICINE FEB 2004, vol. 6 Suppl 1, February 2004 (2004-02), pages S212-S222, XP002715192, ISSN: 1099-498X * page S216, paragraph "Neuroprotection" - page S217 * * figure 2 *	1-11	
A	MARCO A. PASSINI ET AL: "CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy", JOURNAL OF CLINICAL INVESTIGATION, vol. 120, no. 4, 1 April 2010 (2010-04-01), pages 1253-1264, XP055040159, ISSN: 0021-9738, DOI: 10.1172/JCI41615 * abstract * * page 1254, left-hand column, paragraph 1 * * page 1254, right-hand column, paragraph 2 *	1-11	TECHNICAL FIELDS SEARCHED (IPC)
A	CEARLEY ET AL: "Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 13, no. 3, 1 March 2006 (2006-03-01), pages 528-537, XP005326765, ISSN: 1525-0016, DOI: 10.1016/J.YMTHE.2005.11.015 * Results *	1-11	
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 13 September 2019	Examiner Rojo Romeo, Elena
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 18 24 8250

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	CASSIA N CEARLEY ET AL: "Expanded Repertoire of AAV Vector Serotypes Mediate Unique Patterns of Transduction in Mouse Brain", MOLECULAR THERAPY, vol. 16, no. 10, 19 August 2008 (2008-08-19), pages 1710-1718, XP055022703, ISSN: 1525-0016, DOI: 10.1038/mt.2008.166 * tables 1, 2 *	1-11	
T	BROOKE R. SNYDER ET AL: "Comparison of Adeno-Associated Viral Vector Serotypes for Spinal Cord and Motor Neuron Gene Delivery", HUMAN GENE THERAPY, vol. 22, no. 9, 1 September 2011 (2011-09-01), pages 1129-1135, XP055099540, ISSN: 1043-0342, DOI: 10.1089/hum.2011.008 * the whole document *		
			TECHNICAL FIELDS SEARCHED (IPC)
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 13 September 2019	Examiner Rojo Romeo, Elena
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 18 24 8250

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

13-09-2019

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2010129021 A1	11-11-2010	BR PI1010868 A2	12-06-2018
		CA 2759801 A1	11-11-2010
		CN 102459611 A	16-05-2012
		CN 107083400 A	22-08-2017
		DK 2424991 T3	17-09-2018
		EP 2424991 A1	07-03-2012
		EP 3421603 A1	02-01-2019
		ES 2686504 T3	18-10-2018
		HR P20181423 T1	30-11-2018
		HU E039345 T2	28-12-2018
		JP 5879256 B2	08-03-2016
		JP 6397391 B2	26-09-2018
		JP 2012526046 A	25-10-2012
		JP 2016052309 A	14-04-2016
		JP 2018148927 A	27-09-2018
		KR 20120006073 A	17-01-2012
		KR 20180027619 A	14-03-2018
		LT 2424991 T	25-09-2018
		MX 341073 B	05-08-2016
		MX 356669 B	08-06-2018
		PL 2424991 T3	30-11-2018
		RU 2011149094 A	10-06-2013
		RU 2016140850 A	14-12-2018
		SG 175409 A1	29-12-2011
		SG 10201404528S A	30-10-2014
		SI 2424991 T1	30-11-2018
		US 2013287736 A1	31-10-2013
		US 2016051699 A1	25-02-2016
		US 2017087212 A1	30-03-2017
		WO 2010129021 A1	11-11-2010

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 61327627 B [0001]
- US 20030138772 A [0035]
- US 20070036760 A [0035]
- US 20090197338 A [0035]
- US 61182084 A [0035]
- US 5478745 A [0037]
- US 6001650 A [0038]
- US 6156303 A [0038]
- WO 9810088 A [0051]
- US 5543158 A [0060]
- US 5641515 A [0060]
- US 5399363 A [0060]
- US 5741516 A [0073]
- US 5567434 A [0073]
- US 5552157 A [0073]
- US 5565213 A [0073]
- US 5738868 A [0073]
- US 5795587 A [0073]
- US 5656016 A [0077]
- US 5779708 A [0077]
- US 5797898 A [0077]
- US 5770219 A [0077]
- US 5783208 A [0077]
- US 5697899 A [0077]

Non-patent literature cited in the description

- LIANG Y et al. Characterization of microRNA expression profiles in normal human tissues. *BMC Genomics*, 12 June 2007, vol. 8, 166 [0018]
- XIA et al. *Neurobiol Dis*, 2006, vol. 23, 578 [0030]
- WANG et al. *JBC*, 2008, vol. 283, 15845 [0030]
- WU et al. *Antiox Redox Sig*, 2009, vol. 11, 1523 [0030]
- G. GAO et al. *J. Virol*, June 2004, vol. 78 (12), 6381-6388 [0035]
- G. GAO et al. *Proc Natl Acad Sci USA*, 13 May 2003, vol. 100 (10), 6081-6086 [0035]
- SAMBROOK et al. *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Press [0037]
- K. FISHER et al. *J. Virol.*, 1993, vol. 70, 520-532 [0037]
- GRAHAM et al. *Virology*, 1973, vol. 52, 456 [0039]
- SAMBROOK et al. *Molecular Cloning, a laboratory manual*. Cold Spring Harbor Laboratories, 1989 [0039]
- DAVIS et al. *Basic Methods in Molecular Biology*. Elsevier, 1986 [0039]
- CHU et al. *Gene*, 1981, vol. 13, 197 [0039]
- B. J. CARTER. *Handbook of Parvoviruses*. CRC Press, 1990, 155-168 [0045]
- SAMBROOK et al. *Molecular Cloning. A Laboratory Manual*. Cold Spring Harbor Laboratory, 1989 [0045]
- K. FISHER et al. *J Virol.*, 1996, vol. 70, 520-532 [0045]
- AUSUBEL et al. *Current Protocols in Molecular Biology*. John Wiley & Sons, 1989 [0048]
- RYAN, M D et al. *EMBO*, 1994, vol. 4, 928-933 [0048]
- MATTION, N M et al. *J Virology*, November 1996, 8124-8127 [0048]
- FURLER, S et al. *Gene Therapy*, 2001, vol. 8, 864-873 [0048]
- HALPIN, C et al. *The Plant Journal*, 1999, vol. 4, 453-459 [0048]
- DE FELIPE, P et al. *Gene Therapy*, 1999, vol. 6, 198-208 [0048]
- DE FELIPE, P et al. *Human Gene Therapy*, 2000, vol. 11, 1921-1931 [0048]
- KLUMP, H et al. *Gene Therapy*, 2001, vol. 8, 811-817 [0048]
- BOSHART et al. *Cell*, 1985, vol. 41, 521-530 [0050]
- NO et al. *Proc. Natl. Acad. Sci. USA*, 1996, vol. 93, 3346-3351 [0051]
- GOSSEN et al. *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 5547-5551 [0051]
- GOSSEN et al. *Science*, 1995, vol. 268, 1766-1769 [0051]
- HARVEY et al. *Curr. Opin. Chem. Biol.*, 1998, vol. 2, 512-518 [0051]
- WANG et al. *Nat. Biotech.*, 1997, vol. 15, 239-243 [0051]
- WANG et al. *Gene Ther.*, 1997, vol. 4, 432-441 [0051]
- MAGARI et al. *J. Clin. Invest.*, 1997, vol. 100, 2865-2872 [0051]
- ANDERSEN et al. *Cell. Mol. Neurobiol.*, 1993, vol. 13, 503-15 [0053]
- PICCIOLI et al. *Proc. Natl. Acad. Sci. USA*, 1991, vol. 88, 5611-5 [0053]
- PICCIOLI et al. *Neuron*, 1995, vol. 15, 373-84 [0053]
- COSTANTINI LC et al. *Gene Therapy*, 2000, vol. 7, 93-109 [0057]
- STEIN et al. *J Virol*, 1999, vol. 73, 3424-3429 [0060]

- **DAVIDSON et al.** *PNAS*, 2000, vol. 97, 3428-3432 [0060]
- **DAVIDSON et al.** *Nat. Genet.*, 1993, vol. 3, 219-223 [0060]
- **ALISKY ; DAVIDSON.** *Hum. Gene Ther.*, 2000, vol. 11, 2315-2329 [0060]
- **WRIGHT FR et al.** *Molecular Therapy*, 2005, vol. 12, 171-178 [0065]
- Remington's Pharmaceutical Sciences. 1035-1038, 1570-1580 [0068]
- **MATALON R et al.** *The Journal of Gene Medicine*, vol. 2 (3), 165-175 [0087]
- **FOUST KD et al.** *Nature Biotechnology*, March 2010, vol. 28 (3), 271-274 [0100]
- **DAYA S ; BERNS KI.** Gene Therapy Using Adeno-Associated Virus Vectors. *Clin Microbiol Rev*, 2008, vol. 21, 583-593 [0101]
- **EBERLING JL ; JAGUST WJ ; CHRISTINE CW ; STARR P ; LARSON P ; BANKIEWICZ KS ; AMINOFF MJ.** Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. *Neurology*, 2008, vol. 70, 1980-1983 [0101]
- **FEIGINA ; KAPLITZ MG ; TANG C ; LINT ; MATTIS P ; DHAWAN V ; DURING MJ ; EIDELBERG D.** Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. *Proceedings of the National Academy of Sciences*, 2007, vol. 104, 19559-19564 [0101]
- **CIDECIYAN AV ; HAUSWIRTH WW ; ALEMAN TS ; KAUSHAL S ; SCHWARTZ SB ; BOYE SL ; WINDSOR EAM ; CONLON TJ ; SUMAROKA A ; PANG J-J et al.** Human RPE65 Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 Year. *Hum Gen Ther*, vol. 0 [0101]
- **RAOUL C ; ABBAS-TERKI T ; BENSADOUN J-C ; GUILLOT S ; HAASE G ; SZULC J ; HENDERSON CE ; AEBISCHER P.** Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. *Nat Med*, 2005, vol. 11, 423-428 [0101]
- **KASPAR BK ; LLADO J ; SHERKAT N ; ROTHSTEIN JD ; GAGE FH.** Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model. *Science*, 2003, vol. 301, 839-842 [0101]
- **AZZOUZ M ; RALPH GS ; STORKEBAUM E ; WALMSLEY LE ; MITROPHANOUS KA ; KINGSMAN SM ; CARMELIET P.** Mazarakis ND: VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. *Nature*, 2004, vol. 429, 413-417 [0101]
- **RALPH GS ; RADCLIFFE PA ; DAY DM ; CARTHY JM ; LEROUX MA ; LEE DCP ; WONG L-F ; BILSLAND LG ; GREENSMITH L ; KINGSMAN SM et al.** Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. *Nat Med*, 2005, vol. 11, 429-433 [0101]
- **WU R ; WANG H ; XIA X ; ZHOU H ; LIU C ; CASTRO M ; XU Z.** Nerve Injection of Viral Vectors Efficiently Transfers Transgenes into Motor Neurons and Delivers RNAi Therapy Against ALS. *Antioxidants & Redox Signaling*, 2009, vol. 11, 1523-1534 [0101]
- **FOUST KD ; NURRE E ; MONTGOMERY CL ; HERMANDEZ A ; CHAN CM ; KASPAR BK.** Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. *Nat Biotechnol*, 2009, vol. 27, 59-65 [0101]
- **DUQUE S ; JOUSSEMET B ; RIVIERE C ; MARAIS T ; DUBREIL L ; DOUAR AM ; FYFE J ; MOULLIER P ; COLLE MA ; BARKATS M.** Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. *Mol Ther*, 2009, vol. 17, 1187-1196 [0101]
- **VANDENBERGHE LH ; WILSON JM ; GAO G.** Tailoring the AAV vector capsid for gene therapy. *Gene Ther*, 2009, vol. 16, 311-319 [0101]
- **MCBRIDE JL ; BOUDREAU RL ; HARPER SQ ; STABER PD ; MONTEYS AM ; MARTINS I ; GILMORE BL ; BURSTEIN H ; PELUSO RW ; POLISKY B et al.** Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi. *Proceedings of the National Academy of Sciences*, 2008, vol. 105, 5868-5873 [0101]
- **MCCARTY DM.** Self-complementary AAV Vectors; Advances and Applications. *Mol Ther*, 2008, vol. 16, 1648-1656 [0101]
- **BOILLEE S ; YAMANAKA K ; LOBSIGER CS ; COPELAND NG ; JENKINS NA ; KASSIOTIS G ; KOLLIAS G ; CLEVELAND DW.** Onset and progression in inherited ALS determined by motor neurons and microglia. *Science*, 2006, vol. 312, 1389-1392 [0101]
- **XIA X ; ZHOU H ; HUANG Y ; XU Z.** Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. *Neurobiol Dis*, 2006, vol. 23, 578-586 [0101]
- **YAMANAKA K ; CHUN SJ ; BOILLEE S ; FUJIMORI-TONOU N ; YAMASHITA H ; GUTMANN DH ; TAKAHASHI R ; MISAWA H ; CLEVELAND DW.** Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. *Nat Neurosci*, 2008, vol. 11, 251253 [0101]
- **DIGIORGIO FP ; CARRASCO MA ; SIAO MC ; MANIATIS T ; EGGAN K.** Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. *Nat Neurosci*, 2007, vol. 10, 608-614 [0101]
- **NAGAI M ; RE DB ; NAGATA T ; CHALAZONITIS A ; JESSELL TM ; WICHTERLE H ; PRZEDBORSKI S.** Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. *Nat Neurosci*, 2007, vol. 10, 615-622 [0101]

- **WANG Y ; OU MAO X ; XIE L ; BANWAIT S ; MARTI HH ; GREENBERG DA ; JIN K.** Vascular Endothelial Growth Factor Overexpression Delays Neurodegeneration and Prolongs Survival in Amyotrophic Lateral Sclerosis Mice. *J Neurosci*, 2007, vol. 27, 304-307 [0101]
- **STORKEBAUM E ; LAMBRECHTS D ; DEW-ERCHIN M ; MORENO-MURCIANO M-P ; APPELMANS S ; OH H ; VAN DAMME P ; RUTTEN B ; MAN WY ; DE MOL M et al.** Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. *Nat Neurosci*, 2005, vol. 8, 85-92 [0101]
- **WU, W. P. ; XU, X. J. ; HAO, J. X.** *J. Neurosci. Methods*, 2004, vol. 133, 65-69 [0101]
- **PAPAIIOANNOU, V. E. ; FOX, J. G.** *Lab. Anim. Sci.*, 1993, vol. 43, 189-192 [0101]